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Abstract  
Co-crystals are a solid phase phenomena that could enhance the physicochemical 
properties of an active pharmaceutical ingredient. A co-crystal has never been 
incorporated into a liquid dosage form with the assurance of maintaining its co-crystal 
state until absorption under defined conditions. This study aims to develop a liquid 
formulatiln with a nevirapine co-crystal. 
A protocol was developed to investigate all the five co-formers that were used to make 
the nevirapine co-crystals to-date. The most appropriate co-former was selected for a 
liquid dosage form to study the integrity and the scaling up of the co-crystal in a 
suspension formulation. Co-formers used were viz. saccharin, glutaric acid, salicylic 
acid, rac-tartaric acid and maleic acid. These were characterized according to their 
physical, chemical, pharmacological and pharmaceutical properties. A grading scale 
was used to select the most appropriate co-former for a suspension formulation. 
Comparatively, saccharin produced the best combination of physical, chemical, 
pharmacological and pharmaceutical properties, especially with regard to the particle 
size and the specific gravity which proved to be very useful as optimal criteria for 
suspension formulation. Upon selection of the ideal co-former, scale-up of the 
nevirapine saccharin co-crystal was performed from a small scale of 350 mg to a large 
scale of 5 g. Nevirapine-saccharin (NVSC) co-crystals were prepared utilizing the slow 
evaporation technique, using methanol as the solvent and the percentage yield of the 
co-crystals were > 80 %.  The identity of co-crystals was confirmed using hot stage 
microscopy (HSM), differential scanning calorimetry (DSC), fourier transform infra-
red (FTIR) and thermogravimetric analysis (TGA). 
Three co-crystal suspension formulations were prepared using the excipients identified 
in the branded, Viramune® suspension, with each formulation containing viscosity 
enhancers such as aerosil 200, carbopol 971G and carbopol 974P.  To ascertain the co-
crystal integrity in the suspension, it was filtered and the filtrate was identified with 
DSC and FTIR while the filtered solution was identified with ultraviolet spectroscopy 
(UV). The co-crystal suspension formulation with optimal pH, viscosity and assurance 
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of co-crystal integrity was the carbopol 974P formulation. The UV and DSC of the 
filtrate of the suspension revealed that the co-crystal had not separated into its 
individual components and remained intact while in suspension form irrespective of 
the excipients added. 
This formulation proceeded to the quality control stage. It was assessed for its pH, 
viscosity and dissolution according to the USP 32 standards and compared to the 
branded nevirapine suspension, Viramune ®, presently on the market. The suspension 
was characterized for particle size, zeta potential and polydispersity index. The 
dissolution results assayed by High Performance Liquid Chromatography (HPLC) 
revealed a drug release of 86 % in the Viramune® suspension while the NVSC co-
crystal suspension achieved a drug release of 94% within 30 minutes of dissolution.  
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Chapter 1 Introduction 
1.1 Process of drug discovery to drug delivery 
The discovery of a potent compound necessary for therapeutic effect is a significant 
milestone in the drug discovery process. However, this compound can only produce its 
effect when sufficient quantity reaches the site of action at a suitable rate upon 
administration. For a drug to reach its site of action it has to be formulated into a dosage 
form.  
To gain approval for public use, the discovered drug has to undergo a well-defined and 
extensive process laid out by regulatory bodies such as the Food and Drug 
Administration (FDA) in the United States of America or the Medicines Control 
Council in South Africa. The proposed drug has to be physically, chemically and 
biologically characterized for pharmaceutical effects, pharmacological effects, 
toxicological effects and for potential therapeutic application.1 Preformulation studies 
describe the physical and chemical properties of the drug. It deals with the rational, 
science-based requirements for drug substances, some of which include 
physicochemical stability, consistency and solid state properties such as structural 
properties, dimensional properties, chemical, mechanical and electrical properties.2  
Formulation studies subsequently follow preformulation studies, this segment deals 
with the final composition of the active drug and functional excipient substances used 
in the dosage form. It focuses on the stability of the product and drug release properties 
that are necessary for the product to have an optimal therapeutic effect.2  
The formulation phase deals with the development of a stable, bioavailable and optimal 
dosage form for a specific route of administration. The purpose of the formulation 
phase is to formulate the active drug into a suitable dosage form and to find the most 
feasible formulation strategy appropriate for scaling up and production in the 
manufacturing industry.1 The preparation of an acceptable dosage form should be in 
accordance with regulatory frameworks such as the United States pharmacopeia, 
European pharmacopeia, Japanese pharmacopeia or Indian pharmacopeia, a reference 
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book consisting of directions for identification of medicines, published by the authority 
of a government.  
Formulation involves appropriate consideration of each ingredient and its role in the 
final product. These considerations include the physical, chemical and biological 
characteristics of these ingredients together with the compatibility thereof, to create a 
product that will enhance patient compliance (i.e. easy to administer, palatable and well 
tolerated) as well as stable and an efficacious drug product.3 
Thereafter, the drug undergoes a carefully developed program of preclinical and 
clinical studies to prove the drug’s safety and effectiveness for its proposed use.1   
1.2 Formulation 
Formulation studies develop the initial features of the proposed pharmaceutical product 
or dosage form. It is vital for a drug to be formulated in a suitable dosage form because 
inappropriate dosage forms or invalidated manufacturing processes can result in 
disastrous consequences during clinical trials. The final formulation includes 
excipients which have specialized functions and fashion medicinal agents into 
efficacious and appealing dosage forms.4   
1.3 Dosage Forms  
Drugs are rarely administered alone because minute quantities are required for 
therapeutic effect. The primary reason for incorporating a drug substance into a dosage 
form is for easy handling. Dosage forms are designed to provide the drug in a suitable 
form for absorption from the selected route of administration.5  
Most drug substances used today are unpalatable and unattractive in their natural form. 
An appropriate drug will only have its beneficial effect if the patient adheres to the 
therapeutic regimen. Modern pharmaceutical formulations aim to satisfy the triple 
combination of flavour, taste and colour as this triad contributes to patient 
acceptability.3  
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Information gathered from the preformulation studies of the active pharmaceutical 
ingredients (API) can be used as a framework in the fabrication of a dosage form.  
Dosage forms can be designed by alternative delivery routes to maximize therapeutic 
response. The most common and convenient route of administration is the oral route 
and one of the ways in which the rate and extent of transportation of the drug into the 
blood circulation can be controlled is by the addition of excipients.  
Dosage forms are classified into solid dosage forms such as tablets, capsules, powders 
and granules while liquid dosage forms comprises of solutions, syrups, suspensions 
and emulsions.  
For a medicinal agent to be formulated into a dosage form, the age of the patient and 
the manner in which the disease is treated is considered (local or systemic action). 
Adults are given dosage forms that require less frequency of administration without 
compromising the efficacy. Tablets and capsules are usually given to adults because of 
their simplicity in storage and handling. Oral dosage forms are also most convenient in 
the self-administration of medication. 
 
Different dosage forms are preferred according to the age of the paediatric patient. 
Suppositories are preferred for neonates while solutions and syrups for infants. Liquid 
preparations usually utilize benzyl alcohol as a preservative and this is not suitable 
when administered to neonates due to immature metabolic function, however it is 
suitable for infants.6 Solutions, syrups, suspensions or effervescent dosage forms can 
be administered for two to five year olds. The taste of a bitter drug can be masked by 
using these dosage forms hence they are suitable for administration for two to five year 
olds.  A solid dosage form such as tablet or capsule is generally acceptable from six 
years onwards.6 At this age, it is generally considered safe to swallow a tablet.6 
With respect to the paediatric population, dosage forms are challenging to develop for 
this particular group because the prerequisites such as a measurable dosage form to 
administer based on body weight and taste masking are unique for paediatric oral 
formulations.  
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The formulation philosophy for developing a paediatric dosage form is ‘‘from simple 
to complex,’’ which involves minimizing the number of excipients and developing the 
simplest possible formulation and manufacturing process.6  
Therapeutic situations also affect the selection of a dosage form, for instance in motion 
sickness a patient may be uncomfortable in taking medication orally hence skin patches 
can be used instead.1  
1.3.1 Liquid dosage forms  
Liquid dosage forms are typically utilized by geriatric and paediatric patients. In 
comparison to solid dosage forms, they have an advantage of faster onset of action due 
to the absence of the disintegration step thus they have a more rapid absorption.5 Liquid 
dosage forms also provide greater convenience in administration, where larger doses 
are required.7 Many people, particularly the paediatric and elderly groups struggle to 
swallow solid dosage forms and thus prefer a drug that is dispersed in a liquid.8  
Challenges involved in developing liquid dosage forms include stability of the drug in 
solution, solubility of the drug and an acceptable taste. An additional challenge that is 
observed is that the oral liquid dosage forms have a risk of microbial contamination.  
1.3.1.1 Solutions 
Solutions are defined as liquid preparations that contain one or more chemical 
substances dissolved in a suitable solvent or mixture of mutually miscible solvents.1  
Types of solutions  
Solutions can further be classified as oral solutions, otic solutions, ophthalmic solutions 
or topical solutions. Oral solutions can further be categorized into aqueous solutions 
and non-aqueous solutions. Aqueous solutions containing sugar are classified as 
syrups. Solutions containing hydroalcoholic solutions are known as elixirs and 
solutions prepared from crude drugs are referred to as tinctures.  
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Preparation of solutions  
In formulating a solution, considerations such as the solubility and stability of the solute 
in the solvent to be employed is important. Upon administration of solutions, the 
absorption form the gastrointestinal tract into systemic circulation is more rapid than 
suspensions or solid dosage forms of the same drug. For a drug to be formed as a 
solution it is necessary for the drug to be soluble in an aqueous system. Solvents that 
can be employed in the preparation of solutions are ethyl alcohol, ethanol, glycerol, 
propylene glycol and water.9  
Solutions can be prepared by simply dissolving the solute in the solvent. A 
pharmaceutical product that is formulated in this manner is calcium hydroxide solution, 
where calcium hydroxide is mixed with water. Solutions can also be prepared by 
reacting two or more solutes in a suitable solvent. An example of this is aluminium 
subacetate, it is prepared by reacting aluminium sulphate solution with calcium 
carbonate and acetic acid.1  
Nearly 80 – 90 % of drugs are poorly soluble.10 The term ‘poorly soluble’ is used when 
30 to 100 parts of solvent are required for one part of solute. Thus, large amounts of 
solvent are required to dissolve minute amounts of the drug. In practice, solutions are 
preferred to be given as 5 ml or 15 ml (equivalent to one teaspoon and tablespoon, 
respectively). Thus, for poorly soluble drugs in a solution form, doses will have to be 
increased to more than a teaspoon or tablespoon and this would hamper patient 
acceptability. 
1.3.2 Disperse systems  
Dispersed systems consist of particles, known as the dispersed phase which is 
distributed throughout a medium known as the continuous or dispersion medium.11 
Dispersed systems are classified on the basis of the mean particle diameter of the 
dispersed matter. Three types of disperse systems exist: molecular dispersions, 
colloidal dispersions and coarse dispersion systems.  
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1.3.2.1 Suspensions 
Suspensions are a class of dispersed systems in which a finely divided solid material 
known as the internal phase is dispersed uniformly in a liquid dispersion medium which 
is known as the suspending medium.12  
The internal phase consists of insoluble solid particles which has a size of 0.5 to 5 µm 
and which are maintained uniformly throughout the suspending vehicle with the aid of 
a single or a combination of suspending agents. 
Types of suspensions 
Suspensions can be classified according to their size. Colloidal suspensions are those 
that have a particles size of less than 1 µm, coarse suspensions contain particles that 
are greater than 1 µm in size and nano suspensions consists of particles smaller than 1 
µm. The practical upper limit for individual suspendable solid particles in coarse 
suspensions is approximately 50 to 75 µm.12   
Flocculated & Deflocculated suspensions 
In a flocculated system, light, fluffy conglomerates that are held together by weak Van 
der Waals forces called flocs are formed.11 They settle rapidly but they do not form a 
hard cake and thus they can be easily resuspended.  
Flocs tend to fall together, producing a distinct boundary between the sediment and 
supernatant liquid. The liquid above the sediment is clear because even the small 
particles in the system are associated with the flocs. However, from an aesthetic point 
of view, flocculated suspensions have a supernatant layer which may be unattractive. 
Floc formation of particles decreases the surface free energy between the particles and 
liquid medium thus acquiring thermodynamic stability. The structure of flocs contains 
small amounts of liquid entrapped within the flocs. The entrapment of liquid within the 
flocs increases the sedimentation volume and the sediment is thus easily redispersed 
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by a small amount of agitation. To prepare a flocculated suspension, a flocculating 
agent is used to produce the formation of flocs.11  
In a deflocculated suspension, larger particles settle more rapidly than smaller particles. 
There is no clear boundary formed and the supernatant remains turbid for a long period 
of time. During the initial stages of settling, clear or turbid supernatant is a good 
indication of whether the system is flocculated or deflocculated, respectively (Fig. 
1.1).11   
 
Figure 1.1 Differences between flocculated and deflocculated suspension 
Preparation of suspensions  
Suspensions can be formed through either precipitation methods or through dispersion 
methods. Precipitation methods can further be divided into organic solvent 
precipitation, precipitation effected by changing the pH of the medium and double 
decomposition.  Organic solvent precipitation can be achieved by dissolving drugs in 
water-miscible organic solvents and then adding the organic phase to distilled water. 
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Ethanol, methanol, propylene glycol and polyethylene glycol are examples of organic 
solvents.13  
The technique of changing the pH of the medium is applicable to the drugs whose 
solubility is dependent on pH. For example, in the case of the drug estradiol, 
suspensions can be prepared by changing the pH of its aqueous solution.14  
The dispersion method consists of a vehicle that is formulated so that the solid phase 
is easily wetted and dispersed. Glycerin and sorbitol are generally used in cases where 
a hydrophobic drug is needed to be adequately wet. The use of a surfactant can also be 
accomplished to improve dispersion. Small quantities should be tested to see which 
approach works better, the dispersion method or usage of a surfactant.14 
1.3.2.2 Emulsions  
An emulsion is a dispersion in which the dispersed phase is composed of small globules 
of a liquid distributed throughout a vehicle in which it is immiscible.1  
Two phases exist in emulsions, the dispersed phase and the dispersion medium. The 
particle size of the dispersed phase is between 0.1 to 100 µm.14  
Types of Emulsions 
There are two types of emulsions, oil-in-water and water-in-oil emulsions (Fig 1.2). 
When oil droplets are dispersed throughout the aqueous phase it is referred to as an oil-
in-water emulsion. Water soluble drugs are released more quickly from oil-in-water 
emulsions because of the presence of hydrophilic parts that are attracted to the external 
phase. The oil is readily absorbed in the gastro intestinal tract due to its high 
permeability and thus it is suitable to be used internally.14 This type of emulsion is 
suitable for medicinal oils that have a bitter and oily taste. An example of this is liquid 
paraffin emulsion, the water forms a continuous phase and the liquid paraffin is 
surrounded by a thin film emulgent which masks the bitter and oily taste of the drug.14  
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When water is dispersed as globules in oil, it is referred to as a water-in-oil emulsion. 
Oil soluble drugs are formulated as water-in-oil emulsions. They have an occlusive 
effect and greasy in texture, therefore making it suitable for cleaning the skin from oil 
soluble dirt. This makes it suitable to be used externally. An example of this is cold 
cream, it is greasy and not water washable and is used externally to prevent evaporation 
of moisture from the skin.14  
         
Figure 1.2 Illustration of oil in water emulsion and water in oil emulsion  
An important parameter to the formulation of emulsions is stability. Instability of 
emulsions is shown by flocculation, creaming, coalescence or phase inversion.14 
Flocculation of emulsions is the same as flocculation of suspensions, where small 
particles aggregate to form a larger particle that is redispersable upon shaking. 
Creaming is a phenomenon in which the dispersed phase separates on top of the 
continuous phase. This can also be redispersed upon shaking. Coalescence is presented 
when the mechanical or electrical barrier is insufficient to prevent the formation of 
progressively larger droplets. Phase inversion occurs when the dispersed phase 
becomes the continuous phase, for example when oil-in-water becomes water-in-oil.  
 
 
Lipophllic part  
 
Lipophllic part  
 
Hydrophilic part  Hydrophilic part  
 
  
 
Oil in water emulsion Water in oil emulsion 
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Preparation of emulsions  
Emulsions can be prepared by mainly two methods, the dry gum method and the wet 
gum method. Both these methods utilize gum, water and oil. In the dry gum method 
the oil is triturated with gum and with a little amount of water to form a primary 
emulsion. The trituration process is continued until a clicking sound is heard. Water is 
slowly added to form the final emulsion.  In the wet gum method, the gum and water 
are triturated to form a mucilage.14 Oil is added in small quantities to form the primary 
emulsion. Thereafter, water is added to make the final emulsion.  
The membrane emulsification method is a relatively novel concept, whereby droplets 
are generated to produce an emulsion. Pressure is applied directly to the dispersed 
phase which seeps through a porous membrane into the continuous phase. Droplets are 
formed and remain detached from the surface due to the shear motion between the 
continuous phase and membrane surface.15  
1.4 Human Immunodeficiency Virus (HIV) 
Since the discovery of HIV in 1983, efforts have been made by researchers towards the 
discovery of anti-HIV drugs.16 
One new infection occurs every ten seconds or 7400 new infections occur every day. 
33 million people are now living with HIV, 67% of them live in sub-Saharan Africa.17 
Despite these alarming statistics, the use of antiretroviral drugs is useful in limiting the 
pandemic and prolonging the lives of those infected. The roll out of antiretroviral drugs 
has a significant reduction in Acquired Immune Deficiency Syndrome (AIDs) related 
mortality and improved survival. Highly Active Retroviral Treatment (HAART) is a 
triple drug combination therapy consisting of nucleoside reverse transcriptase 
inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, each 
class of the anti-retroviral agent targets a different step in the viral cycle of the HIV 
thus preventing immune deterioration.16 
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1.5 Nevirapine  
Nevirapine (Fig 1.3) is a potent Non-Nucleoside Reverse Transcriptase Inhibitor 
(NNRTI). It was the first approved drug from this class in 1996 by the FDA.18  
 
Figure 1.3 Chemical structure of nevirapine 
1.5.1 Synthesis of nevirapine 
Researchers at Boehringer Ingelheim Pharmaceuticals discovered nevirapine. The 
synthesis of nevirapine begins with acylation of 3-amino-2-chloro-4-methylpyridine 
with 2-chloronicotinoyl chloride to form 2,2ʹ-dichloro amide. Thereafter, the 2ʹ-
chlorine atom is displaced by cyclopropylamine. Nevirapine synthesis is complete by 
ring closure/cyclisation which is achieved by heating under reflux.18  
1.5.2 Physiocochemical properties of nevirapine  
Nevirapine is classified as the dipyridodiazepones class of compounds. The chemical 
name for it is 11-cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2b:2ʹ,3ʹe] 
[1,4]diazepin-6-one. The molecular formula is C15H14N4O. The molecular weight is 
266.30 g/mol.19 It is a white, or almost white, crystalline powder. It is a weak base with 
a pKa value of 2.8 and exhibits pH dependent solubility. Nevirapine is a hydrophobic 
molecule and is classified as a class II drug according to the Biopharmaceutical 
Classification System (BCS).   
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1.5.1 Pharmacological properties  
1.5.1.1 Mechanism of action  
Nevirapine, an NNRTI, acts by binding directly to the HIV reverse transcriptase 
enzyme and it blocks the ribonucleic acid dependent and deoxyribonucleic dependent 
polymerase activities by causing a disruption of the enzyme catalytic site.20  
1.5.2.2     Use of nevirapine  
Nevirapine has demonstrated potent and sustained antiviral activity when used in 
HAART with drugs of the nucleoside and protease inhibitor classes. Nevirapine is used 
for the treatment of HIV-1 infection in both young and adult patients. It is the 
blockbuster drug for prevention of mother-to-child transmission of HIV. Reduction of 
HIV transmission by 40% is achieved by administration of a single dose of nevirapine 
to the mother during labour and to the infant after birth.21  
1.5.2.3 Dosage of nevirapine  
Nevirapine is given to adults as 200 mg orally for 14 days followed by 200 mg twice a 
day. The paediatric dose of nevirapine for 2 months to 8 years old is 4 mg/kg once daily 
for 2 weeks thereafter 7 mg/kg twice daily. For children over 8 years old 4 mg/kg is 
given once daily, for two weeks thereafter 4 mg/kg is given twice a day. A maximum 
of 400 mg/day of nevirapine is advised. In South Africa, it is available under the trade 
names Viramune®, Aspen Nevirapine®, Auro-Nevirapine®, Cipla Nevirapine®, 
Sonke-Nevirapine® and Adco-Nevirapine®.  
1.5.3 Pharmacokinetics 
1.5.3.3 Absorption  
Nevirapine is readily absorbed (greater than 90%) after oral administration. Peak 
plasma nevirapine concentrations of 2 ± 0.4 µg/mL are attained by 4 hours following a 
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single 200 mg dose.20 Following multiple doses, nevirapine peak concentrations appear 
to increase linearly in the dose range of 200 to 400 mg/day.  
Upon administration of Viramune® with either a high-fat breakfast or antacid, the 
extent of absorption is comparable to that observed under fasting conditions. Thus, 
Viramune® can be administered with or without food or antacid.20  
1.5.3.2 Distribution  
Nevirapine is highly lipophilic and is nonionized at physiologic pH. After intravenous 
administration to healthy adults, the volume of distribution of nevirapine is 1.21 L/kg, 
this indicates that nevirapine is widely distributed. Nevirapine readily crosses the 
placenta and is found in breast milk. Nevirapine has a half-life of 45 hours. A single 
dose is decreased by auto-induction to about 25 to 30 hours after multiple dosing.20  
1.5.3.3 Metabolism  
Nevirapine is extensively metabolized by P450 enzyme to hydroxylated glucuronides. 
The multiple dose pharmacokinetics is characterized by metabolic autoinduction of 
cytochrome P450 isoenzymes, 3A (CYP3A) and 2B6 (CYP2B6) resulting in a 1.5 to 2 
fold increase in nevirapine apparent systemic clearance as treatment continues from a 
single dose to 2 weeks of dosing with 200 mg/day or higher.20  
1.5.3.4     Excretion 
In vivo and in vitro trials have shown that more than 80 % of radioactivity in urine is 
made of glucuronide conjugates of hydroxylated metabolites; this indicates that 
cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of 
glucuronidated metabolites are the main route of nevirapine biotransformation and 
elimination in humans. Less than 3 % of the dose is excreted in the urine as the parent 
compound.20 Renal excretion plays a minor role in elimination of nevirapine.  
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1.5.3.5     Protein binding  
Nevirapine is 60 % bound to plasma proteins in the plasma concentration range of 1-
10 µg/mL. The concentration in human cerebrospinal fluid is 45 % of the concentration 
in plasma; this ratio indicates that it is approximately equal to the fraction not bound to 
the plasma proteins.7  
1.5.4 Pharmaceutical aspects  
1.5.4.1 Solubility  
The solubility of the anhydrous nevirapine is 0.123 mg/mL.19 It is practically insoluble 
in water; however it is sparingly soluble or slightly soluble in methylene chloride and 
slightly soluble in lower alcohols. Interestingly, it is highly soluble at a pH of less than 
three, due to protonation of its weak basic functional group.6 The aqueous solubility 
decreases with an increase in pH to 0.1 mg/mL at neutral pH. 
Nevirapine is a hydrophobic drug and at doses of 50 mg and higher it exhibits 
characteristics of solubility rate-limited absorption (delayed time-to-peak, multiple 
peak concentrations) which could lead to a slight decrease in bioavailability.20 
1.5.1.2 Stability  
Nevirapine is stable at room temperature.19 Nevirapine has a high stability in the solid 
form and it is not susceptible to degradation under light exposure. It has a high melting 
point (246 °C) and exhibits low hygroscopicity.22  
1.5.1.3 Dosage form  
Nevirapine is currently being used in the form of tablets (200 mg) and a suspension (50 
mg/5mL). Nevirapine anhydrous and nevirapine hemihydrate are used in tablets and 
suspensions, respectively (Fig. 1.4). It is also used in fixed dose combinations together 
with two other antiretroviral drugs (Lamivudine and Zidovudine).   
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Figure 1.4 Structure of nevirapine and nevirapine hemihydrate (from left to 
right) 
1.6 Classification of solids  
Drug substances that are incorporated in dosage forms today are usually solid materials 
that are pure chemical compounds that are either in crystalline or amorphous form. The 
selection of the proper form of the drug is of paramount importance to ensure optimal 
solubility, absorption and stability characteristics. 
Solvates, salts, co-crystals, hydrates and cyclodextrin inclusion complexes represent 
multi-component systems while polymorphs represent single-component systems (Fig. 
1.5). Polymorphism is defined as materials with the same chemical composition and 
different lattice. The multi-component systems are bound together by means of non-
covalent bonds viz. hydrogen bonding, π-π interactions or Van der Waals forces.23  
 
Figure 1.5 Classifications of solids based on internal structure of compounds24 
1
2
  H2O 
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Each crystalline form of an API has unique physicochemical properties that can influence 
the bioavailability, manufacturability, purification, stability and other performance 
characteristics of the drugs.25 Thus, selection of the appropriate form is of paramount 
importance for drug development and formulation.  
1.7 Strategies to improve solubility of an API  
Solubility is a key determining factor in the formulation of dosage forms, since 
molecules that are poorly soluble may lead to slow dissolution rates, insufficient and 
inconsistent systemic exposure and consequent sub-optimal efficacy in patients.26 
About 40 % of drugs that are administered as a tablet have poor solubility. What is 
more concerning is that 80–90 % of drug candidates in the Research & Development 
pipeline have a low solubility problem, prohibiting them from advancing into clinical 
trials.10  Despite this alarming scenario, solubility problems can be overcome by either 
the physicochemical modification route or by formulation of the API into special 
dosage forms (Fig. 1.6).27  Physicochemical modification can be achieved by 
application of crystal engineering to form either solvates, hydrates, polymorphs co-
crystals or cyclodextrin inclusion complexes, thus ensuring the most appropriate solid 
form of the drug. Alternatively, special dosage forms such as solid dispersions, self-
emulsifying formulations or liquid-filled capsules may be developed to improve the 
solubility profile of the compound.  
 
Figure 1.6 Modification of API to improve solubility27 
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1.7.1 Supramolecular derivatives of nevirapine  
Nevirapine is a poorly soluble API which has undergone physicochemical modification 
in an attempt to improve its solubility (Fig. 1.7).  
 
Figure 1.7 Derivatives of nevirapine 
In its structure, the amide function (-COHN) of nevirapine makes it a viable candidate 
for crystal polymorphism or pseudopolymorphism. This can be achieved by interacting 
the drug with various solvents that present with unique physicochemical properties. 
Nevirapine has three polymorphic forms (Form I, II, III)28,29 and it has numerous 
solvates with (ethanol, acetonitrile, chloroform, tetrahydrafuron, toluene, mixed 
ethanol-water, ethyl acetate, dichloromethane, 1,4 dioxane and  water). 30,31  
To date there are five co-crystals of nevirapine that can be formed with saccharin, 
glutaric acid, salicylic acid, rac-tartaric acid and maleic acid32 and a cyclodextrin 
inclusion complex can be formed with beta cyclodextrin.33  Table 1.1 shows that the 
co-crystal and solvate of nevirapine have different structural parameters compared to 
nevirapine, thus these nevirapine derivatives exhibits unique physicochemical 
characteristics. As mentioned previously, physicochemical properties are pertinent 
towards dosage formulation.  
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(e.g. Nevirapine maleic acid co-crystal )  
Cylclodextrin Inclusion 
complex 
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 Nevirapine Nevirapine maleic 
acid co-crystal 
Nevirapine ethyl acetate 
solvate (2:1) 
A (Å)  6.9177(2) 7.4001(5) 7.7744(3) 
B (Å) 18.7759(5) 10.4599(7) 8.4447(3) 
C (Å) 9.6075(3) 23.256(2) 12.4449(5) 
Α (deg) 90.0 90 84.610(3) 
Β (deg) 97.026(1) 98.968(1) 89.455(3) 
ϒ (deg) 90.0 90 68.243(2) 
Table 1.1 Unit cell dimensions of nevirapine, nevirapine co-crystal and of 
nevirapine solvate32, 33 
Formulation of dosage forms have been attempted with two of these nevirapine 
derivatives, i.e. the cyclodextrin inclusion complex33 and the nevirapine glutaric acid 
co-crystal.34 To further the knowledge base on the formulation of the nevirapine 
derivatives, a nevirapine co-crystal will once again be used, however this time in a 
liquid dosage form.   
1.8 Choice of liquid dosage form  
A formulation scheme to strategize working with early formulations along with 
enhancement techniques was illustrated by Li et al.35 The study emphasized the drug’s 
physicochemical properties required prior to development work (Fig 1.8).  
It states that for oral dosage forms, a solution formulation is preferred. It commences 
with aqueous media and buffers. If there is no good solubility, then solution approaches 
such as co-solvents, cyclodextrins or micelles are utilized.35 For a suspension 
formulation, options such as conventional suspensions and micronized suspensions 
exist. However, the combined pH of the formulation with excipients needs special 
attention. Thereafter, if no solution vehicles are appropriate for formulation or if there 
is no adequate solubility, a novel preparation can be explored. Furthermore, the choice 
of dosage form is based largely on the drug compound used in the study.35  
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 Figure 1.8 Formulation scheme for drugs administered by oral route35 
 
The following section discusses the possibility of formulation of nevirapine as a liquid 
dosage form, applying the formulation scheme suggested by Li et al.35   
1.8.1 Formulation of nevirapine as a solution 
To form a solution, nevirapine has to be suspended in an aqueous or non-aqueous 
solvent. Nevirapine is a poorly soluble drug. It has an aqueous solubility of 0.123 
mg/mL. To get a therapeutic effect for a 12 kg child, a dose of 50 mg is required. If 50 
mg were to be dissolved in water, it would require 406 mL. This is not practical because 
almost half a litre of solution is required for one dose for a child. Therefore, formulation 
of a solution for nevirapine is not feasible. 
Drug/physicochemical /study 
purpose /dose, animal species
Solution (e.g. 
water, pH 
buffers)
Yes No
Cosolvents & pH, 
cyclodextrins & pH, 
micelles & pH
Yes No
Suspensions 
(e.g. 0.5% 
methylcellulose)
Yes No
Micronized 
suspension
Yes No
Novel formulations (e.g. nanosuspension) 
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Furthermore, since nevirapine exhibits pH dependent solubility, the drug is soluble at 
acidic pH values and at an acidic pH the drug is not suitable for consumption, hence it 
is not appropriate to formulate a solution.  
1.8.2 Formulation of nevirapine as an emulsion  
For a drug to be formulated as an emulsion, the drug has to be in a liquid form. This is 
not an option for nevirapine since it exists as a solid crystalline powder.  
1.8.3 Formulation of nevirapine as a suspension  
Suspensions are often selected as a pharmaceutical dosage form when the drug is 
insoluble in water or aqueous fluids and when attempts to solubilize the drug by the 
use of co-solvents, non-ionic surface active agents and other solubilizing agents would 
compromise the stability or safety.12 
Suspensions are also preferred in contrast to emulsions because they exhibit a higher 
rate of bioavailability when compared to solid dosage forms (Fig. 1.8).12 
 
 
Figure 1.9 Selection process of a liquid dosage form for nevirapine 
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Suspensions have an advantage in that it can be designed for organoleptic reasons such 
as to mask the bitter taste of the drug. Paracetamol and chloramphenicol are case in 
point scenarios, where the drug can be prepared in soluble form, but the bitter taste of 
the solution would easily prevent the patient from using the correct dose, whereas the 
dispersed or non-dissolved form is essentially tasteless.6  
Suspensions can also be designed for patients that have difficulty in swallowing due to 
certain pathologies particularly in the gastro-intestinal tract.6 Many patients suffering 
with HIV present with minor to major oral and throat infections which can cause pain 
while swallowing tablets.7 This is applicable in the case of nevirapine, where it can 
cause mouth ulcerations during the first 14 days.36 Suspensions would be suitable for 
these individuals. 
Suspensions pose an added advantage in that the dissolution of drug particles and 
subsequent absorption commence upon dilution into gastrointestinal fluids, unlike 
tablets and capsules where the dosage form has to first undergo disintegration.12 The 
large surface area of the dispersed drug ensures a higher degree of availability for 
absorption.  
1.9 Current production method of Viramune ® suspension  
Ingredient  Role  Amount g/100ml  
Nevirapine hemihydrate Active ingredient  0.10 –  50 
Carbomer 934P Viscosity enhancer 0.17 – 0.22 
Polysorbate 80 Wetting agent  0.01 – 0.20 
Sorbitol solution Adjust density  5.00 – 30.00 
Sucrose Sweetener 5.00 – 30.00 
Methylparaben Preservative  0.15 – 0.20 
Propylparaben Preservative  0.02 – 0.24 
Sodium hydroxide Buffering agent q.s. to pH 5.5 – 6 
Purified water, USP Vehicle  q.s. ad 100 ml  
Table 1.2 Production ingredients of Viramune® suspension37 
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Currently, nevirapine hemihydrate is used in preparation of the suspension through the 
pH modification method. It is prepared by heating a portion of purified water to 
approximately 70 °C and the methylparaben and propylparaben are added while 
constantly mixing. After the parabens have completely dissolved, the solution is 
allowed to cool down to less than 35 °C, and then the carbomer 934P is dispersed in 
the solution while mixing. The pH is adjusted between pH 5.5 - 6 with 20% sodium 
hydroxide solution. The gel is continually stirred for approximately 20 minutes and the 
pH is re-measured. The sorbitol solution is added while mixing followed by the 
addition of sucrose. The solution is mixed for 30 minutes. The polysorbate 80 is then 
dissolved in a portion of purified water, and the nevirapine is then added to the 
polysorbate 80 solution. This mixture is homogenized for at least 40 minutes. The 
nevirapine and polysorbate 80 drug concentrate is thoroughly blended into the 
carbomer gel. The suspension is adjusted to volume or weight with purified water and 
blended for 30 minutes.37  
1.10 Challenges with Viramune® suspension 
The anhydrous form of nevirapine when formulated in aqueous suspension, slowly 
converts to the hemihydrate form, yielding crystals of the hemihydrate which, over 
time, grows so large as to adversely affect drug dissolution and pharmaceutical 
performance, hence the nevirapine hemihydrate form is used in the formulation of 
suspensions.37 Possible adverse effects of excipients pose a problem in the current 
nevirapine suspensions. Sucrose can promote the formation of dental caries.38 The 
problem with suspensions is that 13 % of the dose remains in the cup; this is due to the 
viscosity of the suspension. Children are given doses according to weight, thus it might 
affect therapeutic outcomes.39   
1.11 Research objectives  
Given the major drawback of nevirapine which is poor solubility, nevirapine co-
crystals can be formed to counteract this problem. Furthermore, suspensions can be 
formulated to improve its bioavailability; the hypothesis is therefore to integrate these 
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two concepts, namely co-crystal formation into a suspension and prove that the 
preparation will remain stable during its shelf-life and have an enhanced effect upon 
dissolution.  
The objectives of this study are as follows:  
1.10.1 To develop a protocol to select an appropriate co-former to form the nevirapine 
co-crystal that is suitable for formulation of suspensions.  
1.10.2 To select an appropriate co-former and formulate the nevirapine co-crystals 
with the chosen co-former.  
1.10.3 To scale-up formulation of the chosen co-crystal.  
1.10.4 To establish whether the co-crystal is retained in the suspension during a set 
shelf-life and attempt to protect the co-crystal in the suspension, if necessary.  
1.10.5 To assess the formulated co-crystal suspension according to the particle size, 
zeta potential, pH, rheology and viscosity according to USP 32 standards. 
1.10.6 To perform dissolution tests on the suspension according to USP 32 standards.  
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Chapter 2 Literature Review 
A pharmaceutical suspension is a coarse dispersion of finely divided solid particles of 
a drug dispersed in a liquid medium in which the drug is not readily soluble. An 
aqueous suspension is a useful formulation system for administering an insoluble drug 
such as nevirapine. A large surface area of a dispersed drug ensures high availability 
for dissolution and hence absorption.1  
2.1 Features of an ideal suspension  
Besides therapeutic efficacy, chemical stability of the components of formulation and  
aesthetic appeal of the preparation, a suspension should have the following features2:  
 A pharmaceutical suspension should settle slowly and should be readily 
dispersed upon moderate agitation of the container.  
 The particle size should remain constant throughout long periods of 
undisturbed standing.  
 It should be readily and evenly pourable and have no crystal growth.  
2.2 Factors affecting formulation of suspensions  
Suspensions are biphasic formulations, thus the challenges include both chemical and 
physical stability. Several factors that govern the formulation of an ideal suspension 
are depicted below.  
2.2.1 Particle size  
Drug particle size is an important factor that can influence the product appearance, 
settling rates, drug solubility, in vivo absorption, resuspendability and overall stability 
of the suspension.  
Finely divided drug particles dissolve at a greater rate and have higher relative 
solubilities than similar macroparticles.3 Particle size has to be fine in nature to ensure 
the production of a uniform suspension. Larger particles tend to settle faster due to the 
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gravitational force while smaller particles easily form a hard cake at the bottom of the 
container.   
Knowledge of the particle size distribution provides direction to the formulator.  The 
capability of measuring the particle size distribution is of definite value to the 
formulator since it is one parameter the formulator has control over, by milling and 
sieving. Wide distributions in particle size leads to high density suspensions whereas 
widely differing particle shapes leads to low density slurries.3  
Crystal growth can occur due to Ostwald’s ripening,3 which is the growth of larger 
particles at the expense of smaller ones due to a difference in solubility rates of different 
particle sizes (Fig. 2.1). Change from one polymorphic form to another can also cause 
crystal growth.  
 
Figure 2.1 Ostwald’s ripening process 
Particle growth is a destabilizing process which can result from temperature 
fluctuations. Temperature fluctuations can change the particle size distribution and 
polymorphic form of the drug thus, altering the absorption rate and consequently 
bioavailability. Particle growth is of more importance when the solubility of the drug 
is dependent on temperature. Thus, when the temperature is increased, crystals of the 
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drug may dissolve and form supersaturated solutions which favour crystal growth. This 
can be inhibited by the addition of surfactants or polymers.3  
A particle size range of 50 to 75 µm has good flow properties for a suspension dosage 
form. The ideal particle size for suspensions is 1 to 50 µm.2 When the individual 
particles are smaller than this range, most solids tend to exhibit aggregation in the dry 
state. Particles in the range of 10-50 µm has increased surface free energy.3 The powder 
can become damp if there is a tendency to attract moisture, causing the particles to “ball 
up.”3 This can occur because the pores between powder particles become smaller with 
decreasing particle size which causes the surface area to become more accessible to 
liquid penetration.  
2.2.2 Particle shape 
Information of the shape of a particle is an important property since the shape can 
contribute to the understanding of the packing of the sediment and settling 
characteristics. In liquids, suspended material is seen as spherical shapes. Substances 
that are used to promote the stabilization of suspensions are termed suspending agents. 
These agents have rod-shaped or plate like structures. Rod-shaped structures act as 
suspending agents due to a large surface area, when in contact with water they produce 
a continuous network of rods that extends throughout the entire vehicle.4  
Ellipsoid shapes are also seen in colloids. Oval-shaped and spherical shaped powders 
flow with greater ease than needle-shaped powders and may enable processing of 
powders into a dosage form.5  
Shape and size can have an influence on the prospects for reversible change. Attraction 
between two dispersed particles will be affected by the surface characteristics of the 
particles. Particles that have the ability to exert attractive forces across a large surface 
will most likely result in greater attraction and adhesion forces.5 
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2.2.3 pH 
A well formulated suspension should exhibit excellent physical stability over a wide 
range of pH values. For drugs that possess ionizable acidic or basic groups, the pH of 
the vehicle influences drug stability or solubility.  A desired pH value is achieved by 
the use of a pharmaceutically acceptable buffer. The use of salts and buffers should be 
cautioned, because small changes in electrolyte concentration will modify the surface 
charge of suspended particles. A pH of 4-10 indicates stability.3 
Another consideration that should be made is that the viscosity of some materials 
changes as a function of pH. This is due to a concept known as the point of zero charge; 
this is the pH at which the net surface charge is zero. The pH range should be narrow 
because the magnitude of the charge on the drug particles can differ significantly with 
pH. Control of pH can prevent large changes during storage. Buffers are utilized to 
control potential changes in pH. Buffering components are selected on experimental 
basis so as not to adversely affect the physical stability of the final suspension.3 The 
amount of buffer capacity needed is usually between 0.01 and 0.1M. A combination of 
buffers can be used to get a wider range of pH.6 Furthermore, pH of the formulation 
should be considered as it may influence the dissolution of pH dependent drugs like 
nevirapine.  
2.2.4 Temperature  
Temperature is another factor that can affect long-term stability of suspensions.3 
Certain suspending agents can tolerate higher temperatures during processing. To bring 
about solubilisation of one ingredient the preparation may have to be heated and the 
long-term effect of such a process on the product must be evaluated, this is especially 
necessary for drugs that degrade at low temperatures. Degradation of the drug will not 
allow for the necessary therapeutic effect. With regards to physical stability, viscosity 
of suspensions generally decreases with an increase in temperature and thus, this is an 
important variable to consider during formulation.  
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2.2.5 Sedimentation rate  
Sedimentation has an effect on both the physical and functional properties of 
suspensions. To acquire a uniform dosage it is necessary to control sedimentation. 
Stokes’ law is an expression describing the resisting force on a particle moving through 
a viscous fluid and showing that a maximum velocity is reached in such a case.     
Stokes’ equation (Equation 2.1) states that (v) is the terminal settling velocity which is 
equal to the square of the diameter of the settling particle (d) times gravitational 
acceleration (g) multiplied by the difference in density of settling of solid and density 
of the liquid ( 𝜌𝜌 −  𝜌𝑠 ) divided by the viscosity of the dispersion medium(𝜂) (Fig. 
2.2).    
Equation 2.1 Stokes’ equation 𝑣 =  
𝑑2𝑔 (𝜌𝜌− 𝜌𝑠 )
18 𝜂
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Factors affecting particle according to Stokes’ law 
The various factors that contribute to the rate of settling are embodied in Stokes’ law. 
Stokes’ law can be used in an ideal setting, in which uniform, perfectly spherical 
particles settle without collision or producing turbulence with other particles, and 
without chemical or physical affinity for the dispersion medium. Stokes’ law may not 
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be applied to a lower size limit of about 0.5 μm. Suspensions with a concentration of    
2 g of solids per 100 mL may have conditions that conform to Stokes’ law. In 
suspensions greater than this concentration, particles interfere with one another and 
Stokes’ law can no longer be applied. Stokes’ law cannot be applied to the usual 
pharmaceutical suspension in which the particles are irregularly shaped and are of 
various diameters, where particles collide and produce turbulence. Yet, the general 
concepts of the equation give an indication of the factors that are important to the 
particles in a suspension and give an idea to the possible modifications that can be made 
to a formulation to decrease the rate of sedimentation.2 
The velocity of a particle can be reduced by decreasing particle size and minimizing 
the difference between the densities of the solid and the liquid. The rate of descent of 
particles is proportional to the density of the particles in a suspension. The density of 
the solid is constant but changing the density of the liquid so that it is similar to the 
solid will minimize the difference between the two densities, thus leading to low 
velocity. Settling velocity is proportional to the second power of the particle diameter, 
hence agglomerates and flocculates will settle more rapidly than dispersed particles. 
Gravity and buoyancy affect the particle thus it could either have an upward movement 
(creaming) or a downward effect (sedimentation).3  
In pharmaceutical suspensions where aqueous vehicles are used, the density of the 
particles is generally greater than that of the vehicle. This is a desirable feature because 
if particles have a lower density than the vehicle, the particles would tend to float and 
floating particles are difficult to distribute uniformly.  
The rate of sedimentation can be reduced by increasing the viscosity of the dispersion 
medium. Viscosity can be increased by altering the vehicle and the solid particles. As 
the proportion of solid particles increases, so does the viscosity. A product with too 
high a viscosity is not desirable because it is difficult to redisperse the suspension. 
Thus, increase in viscosity should be done within limits of practicality.3  
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2.2.6 Physical stability  
Suspensions are thermodynamically unstable systems. At the time of examining the 
product, it is only the apparent stability that is being assessed.  
Suspensions do not form spontaneously. Suspensions may appear to remain stable for 
a long period of time; however, thermodynamics dictates that it will change to a lower 
energy state. These changes could either be reversible or irreversible. A large amount 
of energy would be required to get out of the maximum or minimum energy state. 
However, if the change is slow enough relative to the anticipated shelf life, then the 
thermodynamics may have little practical influence.3  
In a suspended system, particles are thermally mobile and can occasionally collide due 
to their Brownian motion. As the mobile particles approach each other, both attractive 
and repulsive forces are at work. If the attractive forces are greater than repulsive 
forces, agglomerates can grow in the suspension. This phenomenon is termed 
‘flocculation’ or ‘coagulation’ and it represents an unstable system. If repulsive forces 
are greater than attractive forces, a more stable suspension will occur. Thus the balance 
between these forces specifies the overall characteristics of the system.3  
Physical stability of a suspension can be adjusted by an alteration in the dispersed phase 
rather than major changes in the dispersion medium.  Adjustments that can be done to 
the dispersed phase are change in particle size, uniformity of particle size and 
separation of particles so that they do not aggregate and form a solid mass upon 
standing.2  
2.2.7 Chemical stability 
Insoluble drug materials when suspended in a liquid medium have some intrinsic 
solubility which may trigger a chemical reaction such as hydrolysis, which leads to 
degradation.  
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Particles that are completely insoluble are unlikely to undergo chemical degradation. 
Decomposition of a suspension is assumed to be solely due to the amount of the drug 
dissolved in the aqueous phase. The solution is responsible for drug decomposition and 
the drug will be released from insoluble suspended particles within the range of 
solubility.3  
In a zero-order system the rate of a process such as decomposition is independent of 
the concentration of the reactants.7 Primarily suspensions behave as a zero order system 
because the amount of drug in the solution remains constant in spite of the 
decomposition with time.3 However, once all the suspended particles have been 
converted into the drug in solution, the entire system changes from zero order to first- 
order. A first-order system is defined when the rate of a process is determined by one 
concentration term.7 Thus, suspensions are known to have apparent zero-order kinetics. 
The suspension is stable until the system follows first-order kinetics. If the suspensions 
are concentrated, the system will require more time to convert from zero- order to first-
order. This is why a concentrated suspension is stable enough on the market as 
compared to the diluted one. Concentrated suspensions affects physical stability of 
suspensions, thus production should optimize both physical and chemical parameters 
of the dispersed particles to attain the desired stability of suspensions.3   
2.2.8 Temperature stability  
Increasing the temperature may lead to flocculation of sterically stabilized suspensions 
(suspensions that are stabilized by non-ionic surfactants). When a suspension is heated, 
the energy of repulsion between the particles is reduced due to dehydration of the 
polyoxyethylene groups of the surfactant. Increasing the temperature brings the 
polyoxyethylene groups closer and consequently reduces the space available for the 
drugs in this region. The attractive energy is increased and thus, the particles flocculate.  
During the freezing process, particles can overcome the repulsive barrier formed by 
ice. It forces the particles in close proximity to experience strong attractive forces and 
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form aggregates. For example, when the ice melts, particles remain as aggregates 
unless work is applied to overcome the attractive force.3  
2.2.9 Viscosity and rheology 
Viscosity is expressed as the resistance of a fluid to flow under an applied stress. 
Viscosity is a property arising from friction between neighbouring particles moving at 
different velocities. Fluids with no resistance are termed, ideal fluids. All fluids that 
have viscosity are termed, viscid. It is termed viscous if it has a viscosity greater than 
water, if it is less than water it is termed, mobile.  The viscosity of a suspension should 
be high at low shear rates so that the particles settle slowly or remain suspended in the 
continuous phase.3  
The rheology of a particular product can affect patient acceptability, physical stability, 
and even biological availability. Viscosity has been shown to affect absorption rates of 
drugs from the gastrointestinal tract.8 When classifying materials according to types of 
flow and deformation, it is customary to categorize them as Newtonian or non-
Newtonian systems.8 This is dependent on whether or not their flow properties are in 
accordance with Newton's law of flow.8 Newton’s law of flow states that the higher the 
viscosity of a liquid, the greater is the force per unit area (shearing stress) required to 
produce a certain rate of shear.8 
However, the majority of fluid pharmaceutical products are not simple liquids, thus 
they do not follow Newton's law of flow. These systems are referred to as non-
Newtonian. Non-Newtonian behaviour is generally exhibited by liquid and solid 
heterogeneous dispersions such as colloidal solutions, emulsions, liquid suspensions, 
and ointments.8 
In Newtonian fluids, viscosity is constant over a wide range of shear rates whereas in 
non-Newtonian fluids, they exhibit a variety of different correlations between shear 
stress and rate. When non-Newtonian materials are analysed in a viscometer they 
exhibit four types of flow viz.  plastic, pseudoplastic, dilatant and thixotropic.8 
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In plastic or Bingham type of flow, fluids that have linear shear stress/shear strain 
require a finite yield stress before they begin to flow. As seen in figure 2.3, the graph 
for plastic flow does not start from the origin, implying that it requires force for it to 
flow. An example of this type of flow is seen in toothpastes, where a force is required 
to expel it out of the tube. In pseudoplastic type of flow, apparent viscosity decreases 
with increased stress. This can be seen in polymers in solution, an example of this is 
tragacanth. In dilatant type of flow, apparent viscosity decreases with increased stress. 
An example of this type of flow is seen in oobleck’s mixture, where it appears to be 
runny in nature when no stress is applied and once stress is applied it behaves as a solid 
(Fig. 2.3). 
 
Figure 2.3 Types of flow for Newtonian and non-Newtonian material 
A thixotropic fluid is a fluid which takes a finite time to attain equilibrium viscosity 
when introduced to a step change in shear rate. The longer the fluid undergoes shear 
stress, the lower its viscosity. Many gels and colloids exhibit a stable form at rest but 
become a fluid when agitated.8 An example of this is bentonite calamine lotion. 
Thixotropy is of particular value for suspensions. During shearing, the yield stress is 
exceeded and the suspensions flow.3 The structure begins to re-form after the 
termination of shear. However, it does not reform immediately. It takes time to rebuild 
the order or structure that existed when the system was at rest. As long as it rebuilds 
itself to a point at which sedimentation is avoided or substantially diminished one can 
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achieve a pharmaceutical suspension of good quality. A thixotropic agent ensures the 
rate at which the structure is rebuilt.3 An example of a thixotropic agent is colloidal 
silicon dioxide.  
2.3 Theory of suspensions 
The initial rate of settling of flocculated particles is determined by the floc size and the 
porosity of the aggregated mass. The rate is also dependent on compaction and the 
rearrangement processes within the sediment. Sediment volume (F) is defined as the 
ratio of the final volume of sediment (Vu), to the original volume of the suspension 
(Vo) before settling. Since sedimentation volume is a ratio, it can have values ranging 
from less than 1 to greater than 1. F is normally less than 1; this means that the ultimate 
volume of sediment is smaller than the original volume of suspension.8  
If F=1, the volume of sediment in a flocculated suspension is equal to the original 
volume of the suspension. The product is then said to be in flocculation equilibrium 
and shows no supernatant on standing (Fig. 2.4).8  
 
Figure 2.4 Flocculated and deflocculated suspensions 
Controlled flocculation can be produced to prevent the formation of compact sediment 
that is difficult to redisperse. Flocculation can be achieved by use of electrolytes, 
surfactants and polymers. Optimum concentration of electrolytes, surface active agents 
or polymers should be used, since change in these concentrations may change a 
suspension from a flocculated to a deflocculated state.8  
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The controlled flocculation approach is capable of achieving the desired physical and 
chemical requisites of a pharmaceutical suspension. If the sedimentation volume is not 
close to or equal to 1, the product may look unsightly. A suspending agent may aid in 
retarding the sedimentation of flocs.8  
Electrolytes act as flocculating agents by decreasing the electrical barrier between the 
particles, thus decreasing the zeta potential and forming a bridge between adjacent 
particles that link them together in a loosely arranged structure (Fig. 2.5). Non-ionic 
and ionic surface active agents can also induce flocculation of particles.8 The zeta 
potential decays exponentially with increase in the distance from the surface of the 
particle. The rate of decay is dependent on the electrolyte content.  
 
Figure 2.5 Zeta potential versus distance from particle surface for electrolytes 
2.3.1 Wetting process  
Wetting of suspended particles is important for proper dispersion. Poor wetting leads 
to poor dissolution and thus, slows down the release of a drug. For the process of 
wetting to occur, particles must be separated into finely divided particles and each 
particle should be individually wet.  
The first step involves wetting of the solid particles by the liquid medium. A layer of 
air is adsorbed on the surface of the particle and this makes it difficult to disperse solid 
particles in liquid. High density particles will float on the surface of the liquid until the 
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layer of air is displaced completely. Entrapment of air on the particle allows particles 
to rise to the surface of the dispersion medium causing particle de-aggregation and can 
lead to instability. A wetting agent or surface active agent serves to remove air from 
the surface and enable easy penetration of the liquid into the solid.3 To do this the liquid 
must displace air at the surface of the solid (Fig. 2.6). An example of a surface active 
agent is polysorbate 80.   
 
Figure 2.6 Effects of adding a wetting agent to solid particle 
The tendency of a solid to be wetted by a liquid is a measure of the interaction of the 
substances. Hydrophobic particles are referred to as particles that are not easily wetted 
by an aqueous vehicle even after the removal of adsorbed air. Hydrophilic particles do 
not require the use of surface active agents because they are easily dispersed in the 
liquid after the removal of adsorbed air. If the solid is hydrophilic it will be wet more 
easily by an aqueous medium. If it is hydrophobic, as in the case of nevirapine, it will 
be more easily wetted by an organic or nonpolar liquid. Use of surface active agents is 
recommended to promote proper wetting of hydrophobic substances. 
The angle that the liquid makes with the solid surface is called the contact angle (Fig. 
2.7). If the contact angle is greater than zero the solid is completely wet by the liquid.  
If the angle is close to 180°, the solid substance would be described as unwettable by 
the liquid in question. If it is less than 90° wetting is spontaneous.3  
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Figure 2.7 Contact angles between solid and liquid 
2.3.2 Brownian motion  
Brownian motion is the random movement of particles. The erratic motion can be 
observed microscopically with particles from 2 to 5 μm.8 This occurs due to the 
bombardment of particles by the molecules of the dispersion medium. The velocity of 
the particles increases with a decrease in particle size. Brownian movement offsets 
sedimentation to a measurable extent at room temperature by keeping the dispersed 
material in random motion. To decrease the Brownian movement, an increase in the 
viscosity can be applied. For example, Brownian motion can be counteracted by the 
addition of 50 % glycerin solution which has a viscosity of about 5 cP.8   
2.3.3 Electrokinetic properties  
Solid particles may acquire a charge due to the presence of a liquid by adsorption of an 
ionic species present in the liquid or by ionization of functional groups of the solid 
particles. Addition of electrolytes allows the solid to become positive or negatively 
charged. In ionization of functional groups of the solid particles, the total charge is a 
function of the pH of the liquid.  
If the solid has a positive charge and anions are present in the liquid, the anions are 
attracted by positively charged particles and they repel the cations. Adjacent to the 
surface of a solid is a layer of tightly bound solvent molecules known as counter ions. 
These are ions of opposite charge to that on the surface layer (Fig 2.8).  
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Two layers are formed at the interface and this is known as the electrical double layer. 
The intensity of electrical forces decreases as the distance increases from the surface 
of the particles. A uniform distribution of ions is achieved and this is known as the zone 
of electroneutrality.3  
The DLVO theory named after Derajaguin and Landau, Verwey and Overbeek gives a 
better understanding for controlling the rate at which particles aggregate depending on 
the distribution of charge.7 
 
 
 
 
 
Figure 2.8 Illustration of the electrical double layer 
The DLVO theory relates the balance of attractive and repulsive forces. Attractive 
forces are seen in agglomerated suspensions and repulsive forces are seen in systems 
that do not show agglomeration, coagulation or flocculation.  
Zeta potential is the difference between the potential of the ions at the tightly bound 
layer and the electroneutral region (Fig 2.9). This plays a significant role in the 
formulation of suspensions. Zeta potential reflects the future stability of suspensions. 
Shear plan Counterion 
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Zeta potential governs the degree of repulsion between adjacent, similar charge and 
solid particles.7  
 
Figure 2.9 Zeta potential  
If the zeta potential is reduced below a critical value, the force of attraction is greater 
than the force of repulsion and particles come together and form a flocculated 
suspension. Electrolytes reduce zeta potential below critical value and the attractive 
forces are greater than repulsive forces causing flocculation to occur.7  
Repulsive forces have a stabilizing influence on suspensions because they work against 
the aggregation of suspended particles. These forces originate from several sources 
such as steric hindrance (the hindering of a chemical reaction, as a result of the 
arrangement in space of the atoms of the reacting molecules) to the close approach of 
particles and electrostatic repulsion. Stabilization requires the net repulsive term to 
exceed the net attractive term.7  
If a polar medium such as water is used, various electrical interactions can occur. 
Functional groups at the surface of a particle can ionize in the presence of a polar liquid. 
The pH of the aqueous medium typical of suspensions is important in this instance. 
Low pH systems will promote a positive charge on the dispersed particle while high 
pH systems will promote a negative charge.7  
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According to the DLVO theory (Fig 2.10), the forces on colloidal particles in dispersion 
are due to the electrostatic repulsion and London-type Van der Waals attraction. These 
forces result in potential energies of repulsion and attraction between particles, VR and 
VA, respectively.
7  
 
 
Figure 2.10 DLVO theory 
There is a strong potential of attraction near the origin and a high potential barrier of 
repulsion at moderate distances. A shallow secondary trough (secondary minimum) of 
attraction can be observed at longer distances of separation. The presence of a 
secondary minimum is important in controlled flocculation. Addition of electrolytes 
can cause coagulation of colloidal particles, however, mixing of oppositely charged 
colloids result in mutual agglomeration.3 
Highly energetic particles tend to group together, so as to decrease the total area and 
reduce the surface free energy. Particles in a liquid suspension tend to flocculate. 
Particles that adhere by stronger forces form aggregates. The formation of any type of 
agglomerate, either floccules or aggregates, is a measure of the system’s tendency to 
reach a more thermodynamically stable state (ΔG = 0, where ‘G’ is surface free 
 
 
 
 
  
47 
 
energy). To reach a stable state, the system has to reduce the surface free energy and 
equilibrium has to be achieved. This can be accomplished by reducing interfacial 
tension or decreasing interfacial area. Interfacial tension can be reduced by addition of 
a surfactant, however, ΔG = 0 cannot be achieved ordinarily. A suspension with 
insoluble particles usually possesses a finite positive interfacial tension and particles 
tend to flocculate.8   
The forces on the surface of a particle affect the degree of flocculation and 
agglomeration in a suspension. Repulsive forces arise from the interaction of the 
electrical double layer surrounding each particle.  
When repulsion energy is high, the potential barrier is also high, thus collision of the 
particles is opposed. The system will remain deflocculated and when sedimentation is 
complete, a formation of closely packed smaller particles filling the voids between the 
larger ones is formed. The particles at the bottom of the sediment are gradually pressed 
together by the weight of the ones above; the barrier is thus overcome by allowing the 
particles to come into close contact with each other. 
To resuspend and redisperse this compact cake, it is necessary to overcome the high 
energy barrier. However, this is not achieved easily by agitation and particles tend to 
remain strongly attracted to each other and form a hard cake due to the accumulation 
of London-type Van der Waals attraction.8  
When particles are flocculated, the energy barrier is still too large to be surmounted 
and the approaching particle remains in the secondary energy minimum which is at a 
distance of separation of 1000 to 2000 Å. This distance is adequate to form loosely 
structural flocs.8  
In deflocculated suspension systems, the dispersed particles carry a finite charge on 
their surface. When particles approach one another, they experience repulsive forces. 
These forces create a high potential barrier, which prevent the aggregation of the 
particles. When sedimentation takes place, the particles form a closely packed 
arrangement.8  
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The lower portion of the sediment gets pressed by the weight of the sediment above. 
This creates a force that is sufficient to overcome the high energy barrier. After this 
energy barrier is achieved the particles come in close contact with each other and 
establish strong attractive forces. This leads to the formation of a hard cake in a 
deflocculated system.  
In the flocculated system, particles are not able to overcome the high potential barrier, 
they also remain loosely attached with each other forming flocs known as the secondary 
minimum. Particles at this stage still experience a high energy barrier but allow the 
suspension to be easily re-dispersed. A secondary minimum flocculation is desirable 
for a suspension. This is favoured by particles greater than 1 µm.8  
The deflocculated system provides the apparent stability, while the flocculated system 
is necessary to achieve the long-term stability. Hence, controlled flocculation 
represents both properties.   
Bearing in mind the above information pertaining to the theory and the factors affecting 
the dosage from to be formulated i.e. suspensions; the next segment provides a 
literature review of the type of supramolecular derivative to be used as the active 
ingredient in the formulation of the aforementioned dosage form i.e. co-crystals, 
commencing from the broad umbrella of supramolecular chemistry and focusing on 
crystal engineering. 
2.4 Supramolecular chemistry   
Supramolecular chemistry is known as the chemistry of the intermolecular bond, 
covering the structures and functions of the entities formed by association of two or 
more chemical species.9 The term supramolecular signifies that which is beyond the 
molecule. As of present, supramolecular chemistry encompasses the study of molecular 
crystals applicable to various fields such as solid-state chemistry, crystal engineering 
and materials science.10  
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The concurrent use of supramolecular chemistry and crystallographic techniques has 
given rise to a niche research field area known as crystal engineering.11 Chemistry deals 
with molecules while crystallography deals with crystals, which are extended, ordered 
assemblies of molecules. The relationship between chemistry and crystallography is 
therefore the interplay between the structure and properties of molecules on one hand 
and those of extended assemblies of molecules on the other.12  Though it is still 
considered a young research field, extensive research has already been done in this area 
and thus it can be considered as a scientific genre on its own.  
2.4.1 Crystal engineering  
The term crystal engineering was first used by Schmidt,11 who wrote a full scientific 
paper in this area. It postulated that under suitable conditions, molecular recognition 
events could be the major factor leading to crystal formation. Lehn9 further took this 
concept and elegantly defined it as the “chemistry beyond the molecule, bearing on the 
organized entities of higher complexity that result from the association of two or more 
chemical species held together by intermolecular forces.” The weak intermolecular 
interactions that form supramolecules are the same as those that act in the formation of 
crystals, thus the link between supramolecular chemistry and crystal engineering 
became obvious.  
The original objective of crystal engineering was to design organic molecules which 
would adopt particular crystal structures within which topochemical reactions could 
take place, leading to regioselective or stereoselective products. Due to its broadened 
scope today, Desiraju has defined it as ‘the understanding of intermolecular 
interactions in the context of crystal packing and in the utilization of such 
understanding is the design of new solids with desired physical and chemical 
properties.’10                                                                                    
Each crystal structure is the result of a delicate balance between a range of 
intermolecular forces, many of which are weak and non-directional. A small change in 
the molecular structure can trigger unpredictable changes in the extended crystal 
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structure. Thus, an improved understanding of the strength, directional behaviour, and 
structural influence is the very essence of non-covalent forces that is the underlying 
focus for initial research into crystal engineering.13  
 
Figure 2.11 Schematic illustrations of salt, solvate, co-crystal and polymorph14 
Application of crystal engineering of an API can result in a salt, solvate, co-crystal or 
a polymorph. Figure 2.11 illustrates the various modifications that can be applied to an 
API. A pharmaceutical drug in the salt form is an ionisable drug that has been combined 
with a counter-ion to form a complex.15 A drug that shows an alternative packing 
arrangement in the crystal lattice than that of the same molecule is known as a 
polymorph.16  A solvated drug is formed when a material is crystallised and in the 
process of crystallisation, solvent becomes trapped in the crystal lattice.7 If the solvent 
used is water then the resulting drug is called a hydrate. A co-crystal is a multiple 
component crystal in which all components are solid under ambient conditions when 
in their pure form.17 More information regarding co-crystal follows, as this was the API 
derivative used in this study.  
2.4.2 Supramolecular synthons 
Supramolecular synthons are structural units within supermolecules which can be 
formed or assembled by known or conceivable synthon operations involving 
intermolecular interactions.12 Synthons are kinetically defined structural units that 
convey the crucial features of a crystal structure, and a critical assumption is that the 
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synthon is a reasonable approximation to the whole crystal. The crystal structure in 
these cases may be viewed as a sequence of kinetically controlled events. Crystals are 
built when robust synthons are formed with strong and directional interactions. Once 
these are formed, they tend not to dissolve.12  This is followed by new synthons that 
are formed which involves slightly weaker and slightly less directional interactions. In 
this manner the building up of a crystal can be rationalized as a series of chemically 
reasonable and logical steps.12 
The intermolecular interactions that are used are the hydrogen bond, including its 
weakest variant, the C−H···π interaction,18 Van der Waals interactions,19 dipole−dipole 
interactions,20 and more recently the halogen bond.21   There has also been mention of 
interactions such as aurophilic22 and argentophilic23 forces and the cation···π 
interaction.24  
2.4.3 Co-crystals  
A co-crystal is a multiple component crystal in which all components are solid under 
ambient conditions when in their pure form.17 A pharmaceutical co-crystal consists of 
an API and one other component known as the co-former.25  
These components co-exist as a stoichiometric ratio of a target molecule and a neutral 
molecular co-crystal former(s) (Fig. 2.12).26  
 
Figure 2.12 Illustration of a co-crystal  
Pharmaceutical co-crystals are non-ionic supramolecular complexes that can be used 
to address solubility, stability and bioavailability issues in pharmaceutical development 
without changing the chemical composition and biological function of the API.25 
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A.  Co-crystal design  
The basic principle of supramolecular chemistry is the molecular recognition between 
complementary molecular fragments that give rise to self-organization of molecules to 
give a supramolecular function. Co-crystal formation is largely based on 
supramolecular structural assembly and heterosynthons (Fig 2.13). These can be 
identified through the Cambridge Structural Database.27 Examples of such 
supramolecular synthons include amide-amide dimers, carboxylic acid–amide dimers 
and pyridine-carboxylic acid dimers (Fig 2.13).  
 
(a) Homosynthons of acid-acid  
and amide-amide dimers 
 
(b) Heterosynthon of acid-amide 
dimers 
Figure 2.13 Schematic illustration of synthons between acids and amides 
The co-former interacts with the API by means of non-covalent interactions such as 
hydrogen bonds, ionic bonds, π-π or Van der Waals forces.28 The directing nature of 
the hydrogen bond in the solid-state, gives control over physical processes apparent in 
the crystalline form such as optical properties, thermal stability, solubility, colour, 
conductivity, crystal habit and mechanical strength.29  
The current advances in this arena have brought about the possibility to produce 
pharmaceutical materials by design. Thus, formation of co-crystals represents a 
potential route to achieve pharmaceutical materials with improved properties of 
interest.28  
During the design of co-crystals, Δ pKa and stereo-hindrance effect should be 
considered. Regarding Δ pKa, it is generally considered that, if the API and the co-former 
have a ΔpKa (pKa (base) - pKa (acid)) < 0, there will be negligible proton transfer and the 
molecular complex will be a co-crystal.28 If the ΔpKa > 3, there will be complete proton 
transfer resulting in complete ionization and formation of a salt. However, for the region 
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of ΔpKa between 0 < ΔpKa < 3, the ability to forecast whether the resulting complex will 
be neutral or charged is inadequate. In these instances, spectroscopic tools are required to 
probe the extent of proton transfer and ionization states to clarify if it is a salt or a co-
crystal.28  
The utilization of hydrogen bonding rules, synthons and graph sets contribute to the 
design and analysis of co-crystal systems.17  The cornerstone of co-crystal synthesis 
involves the formation of ternary phase diagrams for the equilibria involving the 
solvent. The ternary phase diagram is dependent on relative solubilies of the two 
components. The diagram below (Fig. 2.14) represents ternary phase diagrams from 
similar and different solubilities. The numbers 1 and 2 represent component 1 and 
component 2, respectively. Region A consists of a component 1 and solvent, region B 
consist of a mixture of component 1 and co-crystal, region C represents the co-crystal 
exclusively whilst region D consist of a mixture of component 2 and co-crystal, region 
E contains component 2 and solvent and region F is a solution. 30As seen in figure 2.12 
in area C, there is a greater chance of forming a co-crystal with components that have 
similar solubility as opposed to components with different solubilities.  
 
Figure 2.14 Schematic illustration of ternary phase diagrams of two 
components30 
Differences in ΔpKa, collaboration of heterosynthons and formation of ternary phase 
diagrams alone do not dictate the formation of a co-crystal. The ability of an API to 
form a co-crystal is reliant on a range of variables during the crystallization process 
different solubilities similar solubility 
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such as the API co-former ratio, solvents, temperature, pressure and crystallization 
technique.17  
B.  Preparation of co-crystals  
Co-crystals can either be prepared by using solvent based methods or solid based 
methods (Fig 2.15).17  
             
Figure 2.15 Preparation methods of co-crystals 
Slow evaporation 
Co-crystallization by evaporation of stoichiometric solutions is based on the use of 
solvents or solvent mixtures where the co-crystal congruently saturates and a pre-
requisite is that the components should have similar solubility in the solvent. In the 
case of components having non-equivalent solubilities, solution co-crystallization of 
equimolar solution may result in the formation of a single component crystal. However, 
there is a possibility of crystallizing a single reactant or a mixture of individual reactant 
and co-crystal. In these instances, reaction co-crystallization approach may be 
adopted.17 Nevirapine rac-tartaric acid co-crystals was prepared by this method.31 
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Cooling crystallization  
Cooling crystallization method involves manipulating the temperature of the 
crystallization system. This method has gained attention due to the potential of a large 
scale of co-crystal production. Large amounts of reactants and solvent are mixed in a 
reactor containing a jacketed vessel, the system is then heated to a higher temperature 
to ensure all the solutes are totally dissolved in the solvent and it is then followed by a 
cooling down step.17 Co-crystals will precipitate when the solution becomes 
supersaturated as the temperature drops down. An example of a co-crystal prepared by 
this method is caffeine and p-hydroxybenzoic acid.32  
Precipitation  
This involves recrystalization of the co-former and another component which is usually 
an API. Solvents include buffers (pH) and organic solvents. An example of a co-crystal 
prepared by this method is aceclofenac using chitosan as the solvent.33  
Neat grinding  
Neat grinding may also be referred to as dry grinding. It comprises of mixing 
stoichiometric amounts of co-former and API by grinding them together either 
mechanically or using a mortar and pestle.17 This method requires one or both reactants 
exhibiting significant vapour pressures in the solid state. An example of a co-crystal 
formed by this method is the theophylline co-crystals using oxalic acid as the co-
former.34  
Solvent assisted grinding  
This method is also referred to as kneading, solvent drop grinding or wet co-grinding. 
Co-crystal formation by grinding can be achieved by utilizing small amounts of an 
appropriate solvent. The addition of solvent enables the additional degrees of 
orientation and conformational freedom and open molecules at the various interfaces 
thus increasing the opportunities for molecular collisions.17 This is seen in the caffeine-
glutaric acid polymorph.35 
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In comparison to the slow evaporation method, little solvent is used in the former 
method. Thus, it is a cost-effective and a “greener” method. Co-crystals allows 
companies to practice green chemistry, by eliminating the need for use of solvent in a 
chemical reaction and thus reducing the cost of the material as well as the costs of 
dealing with solvent waste.36  
Vapour diffusion  
A solution containing the compound to be crystallized in a solvent is positioned in an 
open tube stored in a desiccator containing a small amount of the solvent. This second 
solvent should be less dense than, and miscible with, the first solvent. As solvent 
equilibrium is reached, the non-solvent diffuses through the vapor phase into the 
solution, and saturation or supersaturation can be achieved. An example of a co-crystal 
formed by vapour diffusion method is diclofenac co-crystals.37  
Twin screw extrusion 
This process is a recommended procedure for scaling up. It is a relatively novel method 
that was explored. Extrusion can be considered as an efficient, scalable and an 
environmentally friendly process. Parameters such as screw design, temperature and 
residence time affect the formation of co-crystals.38 A high mixing screw design was 
used to enhance surface contact between co-crystal components in the extrusion barrel. 
Temperature for the caffeine–oxalic acid co-crystal system was set to 75 °C throughout 
the screw zones.  
Extrusion may be considered as an efficient, scalable, and environmentally friendly 
process for the manufacture of co-crystals compared to solvent crystallization methods. 
Hot melt extrusion 
This method uses the application of heat and pressure to melt a substance and force it 
though an orifice in a continuous process. An example of a co-crystal formed through 
hot melt extrusion is ibuprofen– nicotinamide co-crystal. A single-step, scalable, 
solvent-free, continuous co-crystallization and agglomeration technology was 
developed for this co-crystal using the hot melt extrusion method.  
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C.  Identification of co-crystals 
In certain instances, co-crystal formation is visibly apparent due to the changes in 
physical properties of the new material. This is seen in the formation of a red co-crystal 
of acetaminophen and 2,4-bipyridine dicarboxylic acid, while the individual 
components are white in colour.39 However, it is superior to confirm the formation of 
co-crystals with a wide array of techniques available.  
Single-crystal X-ray diffraction, powder X-ray diffraction and thermal methods such 
as differential scanning calorimetry, thermogravimetric analysis, hot stage microscopy, 
vibrational spectroscopy (Infra-red and Raman) and solid state nuclear magnetic 
resonance encompasses the full battery of techniques that are conventionally used to 
characterize co-crystals.30  
Out of these methods, single-crystal X-ray diffraction is a superior method which 
uniquely determines the crystal form and gives a 3D representation of the structure. 
Powder X-ray diffraction can determine the structure by Rietveldt refinement methods.  
Infra-red and Raman spectra can determine the fingerprint of a particular solid form. If 
particular bands are sensitive to the solid form, vibrational spectra are useful to 
distinguish between polymorphs and co-crystals.30 Differential Scanning calorimetry 
is useful in detecting phase changes that do not result in a change in mass. It is also 
useful in giving an accurate temperature for melting and onset. Thermogravimetric 
analysis is beneficial for determining the onset temperature of co-crystal 
decomposition and loss of volatile component. The stoichiometry of the co-crystal can 
also be established.  Solid state nuclear magnetic resonance can give information on 
chemical shift values for particular solid forms.30  
D.  Advantages of co-crystals  
Co-crystals are in their crystalline form hence they are more stable than their 
amorphous form. Co-crystals are stable because both the solids are ambient at room 
temperature.17 All types of API molecules, irrespective of their ionization capability 
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can form co-crystals. There is no need to make or break covalent bonds since they are 
formed by non-covalent bonding.17 Additionally, there are no by-products involved.17 
Co-formers can be chosen based on their potential use as a pharmaceutical excipient.40 
Co-crystals are preferred over solvates for a number of reasons, solvates are volatile 
and susceptible to desolvation during storage and the solvent loss may revert to the 
amorphous phase. Whereas, co-formers used are unlikely to evaporate from solid-
dosage forms making phase separation and other physical changes unlikely.41  
Solvents used to make solvates are often at a concentration that is not approved by 
regulatory authorities and may have toxicological consequences.42 Whilst, several co-
formers used to make co-crystals are approved by the FDA and listed in the Generally 
Regarded As Safe (GRAS) list.43  
Co-crystals have favourable properties over salts because, formation of salts requires 
the presence of ionisable sites while co-crystals can be employed to acidic, basic and 
even non-ionizable molecules.17 Moreover there are a limited number of counter ions 
available for salt formation.17 
Co-crystals can be patented hence broadening pharmaceutical landscapes. This is 
particularly advantageous for companies that are dependent on rigorous intellectual 
property protection for safeguarding the product revenues; this is highly pertinent to an 
industry which combines extensive regulatory challenges, high research and 
development costs, and inherent risks. Patents are a mechanism that gives the right to 
exclude others from practising a patented invention and affords an economic incentive 
to the inventor.44 Further information regarding co-crystals and intellectual property 
are outlined in the concluding section of this chapter.  
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The ability to modify the solid-state arrangement of molecules provides a way to 
control the intrinsic mechanical and physical properties of solids.45 Table 2.1 depicts 
some examples of the active ingredient that can be enhanced by co-crystal formation.  
Active ingredient of co-crystal Property of drug enhanced 
Fluoxetine Hydrochloride solubility 46 
Benzoquinone colour47 
Adefovir Dipivoxil kinetic stability48  
Caffeine hygroscopicity49  
Theophylline relative humidity34  
Paracetamol compressibility50  
Nicotinamide  thermal stability 51 
AMG-517 decrease in required dose52  
Itraconazole solubility and bioavailability53 
Ibuprofen  moisture sorption and tableting 
behaviour54 
Carbamazepine dissolution rate and suspension 
stability55  
Pyrazinamide –Difunisal 
(drug-drug co-crystal)  
decreased side effects and improved 
aqueous solubility56  
Table 2.1 Example of co-crystals and the property enhanced 
Hence, there is well established evidence that co-crystals can be developed to improve 
certain properties of drugs. Nearly ten years ago, Datta et al. mentioned that there has 
not yet resulted the design of crystals with desired mechanical properties.57 Presently, 
there are a number of publications indicating that co-crystals have been able to improve 
tableting properties. Examples of these are co-crystals of ibuprofen-flurbiprofen and 
caffeine-oxalic acid.58 This indicates the progress of pharmaceutical landscapes. To 
further the progress already made, this study aims to investigate co-crystal’s usage in 
a liquid dosage form.  
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E. Delivery and integrity of co-crystals  
Literature indicates that the behaviour of formulated co-crystals has received minimal 
attention in the pharmaceutical arena. However, this is on route to change as co-crystals 
are in the development pipelines of pharmaceutical companies.59  
Co-crystals have been successfully formulated in solid dosage forms. In 2007 
carbamazepine-saccharin co-crystals which has been one of the pioneer prototypes of 
co-crystals was formulated as a tablet.55 Another case in point illustration of a co-
crystal tablet with superior tabletting properties is theophylline-methyl gallate co-
crystal.34 In 2015 prulifloxcin co-crystals were formulated as an immediate release 
tablet.60 Danazol co-crystal has been formulated with controlled supersaturation by 
preparing aqueous suspensions and capsules.61 There has been evolvement of 
formulation of co-crystals from tablets and capsules to most recently immediate release 
from tablets. Quality control has also been ascertained for these co-crystal tablets. 
However, for the supersaturation preparations no quality control has been performed.  
For successful delivery of co-crystals it is imperative for a co-crystal to be delivered 
intact. In addition to this, the FDA requires data to show that there is complete 
dissociation of the API from its excipient prior to reaching the site of action for 
pharmacological activity.62 Therefore, co-crystals need to be intact until dissolution of 
the drug takes place.  
Co-crystals by definition are crystalline solids formed by non-covalent bonds and when 
formulated as a solid dosage form it is exposed to other excipients which are typically 
solid in nature. Thus, in the case of a solid dosage form the integrity of co-crystals 
formulated in the solid dosage form is not problematic. However, co-crystal 
dissociation into the amorphous form and co-former can be detected upon storage under 
high humidity conditions.63 Thus, regarding solid dosage forms the integrity of the co-
crystal is challenged during storage and not necessarily during the formulation process 
itself.   
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Conversely, regarding formulation of co-crystals in a liquid dosage form, co-crystal 
disproportionation may occur when co-crystals are present in a liquid phase.64 Due to 
the physical interaction, in particular the non-covalent bonding between the API and 
its co-crystal former, these pharmaceutical co-crystals are sensitive to rapid or slow 
dissociation in an aqueous microenvironment losing their effects prior to oral 
administration.65 
The target of pharmaceutical development is to administer pharmaceutical co-crystals 
in formulations where the integrity of the co-crystal is ensured as much as possible. In 
a study done by Márta Venczel the physical integrity of the co-crystal during high shear 
wet granulation process was investigated. In cases where the integrity of co-crystals is 
compromised, cremophor ELP which is used as a solubiliser may be employed to 
ensure the integrity of the co-crystals.65 
The European Medicines Agency also advises that the integrity of the co-crystal during 
the entire manufacturing process should be experimentally confirmed.66 Keeping the 
integrity of a co-crystal as pharmaceutical ingredients after the manufacturing process 
is essential to ensure advantages like faster dissolution kinetics and higher 
bioavailability.  
The faster solubility and dissolution kinetic of co-crystals is responsible for higher 
absorption therefore keeping the integrity of the co-crystal as an API is essential to 
reach the targeted effect and ensure the robustness of the formulation.65 
F. Scaling up of co-crystals  
For co-crystals to be industrially beneficial, the robust preparation of bulk co-crystal 
powders is a prerequisite. Further research is necessary to develop scale-up co-crystal 
systems and implement manufacturing of final dosage forms on commercial scale.67 
Additional developments in screening methodology will further elevate the profile of 
co-crystals on the pharmaceutical and intellectual property landscapes.44 Co-crystal 
screening methods such as slurry conversion, evaporation, and liquid assisted 
grinding/sonication may not be applicable to co-crystal scale-up.  
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Reasonably few studies have been reported on co-crystal scale-up. The most common 
scale-up technique is solution co-crystallization. However, this method requires 
significant development, which can hinder initial discovery and early development in 
the pharmaceutical industry.68 
According to Leung and co-workers68 scaling up of potential co-crystal leads involves 
solvent selection followed by determination of the critical region on the ternary phase 
diagram within which pure co-crystals can be isolated. They developed a general 
method for selecting solvents for co-crystallization and a method for rapid 
determination of the region of stability of co-crystals on the ternary phase diagram of 
API, solvent and co-former. This resulted in a scale-up to 1−2 g of a co-crystal lead. 
From an industrial perspective, chemical engineers are concerned with implementation 
of processes that are developed in the laboratory. As with any other scale-up process, 
co-crystal scale-up requires a proportional amount of API.  However, for some reason 
API’s exhibit differences when produced on a small scale, such as a laboratory scale 
as opposed to a large scale. Hence, scale-up of an API from a laboratory scale 
(milligram) quantity to a large scale (kilogram or ton scale) in a plant without changing 
its optimized properties and reproducibility at an economical level is a major challenge 
in the pharmaceutical industry. Industrial scale-up processes such as cooling, 
antisolvent or reactive crystallization are done in batches.69 The batch method is the 
most common method, however the issue of batch-to-batch variability is a cause of 
concern.  
On the other hand, continuous processing has advantages over batch processing, they 
require smaller process equipment and thus the cost of the equipment may be lower.69 
Continuous processing offers enhanced reproducibility of the crystalline material. 
In order to implement scale-up processes in a pharmaceutical industry, data from 
laboratory activities such as purity, size distribution, shape and crystal form will be 
required.69 As rightly noted by Chen et al. factors such as time, reactant addition, 
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mixing, stability, centrifuging, drying, maintenance of temperature, pH, water content, 
and other related parameters are pertinent in scaling up. 
With regards to time, due to larger volumes of materials being crystallized, materials 
require more time in slurry prior to solid-liquid separation. During the addition of 
reactants, the magnitude of heat released or absorbed must be observed to ensure it is 
a controlled process. The author also suggests that thermal stability of raw materials 
should be pre-determined to detect endothermic or exothermic behaviour.69  
Mixing of solutions and slurries are a critical part of scale-up process. Solids have to 
be suspended and minimizing of secondary nucleation, crystal breakage, and growth 
on surfaces has to be adhered. In the case of antisolvent, the rate and location are crucial 
factors which must be taken into account along with the agitation rate. Stability of raw 
data should be constantly monitored to ensure similar conditions are simulated in a 
pharmaceutical industry.  
On a large scale filtration process, the compatibility of a filter cloth and parameters 
such as time flow, temperature, pressure, weight, pore size and shape should be 
considered.69 Albeit these factors, the successful implementation of scale-up is also 
dependent on financial constraints of the business in question.  
G. Regulatory concerns 
Compared to other classes of solid forms, co-crystals own particular scientific and 
regulatory advantages, however together with these advantages are intellectual 
property issues which confer co-crystals with unique opportunities and challenges.44 
The patent system is at the core of an ongoing policy debate over balancing a 
productive, economically viable, research-based industry with an equitable system for 
maximizing citizens’ access to effective pharmaceutical therapies. 
For a compound to be patented it has to satisfy the triad criteria of novelty, utility and 
non-obviousness.45,70 Co-crystals satisfy all three criteria in the following manner: 
Novelty: co-crystals are new and distinct solid state structures.  
Utility: co-crystals can offer utility with respect to physical property improvements.  
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Non-obviousness: selection of co-former is routine unlike salts where it is obvious an 
acid is required to make a salt from a base.  
As definitions are without a doubt important in patents, the FDA draft guidance 
document provides an analytical framework for defining and classification of co-
crystals. According to the draft released in December 2011, the requirement for 
characterization of a co-crystal is the difference in pKa between the drug and co-former 
should be within a range of three units, this is to rule out the possibility of proton 
transfer and furthermore, the co-crystal should dissociate to release the free API before 
reaching the target site. The FDA proposes that co-crystals be treated as a process 
intermediate en route to a drug product. The labelling of the final product can remain 
confined to the original API.36 The manufacturing of the co-crystal should be in a 
facility that operates in accordance with current good manufacturing practice.   
In the United States, there has been an influx of patent applications in the past decade. 
Patents regarding co-crystals can be broadly classified into methodologies and 
composition patents.36 Methodology patents refer to methodologies related to the 
process to make pharmaceutical co-crystals. Co-crystals are not the sole subject of the 
patent but are explicitly named in dependent claims. An illustration of this is the 
TransForm Pharmaceuticals which claimed a method of producing co-crystals through 
mechanical grinding.71  
Whereas, composition patents relate directly to the formation of co-crystals. The first 
US patent issued in this arena, was in 1999 from Eli Lily & Co. which entailed co-
crystals of cephalosporin complexes with parabens which are usually used as 
preservatives.72 Thereafter, there have been numerous patents in this growing field. 
However, the standards used to evaluate proposed patent claims differ between 
countries. Thus the pace of patent activity in countries outside the United States has 
been trailing slightly slower. In Europe there has been a limited issuance of patents, 
this is due to the organizations determining patentability of co-crystals on a case-by-
case basis.  As this is a growing field of interest in novel research space, it is only a 
matter of time that patents regarding co-crystals may be seen in other parts of the world. 
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Chapter 3 Experimental 
3.1  Materials 
The active ingredient, nevirapine, was obtained from Aspen (batch number BO24277; 
expiry date: 01 June 2016) as a donation. The co-formers viz. saccharin (batch no. 
STBC5795V; Germany), glutaric acid (batch no. STBC348G; China), salicylic acid 
(batch no. SZBCO450V; France), rac-tartaric acid (batch no. MKBJ6801V; India) and 
maleic acid (batch no. BCBB8525V; Austria) were obtained from the company, Sigma-
Aldrich.  The solvent, methanol, was obtained from Merck (batch no. SA1SF61031; 
South Africa).  Sorbitol (batch no. 17816) was obtained from Brunel and polysorbate 
80 (batch no. BCBN3690V) was obtained from Sigma-Aldrich. The viscosity inducing 
agents, viz. aerosil 200 (batch no. 153020513, Germany) was obtained from Evonik 
industries, carbopol 974 P (0101274748, South Africa) and  carbopol 971G 
(0000021275, South Africa) were obtained from Lubrizol. The preservatives; 
methylparaben (BCBL6776V, India) and propylparaben (BCBM0184V, Japan) were 
obtained from Sigma-Aldrich.  
3.2 Compound verification  
All compounds included in this study were supplied with a Certificate of Analysis 
(COA) and the purity of each compound was confirmed by differential scanning 
calorimetry (DSC) and fourier transform infrared spectroscopy (FTIR). Data obtained 
are analysed in chapter 4. 
3.3 Brief overview  
To-date, there are five different co-crystals that were prepared with nevirapine.1 Of 
these, the most appropriate nevirapine co-crystal was selected for a suspension 
formulation. A suspension was prepared with the nevirapine co-crystal and if 
excipients were required, these were selected from the formulation of the branded form 
of nevirapine (Viramune® suspension) and were added when necessary. Quality 
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control tests were performed on the suspension and compared to both, the USP standard 
and the Viramune® branded suspension.  
3.4 Choice of co-former 
Co-crystals are typically found using screening systems. Technological advancements 
in screening have increased the chances of selecting the appropriate co-crystalline API 
form.2 A series of five nevirapine co-crystals was prepared from different co-formers 
viz. saccharin, glutaric acid, salicylic, rac-tartaric acid and maleic acid during a 
thorough screening process.1 Each co-former exhibits a different physicochemical 
property which in-turn could affect the formulation of a selected dosage form. 
Therefore, careful selection of a co-former was required for the methodology of this 
study prior to experimentation and formulation. To select the best co-former for 
formulation of a suspension, each co-former had to be reviewed under the following 
criteria (Table 3.1). This will be expanded upon in chapter 4.  
Physical  dissolution rates as a co-crystal and as a mixture 
 solubility increase of API as co-crystal 
 solubility of co-former in  water 
 melting point of co-former 
 particle size of co-former  
 particle shape of co-former  
 specific gravity of co-former 
Chemical  log P of co-former 
Pharmacological  lethal dose in rats of co-former 
 side effects of co-former 
 antiviral activity against HIV-1 of co-crystal 
Pharmaceutical  method of preparation of co-crystal 
 percentage yield of co-crystal 
 solvent used to prepare co-crystal 
 taste of co-former 
 sedimentation ratio of co-formers  
 excipient use of co-former 
 status of co-former according to FDA  database 
Other  cost of co-former 
Table 3.1 Classification of selection criteria for chosen co-former for suspension 
dosage form 
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After compilation of properties of co-formers according to table 3.1, co-formers were 
graded using an ordinal scale (excellent = 5, good = 4, average = 3, fair = 2 and poor 
= 1). The total score was calculated by adding the scores obtained for each co-former. 
The co-former with the highest score was considered for formulation.  
3.5 Preparation of co-crystals 
Following the selection of an ideal co-former for suspension, the selected co-former 
was then synthesized to form the respective nevirapine co-crystal with either of the 
following methods: 1  
3.5.1 Slow evaporation  
Stoichiometric amounts of co-former and API were individually dissolved in a known 
volume of solvent. The API and co-former must have a similar solubility in the chosen 
solvent. If solubilities, are not similar the least soluble component would precipitate 
out, exclusively.3  
Samples were stirred with the aid of a magnetic stirrer and placed on a hot plate until 
the powders were completely dissolved in the solvent. The temperatures were kept 
below the melting point of the lowest melting component and 10 oC below the 
estimated boiling point of the solvent system.  The two solutions were mixed together 
by adding the solution with the greater volume to the smaller volume.  The solution 
was then stirred and extracted with a syringe, filtered through a 0.45 μm micro-filter 
and placed in a clean glass vial. The vial was sealed with Parafilm® and perforated to 
facilitate solvent evaporation.4 The vial was placed in a fume cupboard at room 
temperature (Fig. 3.1).  
 
Figure 3.2 Process of slow evaporation5 
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3.5.2 Liquid assisted grinding   
A small amount of the appropriate solvent was added to a stoichiometric mixture of the 
API and the co-former. The mixture undergoes mechanical or manual grinding to 
reduce the excessive use of the crystallization solvent.6 The adding of small amounts 
of solvent during the grinding process had shown to enhance the kinetics and facilitate 
co-crystal formation.3 This method is a “greener” approach since it inhibits the use of 
excessive solvent (Fig. 3.2). 
 
Figure 3.3 Process of liquid assisted grinding5 
3.6 Identification of co-crystal  
Upon preparation of the co-crystal, the preparation had to be identified to ensure the 
formation of a co-crystal. Techniques such as hot stage microscopy (HSM), differential 
scanning calorimetry (DSC), thermogravimetric analysis (TGA), fourier transform 
infra-red (FTIR), powder X-ray diffraction (PXRD) and single X-ray diffraction 
(SXRD) were considered to identify the co-crystal, however due to availability only 
HSM, DSC, TGA and IR were used in this study.  
3.6.1 Hot stage microscopy  
HSM is a valuable supportive tool when used in conjunction with other techniques. It 
can be utilized to ascertain the nature of events leading to endotherms or exotherms on 
differential scanning calorimetry (DSC) traces or weight changes observed in 
thermogravimetric analysis (TGA).7  
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Decomposition with gas evolution, and especially loss of water of crystallization from 
hydrates, can be observed by mounting crystals in silicone oil and physically observing 
the phase changes of the sample during a temperature programme. Gas or vapour 
bubbles can be observed emanating from crystals at temperatures correlating with 
decomposition (endotherms) or desolvation (exotherms) in DSC.7  
The samples are mounted with silicone oil under a microscope slide. This is essential 
for solvent detection in the sample.  In this study, a Linkam TH MS600 Temperature 
control stage connected to a T95 Linkpad System Controller was used. Heating of the 
products were controlled at a fixed rate of 10 °C per minute. An Olympus SZX7 
stereoscopic microscope connected to Olympus UC30 colour video camera was 
mounted to capture pictures for the determination of visual observation and 
characterization. The images were recorded and saved by Stream Essential software®. 
3.6.2 Differential scanning calorimetry  
Samples were analysed using a Perkin Elmer differential scanning calorimeter DSC7 
connected with a Perkin Elmer thermal analysis controller TAC7/DX and Perkin Elmer 
thermal analysis gas station. The samples were scanned at a fixed heating rate (10 
°C/min)  under  a N2 gas with a flow rate of 20 mL/min. Samples were removed from 
the mother liquor, dried on a filter paper, weighed (the mass range was 1-2 mg) and 
sealed in a crimped, pricked aluminium pan. The reference used was a sealed empty 
aluminium pan. The calibrations of the DSC was performed by the melting point 
determination of indium which is 165 °C. The samples were heated over the range of 
40-300 °C to see the decomposition. The data were collected and analysed using Pyris 
software®. 
The basic principle of the construction of the DSC cell relies on the sample and 
reference having separate heaters. Sample and reference are maintained at nominally 
the same temperature via the system being operated through platinum resistance 
thermometers and resulting in different amounts of heat being supplied to each 
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specimen as appropriate. The difference in power output to the heaters is monitored.7 
This technique is used to determine the melting point and decomposition of a sample.  
Endothermic and exothermic peaks appearing in the DSC traces are also analysed in 
terms of their onset temperatures and temperature range of the peak. The peaks 
observed in the DSC trace were interpreted in combination with HSM and TGA,  
associated with phase changes and solvent loss respectively. 
3.6.3 Thermogravimetric analysis  
TGA utilizes a thermobalance, which allows for ongoing monitoring of sample weight 
as a function of temperature. This may involve a controlled heating or cooling 
programme or a maintained fixed temperature. The principle of operation is that mass 
deposited on or lost from the surface of a highly polished crystal results in a shift of an 
oscillatory frequency.7 
This method is used to determine small and large weight changes of a sample. It is used 
to establish the stoichiometry of inclusion compounds and to study the decomposition 
of desolvated materials. 
TGA analyses for all complexes were performed on a Perkin Elmer TGA 4000 
instrument under N2 gas purging at a flow rate of 20 mL/min. The Perkin Elmer TGA 
instrument was calibrated using alumel (mp = 156.6 ºC ), perkalloy (mp = 596.0 ºC) 
and iron (mp = 780.0 ºC)  in an automated process in which temperature calibration, 
thereafter furnance calibration was done. The cystals were rapidly dried on a filter 
paper to remove surface solvent. The weighed samples were placed in an open 
porcelain pan. The programmed TGA analyses were carried out over a temperature 
range of 30 ºC to 400 ºC at the predetermined linear heating rate of 10 K/min. This 
technique was primarily used to determine the percentage weight loss.  
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3.6.4 Fourier Transform Infra-Red  
Each molecule has a specific infra-red absorption pattern. FTIR spectral markers that 
correspond to bonds in a synthon are used to identify supramolecular synthons in co-
crystals. All spectra were collected using a Perkin Elmer Spectrum 400 FT-IR 
Spectrometer. The analysis of the spectra conducted used Spectrum software version 
6.3.5. The FTIR spectra of the analysis were compared to the parent compounds 
spectra, where each molecule has a specific infra-red absorption pattern. 
3.6.5 X-ray powder diffraction  
PXRD is an instrumental analytical technique, which has been used to identify 
crystalline materials for almost a century. The technique was originally used to 
examine the nature of crystal lattices by the diffraction of X-rays through the closely 
spaced lattice of atoms. 
X-ray crystallography techniques are concerned only with the structure analysis. This 
technique is especially useful in the absence of good quality crystals for single crystal 
structure determination, it uniquely identifies materials thus allowing for the 
identification of new compounds. It is considered as the most powerful tool for identity 
specification.  
3.6.6 Single X-ray diffraction  
Single X-ray diffraction is the most preferred technique for structure determination. It 
provides an in depth structure of the crystal.  
Single crystals, typically between 0.2  and 0.5 mm in all dimensions, of good quality 
are selected for their ability to extinguish plane-polarised light uniformly.  However, 
SXRD may not be practicable when the numbers of samples become very large and 
there are many cases wherein obtaining a single crystal of an appropriate size is 
problematic. 
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3.7 Scaling up  
Upon preparation and identification of co-crystals, scaling up of the relevant co-crystal 
was explored. Co-crystals in the development phase and scale-up methods are currently 
being explored however, relatively few studies have been reported on co-crystal scale-
up procedures.8  
Early development and screening of co-crystals typically rely on slow evaporation and 
mechanochemical methods, however the main challenge that exists is, “scaling up to a 
multikilogram scale”.9 Solid state grinding that is achieved through the use of a mortar 
and pestle in a laboratory scale, can be transformed to a large scale by utilizing the ball-
mill grinder. This approach is difficult to scale-up for energetic materials since friction 
may be caused from the grinding and result in detonation.  From the methods existing 
to prepare co-crystals, solution co-crystallization remains the most commonly used 
scale-up technique.10   
In this study, the co-crystal was prepared from milligram scale to a gram scale. 
Fourteen batches were prepared, batch 1-8 were prepared in a small fume cupboard 
while batch 9-14 were prepared in a large fume cupboard.   
3.8 Preparation of suspension  
Following the preparation and identification of the relevant co-crystal, preparation of 
suspensions was employed. Three formulations were prepared using the same 
excipients as in the branded version of nevirapine (Viramune®), except that the 
viscosity inducing agent for these formulations varied. Formulation A, B, C utilised 
aerosil 200, carbopol 971G, carbopol 974P, respectively. The preparation of 
suspensions can be divided into two broad categories, the precipitation methods and 
the dispersion method.11  
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3.8.1 Precipitation methods 
Precipitation methods can further be subdivided into organic solvent precipitation, 
precipitation effected by changing the pH of the medium and double decomposition.11  
3.8.2 Organic solvent precipitation  
Water insoluble drugs can be precipitated by dissolving them in water-miscible organic 
solvents such as alcohol, acetone, propylene glycol or polyethylene glycol. The organic 
phase is then added to distilled water under standard conditions and a suspension is 
produced having a particle size in the 1 to 5 µm range. An example of a suspension 
made by this method is Prednisolone suspension,11 it is precipitated from a methanolic 
solution to produce a suspension in water. This type of preparation is useful in cases of 
parenteral or inhalation therapy where fine particles are required. However, the 
disadvantage with this method is that it may be difficult to remove harmful organic 
solvents.  
3.8.3 Precipitation effected by changing the pH of the medium 
Some drugs may be readily soluble at a certain pH and precipitate at another pH. This 
type of drug can first dissolve in a favourable pH and then the solution is poured in 
another buffer system to change the pH of the medium and the drug will form a 
suspension in the medium of the second pH. An example of this is Insulin suspension; 
it has an isoelectric point of 5, when it is mixed with protamine -a basic protein- it 
precipitates between the isoelectric points of the two components (pH of 6.9 – 7.3).11  
3.8.4 Double decomposition method 
This method requires two water soluble reagents to form a water insoluble product. 
This is mostly used for topical suspensions. An example of this is White Lotion®,11 It 
can be prepared by slowly adding zinc sulfate solution in a solution of sulphurated 
potash to form a precipitate of zinc polysulphide. 
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3.8.5 Dispersion methods 
This method comprises of first creating a deflocculated suspension. After a 
deflocculated suspension is made, various techniques are used to alter the suspension 
so that a flocculated suspension is formed (Fig. 3.3).  
 
Figure 3.3 Preparation of suspension by dispersion methods11 
Suspensions are prepared by grinding the insoluble materials in a mortar to a smooth 
paste with a vehicle containing the wetting agent. This forms a deflocculated 
suspension. Once a deflocculated suspension is formed, a structured vehicle can be 
added to convert the deflocculated suspension to a flocculated suspension. 
Alternatively, flocculating agents are added to the deflocculated suspension to form a 
flocculated suspension. If this does not work then an external liquid is added together 
with flocculating agents and a flocculated suspension in an external suspension is 
formed. 
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3.9 Identification of co-crystal in suspension during production 
According to the European Medicines Agency, in its reflection paper published in 
(2014)8, on the use of co-crystals, states that “the integrity of the co-crystal during the 
entire manufacturing process should be experimentally confirmed”.  
This study had to ensure the integrity of the co-crystal pursued continually throughout 
the study. To achieve this target, the formed suspension had to be filtered for analysis.   
In a study by Shiraki et al in (2008)2, transformation behaviour of co-crystal 
suspensions were examined by PXRD analysis and were observed under polarization 
microscopy. This is a good technique as it is considered the most powerful tool to 
characterize a co-crystal.   
In this study, a novel dual approach of identifying the integrity of the co-crystal was 
attempted. The suspension formed with the co-crystal was filtered and the filtrate 
solution was identified by UV, this is a relatively new ideology where the presence of 
co-crystal was tested in the filtered suspension. Furthermore, the residue of the filtered 
suspension of the co-crystal was retained and identified by DSC (Fig 3.4).  Analysis of 
co-crystal tested by UV and DSC is outlined in the following section. 
 
Figure 4.4 Schematic illustration of which component of the formulation was 
studied to ensure the integrity of co-crystal  
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3.9.1 Ultraviolet spectroscopy of the suspension  
UV spectra were recorded on a Cintra ® 2.2 GBC Scientific Equipment Pty. Ltd. 
UV/visible spectrophotometer. Samples were filtered through a Whatman® no.41 filter 
paper as opposed to a membrane filter due to the viscous nature of the sample. It was 
then placed in 1 mL quartz cuvettes and a wavelength scan was performed between 
200-800 nm at a scanning rate of 1200 nm/min.   Absence of absorbance at wavelengths 
where the API and co-former is expected to be seen, indicated that the co-crystal is 
retained. Conversely, the presence of peaks for the API and the co-former indicated 
that the co-crystal had fragmented into its two components.  
3.9.2 Differential Scanning Calorimetry of suspension filtrate 
The suspension was filtered through a filter paper and the filtrate was removed from 
the filter paper and analysed by DSC using the same procedure that was used to identify 
the co-crystal as mentioned in section 3.6.2. The presence of an endothermic peak at 
the melting point of the co-crystal indicated that it was still intact in the suspension. 
Conversely, the presence of two individual peaks at the melting points of the co-former 
and the API suggested that the co-crystal had fragmented.  
3.10 Quality control of suspensions  
Upon assuring the co-crystal integrity in the suspension, the physical characteristics 
such as particle size, pH, viscosity, zeta potential measurement, and dissolution was 
performed in accordance with the methods stated in the USP 32.   
3.10.1 Particle size analysis  
Scanning electron microscopy (SEM) 
The morphology of the co-crystal powder was determined by SEM. The model used 
was LEO1450. A small quantity of co-crystal was placed on carbon adhesive tape and 
was placed on an aluminium stub, thereafter it was placed in a fumehood until it the 
 
 
 
 
  
87 
 
sample was completely dried. The dried co-crystal was then coated with gold palladium 
using an Emitech K550X (England) sputter coater and viewed using a Auriga F50 HR-
Scanning Electron Microscope with working distances of 6.6, 6.7 and 6.8 nm with 
accelerating voltage of 5 kV.  
Zeta sizer 
The stability of a suspension depends on the particle size of the dispersed phase. 
Particle size of particles in suspension was performed by a zeta sizer nano series S90 
which utilizes a dynamic light scattering technique that measures the size of particles 
at the micrometre size range more accurately than particles in the submicron range. 
Photon correlation spectroscopy was used to measure the size of particles in the 
nanometer range by placing 1 mL of sample in a cuvette and inserting it in a Zetasizer 
instrument (Zetasizer nano, Malvern Instruments Ltd., UK). Particle size and size 
distribution were presented by the Z-average and polydispersity index, respectively.   
3.10.2 Determination of pH 
The pH of suspensions determines the stability and characteristics of formulations. 
Therefore, pH of the different vehicles and the pH of different phases of the suspension, 
have to be monitored to ensure optimum pH environment is being maintained. This 
was measured by using a pH meter (Eutech Instruments pH 2700 meter). The pH meter 
was calibrated at room temperature to a pH of 7 initially and further calibarated to a 
pH of 10 and 4.  
3.10.3 Zeta Potential  
The Zeta potential has to be measured to establish the stability of disperse systems. The 
zeta potential was carried out using the Laser Doppler Velocimetry (LDV) principle by 
using the Zetasizer instrument (Zetasizer nano, Malvern Instruments Ltd., UK). The 
principle relies on the Doppler shift in a laser beam used to measure the velocity in 
semi-transparent or transparent fluid flow. The zeta potential was measured by adding 
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700 µL of the suspension in a zeta capillary cell (DTS1070) and the temperature was 
set at 25 ºC, with measurements conducted at an angle of 173º. The intensity-weighted 
mean value was measured and the averages of three measurements were taken.      
3.10.4 Viscosity 
The Brookfield (Model DVII + Pro) viscometer was used for determining viscosity of 
suspensions. It was calibrated with silicone oil at three different temperatures, 25 °C, 
93.3 °C, 149 °C. The Brookfield’s was used because it has an advanced design and 
special device for reading and recording the speed. A small sample adapter (16 mL) 
was used due to the size of the sample available. The small sample adapter was 
connected to a water bath and the temperature was monitored with a thermometer. The 
suspension was placed in a small sample chamber and was placed into the water jacket. 
Small sample spindles were placed in the chamber and the viscosity readings were 
displayed on the digital screen. Rheograms were constructed with the data obtained. 
3.10.5 Dissolution method  
The USP utilizes Method I basket and Method II paddle apparatus to perform 
dissolution studies. According to the USP, the paddle II method should be employed 
for Viramune® suspension. The dissolution media that was used was phosphate buffer 
(pH=6.2).12  
To prepare phosphate buffer (pH 6.8), a volume of 50 mL of 0.2 M monobasic 
potassium phosphate solution was added to a 200 mL volumetric flask.  To this 22.4 
mL of 0.2 M sodium hydroxide solution was added and distilled water was added to 
volume. Details of the preparation of the monobasic potassium phosphate solution and 
sodium hydroxide solutions are listed below.  
 
Preparation of 0.2 M monobasic potassium phosphate solution: 
Dissolved 27.22 g of monobasic potassium phosphate in water in a 1000 mL volumetric 
flask and solution was made up to volume with distilled water. 
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Preparation of 0.2 M sodium hydroxide solution: 
Dissolved 8 g of sodium hydroxide in a 1000 mL of water in a beaker. 
 
The analysis was performed on a Vankel VK 700 (220 V) dissolution apparatus and 
with the Vankel VK 650 A Heater/Circulator Benchsaver® series. 5 mL of the 
suspension was introduced to the system through the orifice located on the top cover 
by means of a syringe, in the dissolution media of 900 mL which was maintained at 37 
°C.  The rotation speed that is recommended was 25 rpm. A 60 minute run was 
conducted. Samples were extracted and replaced with 5 mL of dissolution media at 10, 
20, 30, 45 and 60 minutes intervals.12 1 mL of the dissolution sample was placed in an 
amber 1.5 mL HPLC vial and labelled accordingly.  
The same method above will be employed for the nevirapine co-crystal suspension 
prepared in this study.  
3.10.6 HPLC analysis 
A standard curve of nevirapine was constructed before the assays were performed. 
Phosphate buffer that was prepared was used as the diluent. The stock solution was 
prepared by adding 60 mg of nevirapine dissolved in 120 mL of diluent. This yielded 
a concentration of 500 µg/mL. The flask was placed in a sonicator to aid the dissolution 
of nevirapine. The standard was performed in triplicate to ensure accuracy and 
reproducibility.13  
The HPLC system used for the acquiring the chromatograms and UV spectra was an 
Agilent 1200 series HPLC system, equipped with an in-line degassing system 
(G1322A, Japan), quaternary pump (G1311A, Germany), auto loading sampler 
(G1329A, Germany), thermostatted column compartment (G1316A, Germany) and 
photodiode array detector (G1315B, Germany). Chromatographic separation was 
obtained using a Phenomenex Luna® C18 column (25 cm x 4.6 mm, 5 µm i.d.) with a 
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compatible guard column, both maintained at 35°C. The following specifications were 
used for the HPLC analysis  
Mobile phase 23 % acetonitrile, 77 % water 
Flow rate of mobile phase 1 mL/min 
Column Phenomenex C18 column (25 cm x 4.6 mm, 5 µm i.d.) 
Injection volume  50 µL 
Wavelength  280 nm 
Retention time 3 minutes  
Table 3.2 HPLC specifications for analysis of nevirapine in suspension 
The mobile phase consisted of 23 % acetonitrile and 77 % water was filtered through 
a 0.45 µm filter and degassed prior to use. The flow rate of the mobile phase was 
maintained at 1 mL/min with an injection volume was 50 µL, and peaks were separated 
with an isocratic elution of 23 % acetonitrile. Data acquisition and processing was 
carried out using the OpenLAB™ CDS ChemStation Edition software.  
A reversed phase HPLC separation method combined with DAD detection was 
employed for nevirapine analysis in the suspension. This method had been validated 
by Geldenhuys to ensure accuracy, reliability and reproducibility.13  
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Chapter 4 Results and discussion 
To prepare a nevirapine co-crystal liquid dosage form, a co-former had to be selected. 
To achieve this objective, a protocol was developed to choose the best co-former for 
the selected liquid dosage form, a suspension formulation. From the known five co-
formers available to formulate nevirapine co-crystals viz. saccharin, glutaric acid, 
salicylic acid, rac-tartaric acid and maleic acid,1 saccharin was selected for preparation. 
4.1 Selection of an ideal co-former for suspension  
To develop a protocol to select an ideal co-former, information was gathered from 
primarily literature and electronic databases about each co-former regarding their 
physical, chemical, pharmacological and pharmaceutical properties. A similar protocol 
was established by Sam et al. whereby each formulation was ranked against efficacy, 
safety and patient access.2 Their approach was to define scales for scoring the 
differences for the various criteria in the range from equal to extremely different, 
followed by a weak point and sensitivity analysis. They also emphasized that the 
framework should be used on a case-by-case basis and consider the specific product 
characteristics and medical need.  
In this study, the criteria for the selection of the best co-former included physical 
properties such as dissolution rates as a co-crystal, dissolution rates as a mixture of API 
and co-former, solubility increase when used as a co-crystal, solubility in water, 
melting point, particle size, particle shape, taste and specific gravity.  
Chemical properties such as Log P were considered. Pharmacological properties such 
as lethal dose in rats, side effects and antiviral activity against HIV-1 were part of the 
criteria. Variables relating to pharmaceutical aspects such as method of preparation, 
percentage yield, solvent used to prepare co-crystal, taste, sedimentation ratio of co-
formers and status according to the FDA inactive ingredient database were considered. 
Another variable that was also considered was the cost.      
Thereafter, each of the co-formers was ranked in relation to the other co-formers in a 
table according to an ordinal measurement scale. For the sake of simplicity and better 
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comprehension, the numbers were represented with colours and thus a colour coded 
table was formed. Green represented excellent characteristics, blue represented good, 
orange signified average, yellow meant fair while red indicated the co-former had 
performed poor in that particular property. After compilation of the properties of the 
co-former, the total score for each co-former was calculated by adding the values 
obtained for each co-former. The co-former with the highest total score indicated that 
the co-former performed well in the set criteria and hence it is the recommended choice 
for formulation of the suspension (Table 4.1).  
4.2 Validation for selection of variables  
The subsequent section justifies why the following variables are considered as part of 
the protocol in choosing a suitable co-former for a suspension formulation.  
4.2.1 Physical properties of co-former 
Dissolution rate as a co-crystal 
Dissolution can be defined as the transfer of molecules or ions from a solid state into 
solution.3 The dissolution rate as a co-crystal provided crucial data for formulation as 
a suspension. The dissolution rate of the co-crystal was determined by HPLC at 37 ºC 
at a pH of 7 in six vessels, using water as the dissolution medium.3   
Dissolution rate as a mixture of the API and co-former 
This variable was considered because if the co-crystal was not retained in the 
suspension, the co-crystal would disintegrate into two components i.e. nevirapine and 
the relevant co-former, thus the dissolution expected in such a situation would not be 
the dissolution of the co-crystal but rather the mixture of the API and co-former.  The 
dissolution rate of the mixture was also determined by HPLC at 37 ºC at a pH of 7 in 
six vessels, using water as the dissolution medium.3   
 
 
 
 
 
  
96 
 
Solubility enhancement of the API as a co-crystal 
Solubility enhancement parameter can be defined as a ratio of Scc/Sfree, where Scc is the 
aqueous solubility of nevirapine from the co-crystal and Sfree is the aqueous solubility 
of the pure drug at the same temperature.1 This ratio was derived from dissolution-time 
curves. It gives an indication on the solubility improvement of the co-crystal. This 
variable was chosen because it would ultimately suggest whether or not the API as a 
co-crystal will dissolve in a specific media, at a specific temperature and pH 
comparatively to the API alone. 
Solubility of co-former in water 
The extent to which the dissolution proceeds under a given set of experimental 
conditions is referred to as the solubility of the solute in the solvent.3 In this instance, 
the solubility of the co-former in water was considered, because in cases where the co-
former was to be added as a suspension excipient, this parameter would give an 
indication of whether it would be an aqueous soluble excipient or non-aqueous soluble 
excipient.   
Melting point  
This is the temperature at which the crystal lattice breaks down, owing to the 
molecules having gained sufficient energy from a heating process to overcome the 
attractive forces that hold the crystal together.3 The dissolution profile is closely related 
to the melting point. Low thermal stability implies high water solubility.  
Particle size 
Particle size influences the subsequent physical performance of the formulation and the 
pharmacological performance of the drug.3 A small particle size ensures that the 
particles form floccules and are large enough to ensure they are suspended in the media 
to be used.  Particle size was determined by SEM.  
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Particle shape 
Particle shape can be classified into avicular, columnar, blade, plate, tabular and 
equant. However, deviation of crystal habits from the ideal may often be observed due 
to the alterations in the crystallization conditions.4 With regards to particle shape, a rod 
shape is preferred since rod shaped particles are associated with good sedimentation 
properties. Spherical or ellipsoid shapes are also preferred.5 The shape was also 
characterized by SEM.  
Taste  
This variable contributes to the organoleptic aspects of a suspension. Each co-former 
had a different taste; this variable was considered to see if the co-former could 
contribute to the overall taste of the suspension. 
Specific gravity 
Specific gravity expresses the ratio of the density of a solid or liquid to the density of 
water at standard temperature and pressure.5 Specific gravity of the co-former 
contributes to the density of the co-crystal particle which in turn affects the overall 
density of the suspension. The density of the particles is one of the factors that affect 
Stokes’ law. The velocity of a suspension is directly proportional to the difference in 
the density of the particle and density of the dispersion medium.  
4.2.2 Chemical property of co-former   
Log P  
A Log P value indicates that the molecule has sufficient lipid affinity to cross 
membranes and enough water affinity to diffuse and dissolve in body fluids. The value 
of Log P is only an estimate of the permeability, which is an important absorption 
mechanism of drugs.6 Co-crystals are expanding their territories in not only improving 
solubility but also in permeability. In a recent study, attempts were made to obtain a 
higher lipophilicity, where Ibandronate was crystallized with phenyl-β-D-
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galactopyranoside, however it was unsuccessful.6 Hence, choosing a co-former with a 
good Log P value could possibly influence the permeability of the nevirapine co-
crystal.  
4.2.3 Pharmacological properties of co-former   
Safety 
Safety of the co-former refers to the maximum oral consumption for a human per day. 
This variable was taken into consideration because if it was not safe to be ingested then 
making a suspension with such a co-former would be futile. It was necessary to ensure 
that the amount of co-former that would be used was within the stipulated ranges. 
Along with the maximum consumption, it was necessary to ensure that the co-formers 
were listed in the GRAS list because the aforementioned list is approved by the FDA 
and is permitted for use in pharmaceutical formulations.  
The European medicines agency advises those applicants of novel co-formers to submit 
details of manufacture, characterisation controls with cross references to support safety 
data.7 This indicates that safety consideration is imperative especially in the instances 
where the co-former has not yet been classified by the agency.  
Lethal dose in rats 
The lethal dose (LD50) in rats is the dose at which 50% of the rats are injured.
8  Not 
many studies have been done with respect to toxicity of the co-formers in humans, 
hence lethal dose in rats was considered.  
Side effects 
Side effect is an unintended effect of the drug.9 This was considered because it was 
essential to know if the co-former would have any possibility of side effects if it were 
to be used as a suspension excipient.  
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Antiviral activity 
The antiviral activity against HIV-1 when used as a co-crystal with that specific co-
former was considered to see if there was any improvement in inhibitory concentration 
(IC50) against HIV-1 when compared to pure nevirapine. IC50 value is the concentration 
of the co-crystal where 50% of the virus is inhibited. A viral activity of 0 % indicated 
complete viral inhibition while that of 100 % indicated no inhibition.10    
4.2.4 Pharmaceutical properties of the co-former   
Pharmaceutical use for suspensions 
The pharmaceutical use of the co-former was considered to suggest possibilities of 
using the co-former as a potential excipient for suspensions.  A literature review was 
done to ascertain if the co-formers could perform as a sweetener, suspending agent, 
buffering agent, viscosity enhancer or a wetting agent.     
Status in FDA Inactive Ingredient Database 
The FDA inactive ingredient database gives the approved potency, as a percentage of 
the inactive to be used in a formulation. This information was pertinent in an instance 
where the co-former may be employed as a potential excipient in a suspension.  
Preparation method of co-crystal  
The two options available for preparing the nevirapine co-crystals were slow 
evaporation and liquid assisted grinding.1 The slow evaporation method utilizes large 
amounts of solvent to facilitate the formation of co-crystals. Liquid assisted grinding 
was preferred in contrast to the slow evaporation method since the former was a 
“greener pharmaceutical” method of preparation of co-crystals. Liquid assisted 
grinding was also seen to be more cost-effective due to less solvent usage. Hence, 
methods that used both the methods were rated as excellent, methods that used liquid 
assisted grinding was considered as good and co-formers that were prepared by slow 
evaporation was rated as average.  
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Percentage yield 
Percentage yield is the actual yield obtained over the theoretical yield, expressed as a 
percentage. This gave an indication of whether scaling up of a co-crystal with the co-
former was viable. For this study, a value above 75 % was considered as excellent. 
Values between 70 % –74 % were considered good, while values between 60 – 69 % 
were considered as average, 50 – 59 % was considered as fair and values less than 50 
% were rated as poor    
Solvent  
According to the definition of a co-crystal, the solvent is not present in the co-crystal, 
unless a solvated co-crystal had been prepared. The role of the solvent in this instance 
was to facilitate the formation of non-covalent bonds between co-former and the API. 
Technically, there should be no solvent present in the co-crystal but there might be 
solvent present on the surface of the crystal hence the choice of solvent is of 
importance. The solvent was chosen based on the safety of solvent for human oral 
consumption. With respect to solvent choice, the boiling point of the solvent was also 
considered. A high boiling point meant that it would take a longer time to evaporate 
from the API-co-former preparation thus consuming more time to form the co-crystal 
during scaling up.  
Sedimentation volume test  
The sedimentation volume (F) is defined as the ratio of final or ultimate volume to the 
suspension volume. If the volume of sedimentation in a flocculated suspension is equal 
to the original volume of suspension, then F=1 and this is considered as 
pharmaceutically acceptable. When F=0, it means the total drug has settled and the 
volume of sediment is negligible. Therefore, the greater the volume of F the more it 
will be pharmaceutically accepted.11 
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Cost 
Information on the cost of the co-former in South African Rands was obtained. This 
was considered since this project involved scaling up and thus required a greater mass 
of each ingredient as scaling up progressed.  
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Co-former Saccharin Glutaric acid 
 
Salicylic acid Rac-Tartaric acid Maleic acid  
Dissolution 10 of co-crystal at 37 ºC in 
water at pH 7 
 
14% in 45min 
16% in 180min 10 
30% in 45 min 
59% in 180min10 
20% in 45 min 
32% in 180min10 
14% in 45 min 
41% in 180 min 10 
18% in 45min 
39% in 180min10 
P
h
y
sical p
ro
p
erties 
Dissolution10 of mixture  at 37 ºC in 
water at pH 7 
26% in 45min 
43% in 180min 10 
26% in 45 min 
47% in 180 min10 
49% in 45 min 
65% in 180min10 
24% in 45min                
43% in 180min10 
34% in 45min 
54% in 180min10 
Solubility increase 1.6 times12 3.7  times12 2 times12 2.7  times 2.4 times 
Solubility in water at 25°C and pH 713 1000mg/290ml = (3.4mg/ml)13 430mg/ml13 2.240mg/ml13 206mg/ml13 780mg/ml13 
Melting point of co-former1 223°C1 137°C1 203°C1 228°C1 185°C1 
Particle size  (µm) 169.7 x272 180.1 x 365 410 x 92.4 739 x 493.5 179 x 308.5 
Particle shape rectangular irregular with agglomerates platy irregular irregular 
Specific gravity 0.828g/cm3 1.429g/cm3 1.40 g/cm3 1.76g/cm3 1.59g/cm3 
Log P14 0.9114 -0.29714 2.2114 -0.4814 -0.314 C
h
em
ical 
p
ro
p
erty
 
Maximum oral consumption (g) 0.175 Not available 0.800 2.100 0.035 
P
h
arm
aco
lo
g
ical 
p
ro
p
erties 
Lethal dose in rats (LD50) LD50 oral is 17000mg/kg15,16 LD50 oral is 6000mg/kg 16 LD50 oral 891mg/kg 16 LD50 oral is  7500mg/kg7 LD50 oral is 708mg/kg 16 
Side-effects14 Headaches,  diarrhoea, skin problems 14 None14 Gastric ulceration14 Nausea, vomiting, chronic  toxicity is low14 acute toxic skin, eye, respiratory tract 
irritant14 
Antiviral activity IC 50 mM against 
HIV-110 
0.03710 0.05410 0.03710 0.07210 0.05510 
Method of preparation1 slow evaporation 1 slow evaporation or liquid assisted grinding 
1 
slow evaporation or liquid assisted grinding 
1 
slow evaporation 1 liquid assisted grinding 1 
P
h
arm
aceu
tical p
ro
p
erties 
Percentage yield while scaling up10 78%10 73%10 76%10 60.5%10 110%10 
Solvent used during preparation1 Chloroform, methanol, acetic acid,  1,4-
dioxane, n-hexane, n-heptane, diethyl ether 
and amyl alcohol1 
chloroform1 Chloroform1 amyl-alcohol1 chloroform 1 
Taste sweet (500 times sugar)16 sour(acid)16 sweetish, acrid 16 sour /salty16 Astringent16 
Use Artificial sweetener, the safest sweetener 
out of the five sweeteners in FDA  
database17 
Surfactant, food supplement and improves 
protein synthesis17 
Food preservative, bactericidal and 
antiseptic properties17 
Anti-oxidant, acidulant, sequestrating 
agent, complexing agent, falvouring agent, 
preservative17 
Make salts, acidulant, prevents rancidity  
and buffering agent17 
Status according FDA inactive 
ingredient database18 
Can be used in oral solutions 
(1%),suspensions (0.25%), syrup (0.07%) 
tablets, topical preparations, inhalations 
and aerosols18 
Not included in database since it is a not 
used as an inactive 18 
Not included in database since it can be 
considered as an active ingredient18 
Accepted as food additive and use in 
tablets (15mg), capsules (177.1mg), 
solutions(0.75%), 
suspensions (0.2%)  IM, IV injections, 
topical films, rectal and vaginal 
preparations18 
Can be used for oral syrups, tablets (4mg), 
syrup (0.0345%), capsules (2mg) and 
topical preparations18 
Sedimentation volume test * 
(Ht/Ho ratio at 24 hours) 
0.013 0 0 0.020 0 
Cost /100g15 R 1 98615 R 43715 R 91415 R 31515 R 27115  
 Excellent   Good   Average  Fair  Poor 
 
Table 4.1 Physical, chemical, pharmacological and pharmaceutical properties of nevirapine co-formers 
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4.3 Selection of an ideal co-former for the nevirapine co-crystal 
suspension 
4.3.1 Physical properties of co-formers 
Dissolution rates as a co-crystal at 37 ºC in water (pH =7) 
Nevirapine alone shows a dissolution rate of 16%. The release profile of nevirapine is 
enhanced as co-crystals. Nevirapine-glutaric acid (NVGLT) co-crystal displayed the 
greatest dissolution rate of 59 % in 180 minutes followed by rac-tartaric acid (NVTTA) 
with a dissolution rate of 43% in 180 minutes. Nevirapine-maleic acid (NVMLE) 
displayed 39 % after 180 minutes and nevirapine–salicylic acid (NVSLI) co-crystal 
had a dissolution rate in the same range of 39 % in 180 minutes. Nevirapine-saccharin 
(NVSC) co-crystal had the lowest dissolution rate of 26 % in 180 minutes in 
comparison to the other co-crystals (Fig. 4.1).12   
 
Figure 4.1 Pre-formulation dissolution profiles of pure nevirapine and 
nevirapine co-crystals at 37 ºC in water at pH 7, determined by HPLC12 
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Dissolution rates as a mixture of API and co-former at 37 ºC in 
water at pH 7 
NV:SLI had the greatest dissolution rate as a mixture, 65 % in 180 minutes, followed 
by NV:MLE with a dissolution of rate of 54 % in 180 minutes. This was then trailed 
by NV:GLT exhibiting a dissolution rate of 47 % in 180 minutes. Both NV:TTA and 
NV:SC physical mixtures had the lowest drug release of 43 % in 180 minutes (Fig.4.2).  
The dissolution of mixtures is faster than corresponding co-crystals due to the presence 
of an acidic co-former which lowers the pH significantly, in which nevirapine 
dissolution is highly favourable.      
 
Figure 4.2 Pre-formulation dissolution profiles of pure nevirapine and physical 
mixtures with co-formers at 37 ºC in water at pH 7, determined by HPLC12 
Solubility enhancement as a co-crystal 
The solubility enhancement theory was applied and it was practically determined using 
the HPLC analysis technique. It was found that NVGLT had the greatest solubility 
increase by 3.7 times, followed by NVTTA, NVMLE, NVSLI and lastly NVSC (2.7, 
2.4, 2.0, 1.6 times), respectively.12 The solubility enhancement parameter concurred 
with the dissolution readings obtained in figure 4.1.   
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Solubility of co-former alone in water 
Maleic acid had the greatest solubility at 780 mg/mL but this was marked as red for 
poor since a co-former which is less soluble is preferable in suspensions. Glutaric acid 
had a water solubility of 430 mg/mL and this was marked as yellow. Rac-tartaric acid 
was marked as orange, displaying a solubility of 206 mg/mL. Saccharin was marked 
as blue since it had a solubility of 3.4 mg/mL. Salicylic acid was rated as green for 
excellent, exhibiting solubility at 2.240 mg/mL.  
Melting point of co-former 
Rac-tartaric acid had the highest melting point of 226 °C, followed by saccharin at 203 
°C. Salicylic acid had a melting point of 203 °C while maleic acid had a melting point 
of 185 °C and glutaric acid had a melting point of 137 °C.  A low melting point was 
not favoured, since a low thermal stability meant that it had high water solubility. In 
the case of a suspension, a low thermal stability suggests that the co-former will have 
high water solubility, which is not suitable for suspensions as suspensions are formed 
when the substance have limited solubility.   
Particle size of co-former 
A small particle size was preferred for suspensions as larger particles tend to settle 
faster due to the gravitational force. Ideally a particle size of 1 to 50 µm is suitable for 
suspensions, however, particles are rarely in this particle size range and hence a range 
of 50 to 75 µm is acceptable. Saccharin showed the smallest particle size of 169.7 x 
272 µm. Hence, it was rated as excellent. Maleic acid had a slightly larger particle size 
of 179 x 308.5 µm, hence it was rated as good. This result was followed by glutaric 
acid which had a particle size of 180.1 x 365 µm. Glutaric acid was rated as average.  
Salicylic acid had a particle size of 410 x 92.4 µm and thus it was rated as fair.  Rac-
tartaric acid had the largest particle size of 739 x 493.5 µm therefore it was rated as 
poor.  (figure 4.3 and Table 3.1).  
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a. Saccharin b. Maleic acid  
 
 
c. Glutaric acid  d. Salicylic acid  
 
 
e. Rac-tartaric acid   
Figure 4.3 Particle sizes of co-formers determined by SEM  
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Particle shape of co-former 
For a suspension to be prepared, ellipsoid and rectangular shape or rod-shaped 
structures are preferred.  As seen in figure 4.3, saccharin had a rectangular shape thus 
it was rated as excellent, because a rectangular shape is similar to a rod-shaped structure 
which exhibits good sedimentation properties. Salicylic acid was rated as good as it 
appeared platy in nature and this is similar to a rod-shaped structure. Rac-tartaric acid 
and maleic acid were graded as fair as these co-formers had irregular morphology. 
Irregular particle shapes are not preferred as they do not have a good particle size 
distribution and thus surface area for these particles are not large. Glutaric acid was 
graded as poor as it exhibited irregular particle shape and furthermore it had presence 
of smaller particles adhering onto larger particles. This attribute of particles adhering 
to each other alludes to Ostwald’s ripening process, which is not favourable process in 
pharmaceutical suspensions and hence glutaric acid was rated as poor.    
Taste of co-former 
Taste is a subjective variable; however, generally a sweet taste is acceptable for 
suspensions. Saccharin was rated as the best since it is sweet (500 times that of sugar)17, 
salicylic acid was rated as good, since it had a sweetish and acrid taste.17 Glutaric acid 
had a sour taste and this was rated as average, rac-tartaric acid had a salty taste and was 
rated as fair while maleic acid had an astringent taste17 and was rated as poor.  
Specific gravity of co-former  
A particle with low density was preferred in order to minimize the difference between 
the density of the vehicle and the particle, as this variable was directly proportional to 
the rate of sedimentation and particle size. Saccharin had the least specific gravity 
followed by salicylic acid, glutaric acid, maleic acid and then rac-tartaric acid which 
was predicted due to the order of the particle sizes.   
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4.3.2 Chemical property of co-former   
Log P  
An ideal Log P value is within 1 and 4. Log P values within this range are known to 
have good permeability. Salicylic acid had the best log P value in comparison to the 
other co-formers with a log P value of 2.21. This was in fact the only co-former within 
the range desired hence it was classified as an excellent co-former in this respect. 
Saccharin had a log P value of 0.91 and thus was rated as good. Glutaric acid had a log 
P value of -0.297 and was rated as average. This result was followed by maleic acid 
and rac-tartaric acid which had log P values of -0.48 and -0.3, thus they were graded 
as fair and poor respectively.  
4.3.3 Pharmacological properties of co-former   
Maximum oral consumption  
The maximum amount of oral consumption of the co-former was compared to the 
amount of co-former that could be included in a dose of suspension. The daily dose 
required during the first 14 days is 200 mg. Viramune® is available as 50 mg/5mL, 
thus to meet the required dose, 20 mL per day is administered.   
Mass of nevirapine in 20 mL = 200 mg                
No. of moles of API in 200 mg = 
0.200
266.297
 = 7.510 x 10-4   mol  
No. of moles of co-former needed for 200 mg API in a 1:1 ratio = 7.510 x 10-4   mol 
No. of moles of co-former needed for 200 mg API in a 2:1 ratio = 3.755 x 10-4   mol 
 
Table 4.2 presents the number of moles as well as the mass needed for each co-former 
to prepare a co-crystal that consists of 200 mg of API. Maximum consumption of co-
former approved per day in grams is also presented.      
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Saccharin 2:1 3.755 x 10-4      183.18  0.068 0.175  1.070  
Rac-
Tartaric 
1:1 7.510  x 10-4    150.05  0.112 2.100 1.988 
Maleic 
acid 
1:1 7.510  x 10-4    116.07  0.087 0.035 - 0.052 
Glutaric 
acid 
1:1 7.510  x 10-4    132.11  0.099 Not available X 
Salicylic 
acid 
2:1 3.755 x 10-4      138.12  0.051 0.800 0.749 
Table 4.2 Mass of co-formers needed for one dose of suspension compared to 
maximum consumption of co-former allowed 
The difference between the maximum consumption of co-former allowed per day and 
the mass of co-former needed to form a co-crystal was calculated. Positive values 
indicated that the co-former was within the maximum limit whereas negative values 
meant that the co-former in a daily dose of the co-crystal suspension would exceed the 
maximum limit allowed by the FDA. From table 4.2, salicylic acid was rated as 
excellent as only 0.051 g of co-former is required whilst the maximum limit is set at 
0.800 g per day. Rac-tartaric acid was rated as good, since 0.112 g is needed to prepare 
the co-crystal, which fell within the stipulated limit of 2.100g. Saccharin was then rated 
as average since 0.068 g would be in a daily dose of the co-crystal suspension, while 
0.175 g of saccharin is set as the maximum amount of co-former approved per day. 
Maleic acid followed this result and was rated as poor, as it had a negative value in the 
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difference between the mass of the co-former required for a daily dose and the mass of 
the co-former allowed in a daily dose.  Glutaric acid was also rated as poor as there 
was no data available on the maximum consumption of glutaric acid approved per day.   
Lethal dose in rats 
A high LD50 indicates that a greater amount of co-former is required to cause death in 
50 % of the test population. Thus, a high LD50 value was preferred. Saccharin had the 
highest LD50 of 17000 mg/kg when compared to the other co-formers and thus it was 
rated as excellent. Rac-tartaric acid had a LD50 of 7500 mg/kg and was rated as good. 
Glutaric acid followed this result with a LD50 of 6000 mg/kg and was rated as average. 
While salicylic acid had a LD50 of 891 mg/kg and was rated as fair and maleic acid was 
graded as poor with a LD50 of 708 mg/kg.  
Side effects 
Glutaric acid had no reported side effects so it was ranked as an excellent co-former, 
saccharin and rac-tartaric acid was ranked second best with mild to moderate common 
side effects, maleic acid ranked fair with side effects such as acute toxic skin reactions. 
Salicylic acid ranked the poorest due to its gastric ulceration side effects.  
Antiviral activity of co-crystal 
NVSC co-crystal displayed the greatest antiviral activity, followed by NVTTA, 
NVGLT, NVMLE and then NVSLI.12 Hence, saccharin was ranked as excellent in this 
aspect, followed by co-formers rac-tartaric acid, glutaric acid, maleic acid and salicylic 
acid, respectively (Fig. 4.4).  
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Figure 4.4 Antiviral activities of nevirapine co-crystals against HIV-1, compared 
to pure nevirapine 
4.3.4 Pharmaceutical properties of co-formers   
Pharmaceutical use for suspensions 
Saccharin was rated as excellent in comparison to the other co-formers since it could 
be used as a sweetener. It is one of the safest sweeteners out of the five sweeteners 
approved in the FDA database17 (acesulfame potassium, advantame, aspartame, 
neotame). Salicylic acid was rated as good since it can act as a food preservative and 
has antiseptic properties. Glutaric acid can be used as a surfactant and this was rated as 
average. Maleic acid was rated as fair since it can be used as a buffering agent. Rac-
tartaric acid could be used as a preservative and had other uses which were not relevant 
to the formulation of suspensions so it was rated as poor.  
Status in FDA Inactive Ingredient Database 
Saccharin was ranked as excellent since it had the highest percentage of 0.25 % of the 
total suspension which can consist of saccharin. This value indicated that in an instance 
where saccharin was to be used as an excipient, 0.25 g may be added to a 100 mL 
suspension. Rac-tartaric was ranked as good and followed closely with a limit of 0.20 
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%, meaning that 0.20 g of rac-tartaric acid may be added as an excipient in to a 100 
mL suspension.  Maleic acid was ranked as average and there was no value stipulated 
for it in the FDA inactive ingredient database.  The other two co-formers viz. glutaric 
acid and salicylic acid were not included in this database as they are not commonly 
used as excipients for oral consumption and hence they were rated as fair.   
Preparation method of co-crystal  
As mentioned previously co-crystals of nevirapine can be formulated by means of 
liquid assisted grinding or slow evaporation or by both the methods, depending on the 
co-former.1 Glutaric acid and salicylic acid were favoured since these co-formers can 
be formulated as co-crystals by using both the methods. Maleic acid was ranked as 
good as it can be prepared by liquid assisted grinding only. Saccharin and rac-tartaric 
acid can only be used in slow evaporation and this was rated as average.  
Percentage yield of co-crystal 
Saccharin, salicylic acid and maleic acid had a percentage yield of 78 %, 76 %, 110 % 
respectively.10 These co-formers were rated as excellent as they had a percentage yield 
of above 75 %. Glutaric acid had a percentage yield of 73 % and was rated as good. 
Rac-tartaric acid had the least percentage yield of 60 % and was ranked as average. 
Saccharin yielded a high percentage inspite of its method of preparation i.e. slow 
evaporation. Rac-tartaric acid was another example of a co-former made by slow 
evaporation technique and this co-former showed a yield of only 60%.  
Solvent used to prepare the co-crystal  
With regards to the solvent used to prepare the co-crystal, saccharin was rated as 
excellent since the co-crystal formed with saccharin can be formed with a plethora of 
solvents, thus there are more options of solvents to choose from in the instances where 
reproducibility of producing the co-crystal is low or where challenges may be 
encountered during preparation of the co-crystal.13 Glutaric acid, salicylic acid and 
maleic acid could only be formed with chloroform, these were ranked as good. Rac-
tartaric acid was ranked as fair since it could only be prepared with amyl-alcohol and 
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when compared to chloroform, it has a higher boiling point, meaning that it took a 
longer time for the solvent to evaporate during the co-crystal preparation.   
Sedimentation volume test  
Sorbitol was the chosen vehicle in the co-crystal suspension as it is one of the excipients 
in the Viramune® formulation hence, to perform the sedimentation volume test the 
amount of co-former needed in a 100 mL suspension was calculated and suspended in 
100 mL of sorbitol.  
Volume needed for experiment = 100 mL 
Dosage of Viramune: 50 mg/5 mL 
Therefore amount of nevirapine in 100 mL = 1 g   
No. of moles = 
𝑀𝑎𝑠𝑠 
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 
 = 
1 𝑔
266.297 𝑔/𝑚𝑜𝑙 
= 3.74 𝑋 10−3 𝑚𝑜𝑙 
Co-former Ratio of 
API:co-
former  
Number of 
moles (mol) 
Molecular 
Weight 
(g/mol) 
Mass of co-former  
 (g) 
Saccharin 2:1 1.87 x 10−3 183.18  0.343 
Tartaric 1:1 3.74 x 10−3 150.05  0.561 
Maleic 1:1 3.74 x 10−3 116.07  0.434 
Glutaric 1:1 3.74 x 10−3 132.11  0.488 
Salicylic 2:1 1.87 x 10−3 138.12  0.258 
Table 4.3 Mass of co-formers needed for sedimentation height experiment 
Five graduated cylinders were placed with 100 mL sorbitol and the mass of each co-
former as calculated in table 4.3 was added to each cylinder. The height at time zero 
(Ho) was measured and the height at 15, 30, 46, 60, 90 minutes and 24 hours was 
measured (Ht), where t = 15, 30, 46, 60, 90 minutes and 24 hours.   
The results are tabulated below in table 4.4:  
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Co-former (Ht/Ho) 
15 min 
(Ht/Ho) 
30 min 
(Ht/Ho) 
45 min 
(Ht/Ho) 
60 min 
(Ht/Ho) 
90 min 
(Ht/Ho) 
24hrs 
Saccharin 0.0132 0.0132 0.0132 0.0263 0.0263 0.013 
Rac-tartaric 0.0263 0.0263 0.0263 0.0329 0.0329 0.020 
Maleic 0.0132 0.0197 0.0329 0.0329 0.0329 0.000 
Glutaric 0.0329 0.0329 0.0395 0.0395 0.0395 0.000 
Salicylic 0.0000 0.0000 0.0000 0.0000 0.0000 0.000 
Table 4.4 Sedimentation height experiment of co-formers 
A ratio that is closer to 1 is preferred as this indicates that particles are capable of 
flocculation. Only two co-formers had a value after 24 hours i.e. saccharin and rac-
tartaric acid. The remaining co-formers had settled completely. As seen in table 4.4, 
rac-tartaric acid had a value of 0.020 which was closer to the value 1, while saccharin 
had a value of 0.013 which was rated as good. Thus, rac-tartaric was marked as 
excellent, saccharin as good and the rest of the co-formers as average since all these 
co-formers settled completely after 24 hours (Fig 4.5). 
 
Figure 4.5 Sedimentation height: time ratio of co-formers  
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Cost 
Maleic acid was the cheapest co-former, followed by rac-tartaric acid, glutaric acid, 
salicylic acid and lastly saccharin.  
4.4 Ideal co-former for suspension  
After compilation of the properties of the co-formers, the total score was calculated by 
multiplying the total number of variables for each category according to an ordinal 
scale (excellent = 5, good = 4, average = 3, fair = 2 and poor = 1). Saccharin had the 
highest points of 74. Rac-tartaric acid followed this result closely with 72 points, 
salicylic acid and glutaric acid had 69 and 61 points respectively. Maleic acid had the 
least points with 58 in total.  
 Excellent 
5  
Good  
4 
Average 
3 
Fair 
2 
Poor 
1 
Total 
score* 
Saccharin  9 3 3 2 4 74 
Glutaric acid  4 3 9 2 3 61 
Salicylic acid  5 5 3 7 1 69 
Rac-tartaric acid  6 6 3 3 3 72 
Maleic acid 2 5 5 4 5 58 
*Example for saccharin: (9x5 + 4x3 + 3x3 + 2x2 + 4x1 = 74) 
Table 4.5 Total points of nevirapine co-formers based on physical, chemical, 
pharmacological and pharmaceutical properties according to table 4.1 
According to the total points obtained, saccharin was the most suitable with 74 points. 
Saccharin was chosen in contrast to other co-formers because it was graded as excellent 
in nine variables.  Saccharin was preferred because of its taste, particle size, specific 
gravity, and its status according to the FDA inactive ingredient database. In an article 
review conducted by Changquan Sun, he coined the term “sweet co-crystals”.19 The 
author mentioned the possibility that saccharin co-crystals exhibit a better taste profile 
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than the API alone; this is especially true if the API has a low solubility, which is the 
case with nevirapine.  
Furthermore, it was also advised that sweet co-crystals are beneficial for developing 
chewable tablets, oral suspensions -which is the aim of the project- or solutions, with 
the potential for new intellectual properties. The reason for preparing sweet co-crystals 
is to resolve the problem of delivering a bitter API.  
Viramune® uses the excipient sucrose as a sweetener in the suspension. Using 
saccharin in the co-crystal will eliminate the need of using sucrose as an additional 
excipient in the suspension, as the co-crystal will serve as an API and a sweetener.  
Consequently, using saccharin as the co-former in the nevirapine co-crystal suspension 
is advantageous as it will use less excipients.   
Therefore, according to the protocol developed, saccharin was the chosen co-former to 
prepare a nevirapine co-crystal suspension. The nevirapine-saccharin co-crystal will 
henceforth be referred to as NVSC (Fig. 4.6).  
 
 Figure 4.6 Molecular structure of nevirapine-saccharin co-crystal (2:1)13 
pKa was introduced as an index to express the acidity of weak 
acids 
 
saccharin 
hydrogen bonding 
molecule A of 
nevirapine 
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4.4.1 Structure of NVSC co-crystal  
The NVSC co-crystal consists of two independent nevirapine molecules and a 
saccharin molecule. The two molecules of nevirapine form a pseudocentrosymmetric 
dimer via two N-H•••O hydrogen bonds. The saccharin molecule is linked to a pyridine 
N atom of molecule A of nevirapine via a hydrogen bond N-H•••N.13 
pKa is defined as an index to express the acidity of weak acids. A variable used to 
design a co-crystal is the Δ pKa between the co-former and the API. Nevirapine has a 
pKa of 2.8 while saccharin has a pKa of 1.8, thus resulting in a Δ pKa [pKa (base) - 
pKa (acid)] of 1. This confirmed Sekhon’s theory that the Δ pKa should be less than 
three for formation of a co-crystal,20 which was achieved in the NVSC co-crystal. This 
alone does not guarantee the formation of a co-crystal and variables in the 
crystallization process such as API:co-former ratio, temperature, pressure, solvent and 
crystallization method play a role in the formation of a co-crystal. Details relating to 
the crystallization process are outlined in the following section. 
4.5 Results for preparation and scaling up of the NVSC co-crystal 
The NVSC co-crystal was prepared in a 2:1 ratio by the slow evaporation method. 
Stoichiometric calculations of nevirapine and saccharin were calculated and the 
amounts were weighed accordingly. Thereafter, two 10 mL glass vials with minimum 
volumes of methanol were placed on a magnetic hot plate at 54 °C i.e. approximately 
10 ºC below the boiling point of the methanol. The co-former and the API were added 
separately to each of these vials. The solution of greater volume was added to that of 
smaller volume and the resultant solution was magnetically stirred for 30 minutes. This 
was filtered through a micro filter of 0.45 μm using a syringe and the resultant solution 
was placed in a beaker which was covered with a perforated Parafilm® and allowed to 
crystallise at 20 ºC in a fume cupboard until all the solvent had evaporated.13 
Najar et al.21 foresaw the challenges that lied ahead with respect to scaling up the 
production of the co-crystal, identifying new scale-up methods, and high throughput 
screening of the possible co-crystal with various co-formers and their polymorphs.21 
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The main challenge with scale-up is scaling up to a multikilogram scale. Solid-state 
grinding approaches are particularly difficult to scale-up to a multikilogram scale for 
energetic materials since grinding may present a potential hazard due to friction 
generated during grinding.22  
For the purpose of this study, scaling up operations commenced with batches from 
milligram scale to gram scale. Several batches were made, starting from small 
laboratory scale progressing to a larger laboratory scale (Table 4.6). The batches were 
prepared in the same environment but were evaporated in different sized fume 
cupboards. Batch 1 to 8 evaporated in a small fume cupboard while batch 9 to 14 
evaporated in a large fume cupboard. The batches prepared in the smaller fume 
cupboard took a longer time for the solvent to evaporate, thus the number of days taken 
for the co-crystal to grow was longer. The batches prepared in the larger fume cupboard 
took less time for the solvent to evaporate therefore the growth period for the co-crystal 
was less.  
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  2 13 140 1000 340 1340 1100 82 
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5 23 700 5000 1710 6710 5364 92 
6 20 280 2000 687 2687 2500 96 
7 6 80 500 171 671 660 98 
8 10 80 500 171 671 578 92 
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Table 4.6 Scaling up of NVSC co-crystal  
The percentage yield in the large fume cupboard was 88 to 98 %. The results from the 
large fume cupboard were reproducible; this can be seen with batch 9 and 10, where it 
took 2 days each for 500 mg of co-crystal to be reproduced whilst, batch 7 and 8 which 
were prepared in the small cupboard took 6 and 10 days respectively to produce co-
crystals of the same amount. The volume of solvent was evidently directly proportional 
to the size of the batch prepared (Table 4.6). The results clearly show that co-crystals 
formed from a larger fume cupboard faired better with respect to percentage yield and 
the number of days for the co-crystal to form.  The percentage yield obtained was in 
the range of 80 to 98 % across small and large scale laboratory production. This result 
was in line with the 78 % yield that was noted in literature.10 
It was notable that the number of days taken for the co-crystal to grow was directly 
proportional to the size of the batch (Fig. 4.7). This can be substantiated by the 
recommendations by Chen et al. where it was mentioned that the time required to scale-
up is invariably due to larger volume of materials needed to scale-up.23 Figure 4.7 
illustrates that the greater the size of the batch, more quantity of co-former and API are 
required.  
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10 2 80 500 171 671 588 88 
11 2 80 500 171 671 664 98 
12 2 80 500 171 671 625 93 
13 6 140 1000 340 1340 1080 80 
14 3 280 2000 687 2687 2430 90 
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Figure 4.7 Batch size versus the growth period and mass required 
4.5.1 Challenges encountered during scaling up 
Batch 5 was the largest batch size prepared with 5 g of active ingredient. This batch 
was left to evaporate in a small fume cupboard. The number of days it took for all the 
solvent to evaporate was 23 days.  
Upon slow evaporation, it was found that not all the powder had crystallized; this was 
physically seen as clumps on the sides of the beaker. The powder formed on the sides 
of the beaker was confirmed with DSC as an incomplete crystallisation of the 
nevirapine and saccharin (Fig. 4.8). The powder at the bottom of the beaker was 
confirmed as the co-crystal; however decomposition began earlier at 240 °C. This 
meant that not all the powder had resulted in a co-crystal. The peaks obtained in the 
DSC did not correspond to the melting point of nevirapine (247- 249 °C) and saccharin 
(228 - 229 °C). The peak obtained at 210 °C was close to the melting point of NVSC 
(215 – 230 °C).  However, this was not confirmed as a pure co-crystal due to the 
presence of an endothermic peak at 193 °C. Therefore attempts were made to purify 
the powder to ensure a pure co-crystal is obtained.  
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Figure 4.8 DSC of Batch 5  
Two methods were attempted to purify the powder. Firstly, a seeding strategy similar 
to the generic scalable methodology developed by Sheik et al. for carbamazepine-
nicotinamide co-crystals was explored.24 This method involved adding a small quantity 
of already formed NVSC co-crystal to the powder of nevirapine and saccharin for the 
purposes of introducing nucleation. However, this strategy proved to be unsuccessful 
in the case of NVSC co-crystal. The DSC results showed two individual peaks at 212 
°C and at 240 °C (Fig. 4.9). The peak obtained at 215 °C can be attributed to the co-
crystal while the peak at 240 °C corresponds to the melting point of nevirapine. Thus, 
the co-crystal obtained was not considered pure as the powder consisted of the API 
individually and the co-crystal. 
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Figure 4.9 Purification of batch 5 through seeding strategy 
An alternative method was attempted to purifying the powder. The powder was 
recrystallized by placing it in methanol, according to the temperature used to prepare 
the co-crystal; the stirring time was increased to 3 hours, and then filtered in a large 
5000 mL beaker. Upon evaporation it was indeed confirmed to be the co-crystal (Fig. 
4.10).  
 
Figure 4.10 Purification of batch 5 through recrystallizing with extended stirring 
time and larger surface area 
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The DSC after purifying through recrystallizing with methanol indicated the formation 
of the NVSC co-crystal at 212 °C. This result indicated that the mixing time in the 
scale-up process is to be increased as the batch size increases; this was rightly 
suggested by Chen et al. in their perspective article.23    
These results suggest that scaling up could be increased to the gram scale; however 
certain variables directly affecting co-crystal preparation will also have to be adjusted 
appropriately. These variables include stirring time and surface area available for 
evaporation.   
4.6 Identification of the various batches of NVSC co-crystals  
According to the European Medicines Agency, the formation of a co-crystal should be 
unambiguously demonstrated by means of adequate analytical techniques to rule out 
the possibility of the formation of a purely physical mixture of two or more crystalline 
compounds.7  
This study fully echoes the standpoint of the European Medicines Agency on the 
identification of co-crystals and thus utilized analytical techniques such as DSC, HSM, 
FTIR and TGA.  
Nevirapine has a melting point of 247 – 249 °C, while saccharin displays a melting 
point of 228 - 229 °C. According to the original inventor of the NVSC co-crystal, the 
melting point of the co-crystal was discovered to be in a range of 215-230 °C and 
subsequently decomposition began at 315 °C.13 Figure 4.11 displays the DSC 
endotherms obtained for the NVSC co-crystal, nevirapine the API and saccharin as the 
co-former.   
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Figure 4.11 DSC of NVSC co-crystal, nevirapine and saccharin 
The various batches produced displayed a melting point well within the mentioned 
range thus, confirming the formation of the NVSC co-crystal (fig 4.12 and 4.13). The 
hot stage microscopy and the thermogravimetric analysis further attested the formation 
of a co-crystal by confirming the melting point with no significant mass loss of solvent, 
respectively.  
Nevirapine 
Saccharin
 
 Nevirapine 
NVSC 
 
 
 
 
  
125 
 
4.6.1 Differential Scanning Calorimetry of NVSC co-crystal batches  
 
Figure 4.12 DSC of NVSC batches 1-5 
 
Figure 4.13 DSC of NVSC batches 7-14 
Chen et al. suggested that during scale-up, the thermal stability of raw materials should 
be pre-determined to detect endothermic or exothermic behaviour.23 Thus, this study 
followed suite and performed identification tests of raw materials. All the DSC results 
as seen in figure 4.12 and 4.13 revealed the formation of the NVSC co-crystal by 
displaying a melting point within the melting point range stipulated in literature.1  
 
 
Batch 1 
Batch 2
Batch 3
Batch 4
Batch 5 
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However, a difference that was consistently observed during scaling up was that 
decomposition began much earlier (235-240 °C) in comparison to the earlier studies 
done by Caira et al1  where decomposition at 315 °C was recorded. This difference in 
decomposition could be attributed to the increase in batch size.  
4.6.2 Hot Stage Microscopy of NVSC co-crystal batches  
 Start  Melting  Decomposition  
Batch 
1  
   
 68 °C 230 °C 238 °C 
Batch 
2 
   
 105 °C 226 °C 235 °C 
Batch 
3  
   
 90 °C 236 °C 245 °C 
Figure 4.14 HSM of NVSC batches 1-3 
HSM results showed a melting point in the range of 230-236 °C reaffirming the 
formation of the NVSC co-crystal (fig. 4.14). The decomposition results of HSM and 
DSC were in agreement, with decomposition beginning in a range of 235-250 °C. It 
can be noted that the appearance of the powder was crystalline in nature.     
For HSM of batches 4 to 14 the reader is referred to Appendix A. 
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4.6.3 Thermogravimetric analysis of NVSC co-crystal batches  
 
Figure 4.15 TGA of batch 1-5 
 
Figure 4.16 TGA of batch 6 - 14 
 
 
Batch 1 
Batch 2
Batch 3
Batch 4
Batch 5 
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TGA results of all batches recorded a mass loss of less than 2% (fig. 4.15 and 4.16).  
Mass loss was related to a volatile component which is methanol in this case, the 
solvent that was used to prepare the sample.25 The TGA curve presents a melting point 
in the range of 210 – 230 °C and decomposition at 260 – 275 °C. This is in accordance 
with the results obtained in the DSC and HSM. Thus, confirming the formation of the 
NVSC co-crystal.  
4.6.4 Fourier Transform Infrared of NVSC co-crystal 
 
Figure 
 
Figure 4.17 Indication of functional groups interacting in the NVSC co-crystal13 
Figure 4.17 indicates the functional groups of the NVSC co-crystal that are identified 
in the FTIR spectra. The experimental frequency of the NVSC co-crystal was compared 
to the standard frequency (Table 4.7). Additionally, it was compared to previous 
spectra of the NVSC co-crystal (Fig. 4.18).  
 
O = C-NH 
Aromatic-C=C- 
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Bonds for saccharin Standard frequency Experimental frequency 
S-N-C 975 972 
O = C-NH 1722 1715 
CO-NH 3100 3093 
Aromatic –C = C - 1597 1592 
Bonds for nevirapine Standard frequency26 Experimental frequency  
C-O 1646 1643 
N-H, C-N 3188 3185 
Bonds for NVSC Standard frequency10 Experimental frequency  
S-N-C 975 975 
O = C-NH 1722 1644 
Aromatic –C = C - 1597 1585 
C-O  1646 1643 
Table 4.7 Standard frequency versus experimental frequency of saccharin, 
nevirapine and NVSC 
 
Figure 4.18 FTIR spectra of Saccharin, Nevirapine and NVSC co-crystal  
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S-N-C bond of the NVSC co-crystal appears at 975 cm-1, which is the exact standard 
absorbance of this bond. C-O and aromatic-C = C- could be identified at 1643 cm-1 and 
1586 cm-1respectively; The C-O bond in the NVSC co-crystal is expected to be seen at 
1646 cm-1, and the experimental results identified a peak at 1643 cm-1, these bonds 
signify the formation of NVSC.                                                                                                                                                            
4.7 Method for preparation of nevirapine suspension   
The branded nevirapine suspension, Viramune®, contains the following excipients: 
carbomer, polysorbate 80, sorbitol solution, methylparaben, propylparaben, sodium 
hydroxide and purified water. Viramune ® is prepared by the dispersion technique; the 
aforementioned technique along with the pH modification technique was utilized to 
prepare a suspension using the NVSC co-crystals that were described above (Fig. 4.19).  
 
Figure 4.19 Preparation of nevirapine co-crystal suspension as per pH 
modification method used in Viramune ® 
Excipients were added in a stepwise manner and added only if necessary, this was to 
promote the judicious use of excipients.  
Water heated to 
70 °C and the 
parabens were 
added  
Cooled to 35 °C 
and the viscosity 
agent is slowly 
dispersed
 
 Water heated to 
70 °C and the 
parabens were 
added  
Altered pH by 
adding NaOH 
20% until pH of 
5.5-5.8 was 
achieved 
The gel was stirred 
with a magnetic 
stirrer/propeller 
blade for 2 minutes 
(solution A) 
Added 
polysorbate 80 to 
a small portion of 
water
  
 Water heated to 
70 °C and the 
parabens were 
added  
Allowed the 
polysorbate 80 to 
dissolve, 
excessive stirring 
caused foaming  
Added the weighed 
co-crystals slowly and 
stirred the solution 
until a homogenous 
preparation was 
obtained  
(solution B)  
Blend solution B into 
the solution A gel and 
added sufficient 
quantity of water   
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Three formulations were investigated with different viscosity inducing agent’s viz. 
aerosil 200, carbopol 971G and carbopol 974P. Furthermore, at each stage the pH and 
integrity of the co-crystal were deemed as critical variables.  pH of suspension was 
important to the formulation of the suspension to ensure safe consumption of the 
suspension and to ensure the stability of the preparation while it is on the shelf. 
Retention of the co-crystal in the suspension formulation was crucial as it is essential 
for the suspension to have the desired therapeutic effect upon consumption.   
4.8 Formulation A 
The following combinations were attempted for formulation A, using Aerosil 200 as 
the viscosity inducing agent.  
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Table 4.8 Variations of formulation A 
4.8.1 Formulation A1 (NVSC and sorbitol)  
The purpose of this formulation consisting of only NVSC and sorbitol was to identify 
if the co-crystal was retained in sorbitol alone. To prepare this formulation A1, 250 mg 
of NVSC co-crystal was added to 25 mL of sorbitol in a beaker. The sample was stirred 
at 600 rpm on a magnetic hot plate for 24 hours at room temperature. The sample was 
then filtered through a Whatman® filter paper no. 41 since the sample was too viscous 
to pass through 0.45µm filter membrane.  
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4.8.1.1 pH of formulation A1 
The pH of the sorbitol and NVSC co-crystal was 2.48 at room temperature. This 
showed that the co-crystal had significantly reduced the pH of the sorbitol (pH = 8). 
This was attributed to the acidic nature of the co-crystal.  
4.8.1.2     Co-crystal integrity of formulation A1 
Filtered sorbitol was used as the blank for UV calibration. The suspension was then 
placed in a 1 mL glass UV cuvette by means of a syringe. A wavelength scan was 
performed through ultraviolet spectroscopy from 200 to 800 nm.  
A presence of peaks at 234 nm for nevirapine and 260 nm for saccharin indicated that 
the co-crystal had fragmented into its individual components (Fig. 4.20) and that the 
co-crystal could not be retained in sorbitol alone.  
 
Figure 4.20 UV spectra of formulation A1 
The challenge at this juncture became two fold, the first challenge was to retain the co-
crystal and the second was to adjust the pH of the co-crystal suspension. Hence, the 
baseline
sample 
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next excipient was explored to ascertain if the co-crystal integrity could be maintained 
and to modify the pH in a range of 6-8.  
4.8.2 Formulation A2 (NVSC and aerosil)  
This formulation was explored to ascertain if the co-crystal could be retained in an 
aerosil 200 solution. To prepare this formulation, an aerosil 200 gel was prepared by 
heating 5 mL of water in a small beaker and adding 0.019 g of aerosil 200 powder. 50 
mg of the NVSC co-crystal was added and stirred for 24 hours. The total volume of the 
aerosil 200 and the water that was added was 5 mL, therefore the amount of co-crystal 
added was based on the concentration found in Viramune ® 50 mg/5 mL.  
4.8.2.1 pH of formulation A2 
The pH of aerosil 200 alone was found to be 6.40. The formulation A2, which consisted 
of aerosil and NVSC co-crystal was measured be 2.32. This once again indicated that 
the co-crystal reduced the pH of the aerosil 200 suspension. This was again recognized 
to the acidic nature of the co-crystal.  
4.8.2.2    Co-crystal integrity of formulation A2 
Since, this preparation was more viscous that formulation A1, it could not be filtered 
through a 0.45 µm filter membrane nor through filter paper. Hence, DSC was used to 
determine if the co-crystal was still intact in formulation A2.  
A 1 mL of the suspension was filtered “before” stirring the formulation. The DSC of 
the filtrate indicated that the co-crystal was present (Fig. 4.21). The melting point of 
the NVSC co-crystal was within the range specified in the pre-formulation studies i.e. 
(215 – 230 ºC).13 There was also a broad peak seen between 80 – 120 ºC, this was 
recognized due to the presence of aerosil 200 and water.  
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Figure 4.21 DSC of formulation A2 before stirring 
However, after stirring for 24 hours, a 1 mL suspension was filtered and the DSC of 
this filtrate indicated that there was no presence of co-crystal that should have ideally 
been identified in the range of 215 – 230 ºC, suggesting that the NVSC co-crystal had 
disintegrated into the aerosil 200 media. This is due to the stirring that took place during 
preparation of the aerosil suspension.  This indicated that this formulation was not 
viable because it meant that if the suspension is stirred, the co-crystal is fragmented, at 
the same time, stirring was needed to ensure the preparation is homogenous. Hence, 
this formulation had failed to retain the co-crystal integrity.  
 
Figure 4.22 DSC of formulation A2 after stirring 
 
NVSC 
present 
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4.8.3 Formulation A3 (NVSC, aerosil, sorbitol, sodium hydroxide, and 
preservatives) 
A similar procedure akin to the preparation of Viramune ® was attempted. 5 mL of 
water was heated to 70 ºC by means of a water bath. Preservatives were added to this 
solution (0.018 g of methylparaben and 0.024 g of propylparaben). The temperature of 
the solution was then cooled to a temperature of 35 ºC. Aerosil 200 was added, initially 
0.019 g and thereafter additional 0.100 g was added to ensure the preparation was 
viscous in nature.  Upon addition of 1 mL sorbitol, a total volume of 3 mL was formed. 
Therefore 30 mg of NVSC co-crystal was added and left to stir for 24 hours. 50 µL of 
sodium hydroxide 20% buffer solution was added to modify the pH. Formulation A3 
had good wetting properties, hence usage of polysorbate 80 was omitted.  
4.8.3.1 pH of formulation A3 
Since this formulation had many excipients, the pH was measured at each stage of the 
preparation (Table 4.9). After heating the preservatives and adding the aerosil 200 in 
water, the pH was measured to be 5.82, after stirring the pH increased slightly to 6.43. 
Upon addition of the co-crystal and the sorbitol and stirring the sample for 24 hours 
the pH decreased to 3. To modify the pH, sodium hydroxide was added and the pH 
increased drastically to 12.84.   
 pH 
Preservatives and aerosil 200 5.82 
Preservatives and aerosil 200 (after stirring) 6.43 
Preservatives, aerosil 200, NVSC co-crystal 3.00 
Preservatives, aerosil 200, NVSC co-crystal, 50 µL sodium 
hydroxide 20% 
12.84 
Table 4.12 pH of formulation A3 
4.8.3.2      Co-crystal integrity of formulation A3 
Despite the failed attempt to modify the pH, the suspension was filtered by means of a 
Whatman® filter paper. A DSC was performed on the filtrate to identify whether the 
co-crystal was still present after the addition of various excipients.  
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Figure 4.23 DSC of formulation A3 
There was a broad peak formed between 120 – 180 ºC. This was attributed to the 
components such as aerosil 200 and the preservatives. The co-crystal is ideally formed 
between 215-230 ºC with nevirapine identified at 245-249 ºC and saccharin at 228-229 
ºC. The DSC of the filtrate indicated a sharp peak at 240 ºC (Fig. 4.23). This could 
possibly indicate the presence of the nevirapine, as it is closer to the melting point of 
nevirapine. Thus, indicating that the NVSC co-crystal had fragmented into its API, 
nevirapine, and possibly saccharin had dissolved in the preparation. 
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4.8.4 Comparison of formulation A1 to A3 
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Table 4.23 Comparison of pH and integrity of Formulation A 
From table 4.13, it can be concluded that aerosil 200 does not allow for the co-crystal 
to be intact in a suspension formulation. Furthermore, the pH obtained was not within 
the desired range. Also, formulation A3 that was prepared was not viscous enough thus 
causing particles to settle upon storage. The maximum viscosity achieved was 10.35 
cP at a shear rate of 50 with a SC4-18 spindle (Fig. 4.24). This viscosity was not 
sufficient to suspend the NVSC co-crystal particles.   
 
Figure 4.24 Viscosity versus shear rate of formulation A3  
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Figure 4.25 Shear stress versus shear rate of Formulation A3 
The rheogram (shear stress versus shear rate) of formulation A3 indicated that the 
suspension was pseudoplastic in nature (Fig. 4.25). Yield stress is the point at which 
the preparation begins to deform. The yield value obtained was 4.44 cP. On comparison 
of the yield value to the viscosity obtained (10.35 cP), it showed that the suspension is 
easily deformed and is not viscous enough as it starts sedimenting instantaneously upon 
storage.     
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4.9 Formulation B 
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B1 50 
mg 
10.5  
mg 
      
B2 50  
mg 
10.5 
mg 
7  µL      
B3 165 
mg 
33.6
mg  
30  
µL 
3.7 
mL  
8 
µL 
28.8 
mg 
 
3.84 
mg 
q.s 
Table 4.14 Variations of formulation B  
The above formulations were attempted for formulation B (Table 4.14). The 
formulation included the same excipients as in Viramune® except that formulation B 
used carbopol 971G as the viscosity inducing agent. The carbopol 971G is used for 
oral dosage forms. It is granular in nature and used for tablets and suspensions as well.  
4.9.1 Formulation B1 (NVSC co-crystal and carbopol 971G)  
The purpose of this formulation was to ascertain if NVSC co-crystal could be retained 
in carbopol 971G. To prepare formulation B1, 0.0105 g of carbopol was stirred in 5 
mL of water. The amount was calculated in accordance to what was stated in the 
Viramune® patent. The patent required 0.2100 g carbomer in 100 mL, thus for a 5 mL 
suspension, 0.0105 g carbopol 971G was required. Upon stirring the carbopol 971G in 
5 mL of water, a viscous gel was formed and 50 mg of NVSC was added to this. The 
preparation was stirred together for 24 hours.  
4.9.1.1 pH of formulation B1 
The pH of formulation B1 consisting of carbopol 971G and the NVSC co-crystal was 
found to be 3.02. 
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4.9.1.2 Co-crystal integrity of formulation B1 
 The suspension was then filtered by means of Whatman® filter paper. The filter 
paper was dried in a fume cupboard for 3 weeks. DSC was performed on the filtrate 
(Fig. 4.26).   
 
Figure 4.26 DSC of formulation B1 
The DSC indicated an endotherm at 215 ºC, which was the exact onset of melting point 
at which NVSC co-crystal is expected to be seen.  Hence, it can be concluded that the 
NVSC co-crystal is stable in carbopol 971G.  
The FTIR of the suspension without filtration was performed. It was compared to the 
FTIR spectra of the NVSC co-crystal powder alone. The two spectra were 
superimposed and were found to be identical. Bonds such as C-O and aromatic -C = 
C- could be identified at 1646 cm-1 and 1586 cm-1, respectively; these bonds indicate 
the presence of NVSC. Therefore, it is conclusive that the NVSC co-crystal can be 
retained in carbopol 971G.  
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Figure 4.27 FTIR spectra of formulation B1 
This formulation was able to retain the co-crystal in the suspension; however, the pH 
of this formulation was 3.02, which was unsuitable for oral use. Hence, the next 
formulation aimed to modify the pH suspension whilst retaining the co-crystal in 
carbopol 971G is formulation B2.  
4.9.2 Formulation B2 (NVSC, carbopol 971 G and sodium hydroxide)  
Formulation B2 was prepared by adding 0.0105 g of carbopol 971G to 5 mL of water 
in a beaker. This solution was stirred magnetically and 50 mg of NVSC was added to 
the suspension.  
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
NVSC co-crystal powder
Carbopol 71G NF + NVSC 
3190.32
3059.88
1737.32
1646.51
1586.03
1568.05
1490.81
1464.66
1412.82
1384.15
1349.75
1329.77
1290.52
1244.45
1207.05
1178.85
1164.07
1131.59
1115.12
1075.47
1027.58
944.62
884.99
872.99
829.00
805.82
788.65
754.59
697.15
673.19
655.59
3184.18
3061.55
1643.39
1585.72
1488.14
1465.20
1382.92
1354.06
1288.24
1258.83
1242.31
1209.96
1166.90
1152.85
1107.34
1090.85
1074.81
1047.74
1024.46
975.31
941.67
883.94
819.05
803.28
787.98
756.64
710.55
696.49
655.42
Carbopol  971G + 
NVSC  
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4.9.2.1 pH of formulation B2 
The pH was measured to be 3.02.  To modify the pH, 7 µL of sodium hydroxide was 
added and the pH was re-measured to be 6.95. The addition of sodium hydroxide 
successfully modified the pH (Table 4.15) 
 pH 
Carbopol 971G and NVSC co-crystal 3.02 
Carbopol 971G, NVSC, sodium hydroxide 6.95 
Table 4.15 pH of formulation B2  
4.9.2.2    Co-crystal integrity of formulation B2 
Formulation B2 was filtered through a Whatman® filter paper and the filter paper was 
dried in a fume cupboard for 3 weeks. DSC was performed on the filtrate (Fig. 4.28). 
 
Figure 4.28 DSC of formulation B2 
An endotherm was seen at 242 ºC, this was close to the melting point of nevirapine 
which is at 245 -249 ºC. Hence, FTIR was performed to establish if the co-crystal was 
still intact or if it had separated into the API and co-former.  
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The FTIR spectra of the NVSC co-crystal powder was compared to the NVSC co-
crystal suspension in carbopol 971G (Fig. 4.29). The C-O bond in the NVSC co-crystal 
was expected to be seen at 1646 cm-1 and the experimental results identified a peak at 
1644 cm-1, thus signifying the presence of the co-crystal. S-N-C bond appears at 975 
cm-1, which is the exact absorbance of this bond. This signifies the presence of the 
NVSC co-crystal in the suspension. Hence, this result indicates that the co-crystal was 
still present in the carbopol 971G medium.  
 
Figure 4.29 FTIR of formulation B2 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
NVSC co-crystal powder
NVSC in carbopol 71G NF, NVSC , NaOH
3184.18
3061.55
1643.39
1585.72
1488.14
1465.20
1410.13
1382.92
1354.06
1288.24
1258.83
1242.31
1209.96
1166.90
1152.85
1107.34
1090.85
1074.81
1047.74
1024.46
975.31
941.67
883.94
819.05
803.28
787.98
756.64
710.55
696.49
655.42
3185.94
3062.28
1644.76
1585.92
1488.31
1465.04
1354.31
1288.65
1242.39
1210.55
1153.18
1074.78
1024.88
941.74
884.26
818.88
803.14
788.36
757.04
696.74
Carbopol  971G + NVSC + NaOH 
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Formulation B2 had a pH of 6.95, which was within the target pH required, 
furthermore, the FTIR also indicated that the co-crystal was intact in carbopol 971G 
and sodium hydroxide. However, co-crystal integrity was not confirmed through DSC. 
Hence, formulation B3 was developed to ensure that the co-crystal is present.  
4.9.3 Formulation B3 (NVSC, carbopol 974P, sorbitol, sodium hydroxide, 
polysorbate and preservatives)  
This formulation was prepared using excipient such as sorbitol to enhance the density 
of the suspension medium. A 16 mL of formulation B3 was prepared according to the 
method used to prepare Viramune ® suspension.  In a 25 mL beaker, 4 mL of water 
was heated on a magnetic hot plate at 70 ºC. Preservatives such as methylparaben 
(0.072 g) and propylparaben (0.0096 g) were added to the beaker and stirred at 600 
rpm. The preservative solution was cooled to 35 ºC. Carbopol 971G (0.042 g) was 
added to the preservative solution. To this solution, sodium hydroxide 20%, 30 µL was 
added and magnetically stirred until a gel was formed.  Sorbitol was added to the 
carbomer solution.   
Polysorbate and water were separately stirred on a magnetic hot plate at room 
temperature. The NVSC co-crystal was added to this solution.  
Both the polysorbate drug concentrate and the carbomer gel were magnetically stirred 
together and made up with water was to 16 mL.  
4.9.3.1 pH of formulation B3 
The pH of the preservatives alone in water was 5.54, upon the addition of carbopol 
971G to the solution, pH was 3.23. This was attributed to the acidic nature of carbopol 
971G. The NVSC co-crystal and polysorbate mixture had a pH of 3.32. When the two 
solutions were mixed together the pH was 4.52. To achieve a suspension within the 
target range, sodium hydroxide was added until a pH of 6.42 was achieved (Table 4.16)   
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 pH 
Preservatives, water 5.54 
Preservatives, carbopol, water 3.23 
NVSC, polysorbate and water 3.32 
Sorbitol, carbopol, NVSC, polysorbate , water, preservatives 4.52 
Sorbitol, carbopol, NVSC, polysorbate , water, preservatives, sodium 
hydroxide 
6.42 
Table 4.16 pH of formulation B3 
4.9.3.2   Co-crystal integrity of formulation B3 
Once the suspension was prepared it was filtered through Whatman® filter paper. The 
filter paper was then left to dry in a fume cupboard and DSC was performed on the 
residue on the filter paper (Fig. 4.30).  
 
Figure 4.30 DSC of formulation B3  
The DSC in figure 4.30 indicated a peak at 100 ºC and this could be attributed to the 
water present in the suspension. There were no other peaks in the filtrate indicating that 
the suspension did not contain the NVSC co-crystal.  
Furthermore, FTIR in figure 4.29 was performed on the suspension itself and it did not 
show absorbance of the functional groups such as C-O bond, S-N-C and aromatic-
C=C-, that are present in the NVSC co-crystal. This clearly indicated that NVSC co-
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crystal was not stable in formulation B3 and that suspension excipients are required to 
maintain the formulation of a suspension.   
 
Figure 4.31 FTIR of formulation B3 
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4.9.4 Comparison of formulation B1 to B3 
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B1 50 
mg 
10.5  
mg 
      3.02   
B2 50  
mg 
10.5 
mg 
7  
µL 
     6.95 x  
B3 165 
mg 
33.6
mg  
30  
µL 
3.7 
mL  
8 
µL 
28.8 
mg 
 
3.84 
mg 
q.s 6.42 x x 
Table 4.17 Comparison of pH and integrity of Formulation B1, B2 and B3 
In spite of the co-crystal integrity not being maintained in formulation B3, the viscosity 
of the suspension was measured with a SC4-18 spindle. The viscosity was 94.33 cP 
with a torque of 62.9%. Torque values between 10-100 % are acceptable.  
 
Figure 4.32 Viscosity versus shear rate of formulation B3 suspension 
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The viscosity of this suspension seemed promising in comparison to formulation A 
which contained aerosil 200. However, this formulation was not pursued since the 
integrity of the NVSC co-crystal was compromised. 
4.10 Formulation C 
Formulation C used carbomer 934P as the viscosity inducing agent. This was the same 
agent used in the Viramune® suspension. The following combinations were performed 
for formulation C.  
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C1 50 
mg 
10.5  
mg 
      
C2 50  
mg 
10.5 
mg 
7  
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C3 165 
mg 
33.6
mg  
30  
µL 
3.7 
mL  
8 
µL 
28.8 
mg 
 
3.84 
mg 
q.s 
Table 4.18 Variations of formulation C 
4.10.1 Formulation C1 (NVSC and carbopol 974P) 
To prepare formulation C1, carbopol 974P (0.0105 g) was added to a beaker with 5 mL 
of water. The solution was stirred together by means of a magnetic stirrer. 0.0050 g of 
NVSC co-crystal was added to the solution. 
4.10.1.1 pH of formulation C1 
The pH of the carbopol 974 P in water was found to be 3.35. Upon addition of the 
NVSC co-crystal to the carbopol 974 P solution, the pH was recorded as 4.12.   
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4.10.1.2 Co-crystal integrity of formulation C1 
Preparation C1 was then filtered through Whatman® filter paper and it was placed in 
a fume cupboard where it was allowed to dry. DSC was performed on the residue of 
the filter paper (Fig 4.33)  
 
Figure 4.33 DSC of formulation C1 
The DSC indicated an endothermic peak at 216 ºC. This was the melting point at which 
NVSC was earlier reported.1 Hence, the co-crystal was present in carbopol 974P.  
FTIR analysis was performed on the suspension without filtering to further confirm if 
the co-crystal was retained in carbopol 974P(Fig.4.34).   
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Figure 4.34 FTIR of formulation C1 
The FTIR spectra (Fig. 4.34) of the suspension were compared to the NVSC co-crystal 
powder and were found to be identical. The presence of bonds at 1644 cm-1 represent 
the C-O bond in the NVSC co-crystal while the aromatic -C=C- of the NVSC could be 
seen at 1586 cm-1. The FTIR together with the DSC results confirmed that the co-
crystal was present in carbopol 974P. However, the pH was low and therefore the next 
formulation used sodium hydroxide to alter the low pH.  
4.10.2 Formulation C2 (NVSC, carbopol 974P and sodium hydroxide) 
To prepare formulation C2, 0.0105 g of carbopol 974P was placed in a beaker with 5 
mL of water and the solution was magnetically stirred. 0.050 g of NVSC co-crystal 
was added to this solution while stirring. 10 µL of sodium hydroxide through a 
micropipette was added to modify the pH of the solution.  
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
NVSC co-crystal powder
NVSC + Carbopol 974P
3061.50
1709.25
1644.72
1586.06
1411.58
1353.89
1288.67
1242.12
1165.33
1025.97
884.12
788.05
756.39
696.55
3184.18
3061.55
1643.39
1585.72
1488.14
1465.20
1382.92
1354.06
1288.24
1258.83
1242.31
1209.96
1166.90
1152.85
1107.34
1090.85
1074.81
1047.74
1024.46
975.31
941.67
883.94
819.05
803.28
787.98
756.64
710.55
696.49
655.42
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4.10.2.1 pH of formulation C2 
The pH of the solution of carbopol 974P and the NVSC co-crystal was measured to be 
2.3. To rectify the pH, 10 µL of sodium hydroxide was added to the solution and the 
pH was re-measured and found to be 5.8.   
4.10.2.2 Co-crystal integrity of formulation C2 
Formulation C2 was filtered by means of Whatman® filter paper no. 41 and the filtrate 
was analysed by DSC (Fig. 4.35).  
 
Figure 4.35 DSC of formulation C2 
DSC indicated a presence of an endothermic peak at 218 ºC. This melting point was 
within the range of the melting point of the NVSC co-crystal, thus suggesting that the 
co-crystal was intact in the carbopol 974P, together with sodium hydroxide at a pH of 
5.8.  
FTIR analysis was done on the suspension to further attest if the co-crystal was present 
in the suspension medium.  
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Figure 4.36 FTIR of formulation C2 
The C-O bond in the NVSC co-crystal expected at 1646 cm-1 was present, signifying 
the presence of the co-crystal. The aromatic -C = C- could also be identified at 1586 
cm-1. This result in conjunction with the DSC result establishes the presence of the 
NVSC co-crystal in formulation C2. This formulation was suitable, however, since 
suspensions are prone to microbial contamination, preservatives needed to be added to 
prevent spoilage. Hence formulation C3 was implemented with preservatives and 
sorbitol had to be added to improve the density of the suspension.      
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
NVSC co-crystal powder
Carbopol 974P + NVSC + NaOH
3186.94
3061.42
1737.85
1645.22
1586.12
1489.26
1465.05
1412.19
1383.61
1353.71
1330.23
1289.47
1243.08
1210.76
1164.98
1131.99
1115.47
1075.22
1026.78
942.99
884.71
829.42
788.58
760.84
696.98
673.20
655.75
3184.18
3061.55
1643.39
1585.72
1488.14
1465.20
1382.92
1354.06
1288.24
1258.83
1242.31
1209.96
1166.90
1152.85
1107.34
1090.85
1074.81
1047.74
1024.46
975.31
941.67
883.94
819.05
803.28
787.98
756.64
710.55
696.49
655.42
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4.10.3 Formulation C3 (NVSC, carbopol 974P, sorbitol, sodium 
hydroxide, NVSC, polysorbate and preservatives) 
To prepare formulation C3, a beaker with 4 mL of water was heated to 70 ºC on a hot 
plate and stirred until 200 rpm. Preservatives such as methylparaben (0.027 g) and 
propylparaben (0.0036 g) were added to the water and mixed with a magnetic stirrer. 
The solution was then cooled to 35 ºC and carbopol 974P (0.0285 g) was added slowly. 
The stirring speed was increased to 600 rpm.  Thereafter, 10 µL of 20 % sodium 
hydroxide was added to the solution. The sample was stirred for twenty minutes and 
subsequently 3.46 mL of sorbitol was added to the solution. In a separate beaker 4 mL 
water together with 7 µL polysorbate 80 were stirred at room temperature.  NVSC co-
crystal (0.1552 g) was added to the water-polysorbate mixture. Thereafter, the 
NVSC/polysorbate 80 concentrate was added to the carbopol 974P gel.  
4.10.3.1 pH of formulation C3 
Since this formulation contains several excipients, the pH had to be measured at each 
stage (Table 4.18). The pH of the preservatives in water was 3.16. Upon addition of 10 
µL of 20 % sodium hydroxide, the pH was 8.46. To this solution, the NVSC co-crystal 
and polysorbate 80 was added and this resulted in a pH of 8.08.  
 pH 
Preservatives, water 3.16 
Preservatives, sodium hydroxide 8.46 
Preservatives, sodium hydroxide, NVSC co-crystal, polysorbate 80, 
sorbitol 
8.08 
Table 4.18 pH of formulation C3 
4.10.3.2 Co-crystal integrity of formulation C3 
Since this sample was too viscous to be filtered through a vacuum pressure pump, filter 
paper or through a micro filter, alternate approaches had to be devised to analyse the 
sample.    
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To analyse the sample, 5 mL of the prepared sample was diluted in 5 mL of water. The 
suspension was then slightly stirred with a magnetic stirrer to ensure a homogenous 
suspension is prepared. The resultant suspension was not as viscous before dilution, 
hence it could be filtered and it was left to dry overnight in a fume cupboard.   
The purpose of dilution was to analyse the suspension through DSC and FTIR. The 
integrity of the co-crystal, subsequent to dilution was determined; the rationale was 
that if the co-crystal was present after dilution, it meant that the co-crystal would be 
present in the viscous state as well. Although the converse may not be true as the co-
crystal could be present in the viscous state but upon dilution the co-crystal may 
disintegrate.   
 
Figure 4.37 DSC of formulation C3 
The DSC in figure 4.37 displayed an endothermic peak at 242 ºC. As mentioned 
previously, the NVSC co-crystal should be ideally identified between 215-230 ºC. The 
endothermic peak at 242 ºC could represent nevirapine as it had a melting point of 247-
249 ºC.  To further confirm, if it is nevirapine or if it is the co-crystal at a higher melting 
point due to the additional excipients , FTIR was performed on the suspension.    
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Figure 4.38 FTIR spectra of formulation C3 
The FTIR spectrum of the filtrate was compared to that of the NVSC co-crystal powder 
alone (Fig 4.38). The C-O bond in the NVSC co-crystal was expected to be seen at 
1646 cm-1, and the experimental results identified a peak at 1644 cm-1, thus indicating 
the presence of the co-crystal. The aromatic -C=C- could be identified at 1585 cm-1. It 
was confirmed that the composition of the suspension was analogous to the NVSC co-
crystal, hence it can be concluded that the NVSC co-crystal was retained in formulation 
C3.   
Since, this formulation was diluted, it was less viscous than other preparations, hence 
UV analysis was performed on it. UV analysis was done by filtering the suspension 
and utilising the filtered suspension. A blank was prepared in a similar manner as the 
suspension except that the co-crystal was not added.  
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Carbopol 974P suspension , diluted 
NVSC co-crystal powder
3185.94
3062.72
1644.28
1585.78
1488.67
1464.81
1410.89
1382.95
1354.17
1288.92
1259.59
1242.38
1210.67
1167.52
1153.25
1107.19
1090.78
1074.75
1024.70
941.55
884.31
829.72
802.65
788.29
760.82
710.75
696.71
655.32
3184.18
3061.55
1643.39
1585.72
1488.14
1465.20
1382.92
1354.06
1288.24
1258.83
1242.31
1209.96
1166.90
1152.85
1107.34
1090.85
1074.81
1047.74
1024.46
975.31
941.67
883.94
819.05
803.28
787.98
756.64
710.55
696.49
655.42
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Nevirapine is absorbed at a wavelength of 234 nm whilst saccharin is absorbed at a 
wavelength of 260 nm. The UV analysis shows no peaks at wavelengths of 260 and 
234 nm (Fig 4.39). This indicated that the co-crystal did not dissociate into nevirapine 
and saccharin, hence it is concluded that the NVSC co-crystal is indeed intact in this 
suspension formulation.  
 
Figure 4.39 UV of formulation C3 
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4.10.4 Comparison of formulation C1 to C3 
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C1 50 
mg 
10.5  
mg 
      4.12   
C2 50  
mg 
10.5 
mg 
7  
µL 
     5.80   
C3 165 
mg 
33.6
mg  
30  
µL 
3.7 
mL  
8 
µL 
28.8 
mg 
 
3.84 
mg 
q.s 8.08   
Table 4.19 Comparison of pH and integrity of Formulation C1 , C2, C3 
From table 4.19, it can be concluded that the integrity of NVSC co-crystal is not 
compromised in carbopol 974P. This is verified by the results of the DSC, FTIR and 
UV of the suspension. Furthermore, the pH of formulation C3 was within the target 
range. Hence, this suspension was scaled up and quality control tests were performed 
on it.   
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Chapter 5 Quality control of suspension 
Formulation C3 proved to be successful in the two criteria that were deemed necessary 
for co-crystal suspension formulation viz. co-crystal integrity and pH of the 
suspension. Hence, formulation C3 suspension in a concentration of 50 mg/5 mL was 
scaled up to 50 mL, characterization and quality control tests of this suspension was 
pursed.  The results obtained were compared to the Viramune® suspension and the 
standard that was accepted according to literature.  
5.1 Quality control of suspensions  
5.1.1 Particle size of suspension  
The particle size of the insoluble particle should be in a range of 10 to 1000 µm.1 The 
particle size of the NVSC co-crystal prior to formulation was measured by SEM. The 
particle size of NVSC measured was 248.8 µm x 428.0 µm. As seen in figure 5.1, 
nevirapine had a particle size of 113.2 x 121.6 µm.  
  
Figure 5.1 SEM of NVSC co-crystal and nevirapine (from left to right) 
The particles size of the particles in the formulation was determined by a zeta sizer. 
The particle size determined for the Viramune® suspension was 935 nm while the 
NVSC co-crystal formulation revealed a much smaller size of 574.9 nm. The reason 
for a decrease in particle size after formulation could be due to the agitation the 
suspension undergoes through during formulation stages.  
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5.1.2 Polydispersity Index  
The polydispersity index gives an indication on the particle size distribution that is 
measured through a zeta sizer.  Suspensions are preferred to have a polydispersity index 
of 0.1 to 0.3. Viramune® suspension had a polydispersity index of 0.405 while the 
NVSC co-crystal suspension had a polydispersity index of 0.141. This suggested that 
the NVSC co-crystal suspension met the criteria of the polydispersity index however, 
the Viramune® suspension had a slightly higher polydispersity index which meant that 
the particle size distribution is slightly wider.  
5.1.3 Measurement of pH  
The ideal pH for a suspension for oral consumption should be between 5–8.  
Viramune® suspension had a pH of 6.31, whereas the NVSC co-crystal suspension had 
a pH of 8.01. Thus, both the Viramune® suspension and the NVSC co-crystal 
suspension were within the desired pH range. The differences in pH range could be 
attributed to the variation in the formulation process of the two suspensions, as the 
NVSC co-crystal suspension required more volume of sodium hydroxide than the 
Viramune® suspension.  The NVSC co-crystal required a greater volume of sodium 
hydroxide because the NVSC co-crystal was acidic in nature, which significantly 
reduced the pH of the suspension.  
5.1.4 Viscosity 
For a suspension to have ideal flow properties, it should have high viscosity at low 
shear rates (during storage) and low viscosity at high shear rates. Viramune® 
suspension was measured in a small sample adapter at 25 ºC with a SC4-16 spindle and 
had torque values between 41–99 %. The Viramune® suspension has a maximum 
viscosity of 2513 cP at a shear rate of 5.8 sec-1. This was in accordance to what was 
required, as it obtained a high viscosity at a low shear rate. As the speed of the spindle 
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increases, so does the shear rate, this resultant force causes a decrease in the viscosity 
of the suspension.   
 
Viscosity 
(cP)  
Speed 
(RPM) 
Torque 
(%) 
Shear stress 
(D/cm2) 
Shear rate 
(1/sec) 
2513.46 20.00 41.90 145.78 5.80 
1939.59 30.00 48.50 168.74 8.70 
1616.66 40.00 53.90 187.53 11.60 
1406.10 50.00 58.60 203.88 14.50 
1253.73 60.00 62.70 218.15 17.40 
1144.90 70.00 66.80 232.41 20.30 
1057.27 80.00 70.50 245.29 23.20 
981.12 90.00 73.60 256.07 26.10 
915.40 100.00 76.30 265.47 29.00 
868.18 110.00 79.60 276.95 31.90 
823.82 120.00 82.40 286.69 34.80 
787.22 130.00 85.30 296.78 37.70 
750.70 140.00 87.60 304.78 40.60 
723.85 150.00 90.50 314.87 43.50 
697.35 160.00 93.00 323.57 46.40 
676.80 170.00 95.90 333.66 49.30 
651.86 180.00 97.80 340.27 52.20 
629.55 190.00 99.70 346.88 55.10 
Table 5.1 Viscosity of Viramune suspension 
As seen in figure 5.1, Viramune exhibits a Bingham’s plastic type of flow, where the 
fluids that have a linear shear stress/shear strain require a finite yield stress before they 
begin to flow. This is apparent as the graph does not begin from the origin, indicating 
that the suspension requires force for it to flow. 
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Figure 5.1 Viscosity versus shear rate of Viramune® suspension 
The viscosity results of the NVSC co-crystal suspension is outlined in table 5.2. The 
viscosity of the NVSC co-crystal suspension was also measured in a small sample 
adapter at 25 ºC with a SC4-18 spindle and obtained torque values between 32 – 82 %. 
The NVSC co-crystal suspension has a maximum viscosity of 65 cP at a shear rate of 
20 sec-1. Although the viscosity of this suspension is significantly lower than 
Viramune®, it still meets the specification which states that a high viscosity should be 
obtained at a low shear rate.  
 
Figure 5.2 displays the viscosity of the NVSC co-crystal suspension which exhibits a 
similar flow to the Viramune® suspension. It exhibits a Bingham’s plastic type flow, 
which requires a finite yield stress before the suspension begins to flow.  
 
 
 
 
 
0
500
1000
1500
2000
2500
6 9 12 15 17 20 23 26 29 32 35 38 41 44 46 49 52 55
V
is
co
si
ty
 (
cP
)
Shear rate (1/sec)
 
 
 
 
  
166 
 
Viscosity 
(cP) 
Speed 
(RPM) 
Torque 
(%)  
Shear stress 
(D/cm2) 
Shear rate 
(1/sec)  
64.59 15.00 32.30 12.79 19.80 
47.99 25.00 40.00 15.84 33.00 
38.65 35.00 45.10 17.86 46.20 
34.13 45.00 51.20 20.27 59.40 
31.25 55.00 57.30 22.69 72.60 
29.07 65.00 63.00 24.94 85.80 
27.23 75.00 68.10 26.96 99.00 
25.37 85.00 71.90 28.47 112.20 
24.09 95.00 76.30 30.21 125.40 
23.45 105.00 82.10 32.50 138.60 
Table 5.2 Viscosity of NVSC co-crystal suspension  
 
Figure 5.2 Viscosity versus shear rate of NVSC co-crystal suspension 
5.1.5 Zeta potential  
Zeta potential of the suspension gives an indication of physical stability of the 
suspension. A value more than +30 mV or less than -30mV is preferred for suspensions. 
Viramune® obtained a value of -14.2 mV while the NVSC co-crystal suspension 
obtained a value of -2.37 mV. Both the suspensions did not meet this requirement, 
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however, the Viramune® suspension was closer to the desired zeta potential range 
indicating that it was physically more stable. The Viramune® suspension had greater 
viscosity thus, it was physically more stable as it allowed the particles to be dispersed 
whereas the NVSC co-crystal had a lower viscosity thus the zeta potential was also 
significantly lower. Due to the low viscosity of the NVSC co-crystal suspension the 
particles were not dispersed continually throughout the suspension, hence it had a low 
zeta potential.    
5.1.6 Dissolution 
Dissolution tests are an indication of the cumulative amount of API that passes into 
solution which is studied as a function of time. The test describes the overall rate of all 
the processes involved in the release of the API into a bioavailable form. Dissolution 
studies evaluates the potential effect of formulation and process variables on the 
bioavailability of an API and ensures that preparations comply with product 
specification. It gives an indication of the performance of the preparation under in vitro 
conditions.2  
To analyse the concentration of nevirapine in the Viramune® suspension and the co-
crystal suspension, a calibration curve of nevirapine was constructed in a phosphate 
buffer of pH 6.8. A sixteen point calibration curve, of nevirapine ranged from a 
concentration of 0.3 mg/mL to 0.00234375 mg/mL in triplicate was plotted. A straight 
line with a regression value of R2=1 was achieved (Fig 5.3). Nevirapine compound was 
eluted at approximately 3 minutes at 280 nm. HPLC chromatogram and the peak area 
observed for the dissolution results can be seen in Appendix B. 
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Figure 5.3 Standard curve of nevirapine in phosphate buffer with a pH of 6.8 
The dissolution media that was used was phosphate buffer with a pH of 6.8. This is the 
pH at which nevirapine is absorbed in the body. To simulate in vivo conditions the 
temperature of the dissolution media was 37 °C. Six dissolution vessels were used for 
the study. 5 mL of the suspension was inserted in the vessel by means of a syringe. 5 
mL samples were extracted at 10, 20, 30, 45 and 60 minute intervals and replaced with 
5 mL of phosphate buffer. 1 mL of extracted samples was then placed in HPLC vials. 
Concentration of samples were determined using the peak area of samples obtained at 
3 minutes in the equation obtained in the standard curve.  Cumulative amount of API 
was calculated as a percentage for Viramune® suspension and NVSC co-crystal 
suspension as seen in table 5.3 and 5.4. 
Time 
(min) 
Vessel Number 
1 2 3 4 5 6 
10 40 35 40 45 34 50 
20 70 62 69 77 60 69 
30 86 78 93 93 79 89 
45 98 91 98 98 97 95 
60 100 100 100 100 100 100 
Table 5.3 Percentage release of nevirapine in Viramune® in phosphate buffer at 
pH 6.8 
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Time 
(min) 
Vessel Number 
1 2 3 4 5 6 
10 76 81 84 87 78 87 
20 85 88 92 92 87 93 
30 91 92 96 95 93 96 
45 97 97 98 100 97 98 
60 100 100 100 100 100 100 
Table 5.4 Percentage release of nevirapine in NVSC suspension in phosphate 
buffer at pH 6.8 
According to the USP 32 criteria, 81-100 % of drug release must occur within 30 
minutes of the dissolution study.2 Both the branded version, Viramune® and the NVSC 
co-crystal suspensions met this criteria, with the Viramune® achieving a 86 % drug 
release while the NVSC co-crystal suspension achieved a drug release of 94 % within 
30 minutes of dissolution (table 5.5 and figure 5.4).  
Time  Viramune ® suspension 
(average % dissolved) 
NVSC suspension  
(average % dissolved) 
Standard 
deviation 
10 41 82 20 
20 68 89 11 
30 86 94 4 
45 96 98 1 
60 100 100 0 
Table 5.5 Comparison of average percentage drug release of Viramune ® 
suspension and NVSC co-crystal suspension  
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Figure 5.4 Dissolution profiles of Viramune® suspension and NVSC co-crystal 
suspension 
The NVSC co-crystal suspension dissolved more quickly, this is substantiated by the 
ten minute point, where only 41 % of nevirapine is released in the Viramune® 
suspension whereas 82 % of nevirapine is released in the NVSC co-crystal suspension 
within ten minutes of dissolution.  This is twice the amount of nevirapine that is 
released from the Viramune® suspension, indicating that the NVSC co-crystal releases 
more nevirapine at the ten minute time interval. 
The NVSC co-crystal suspension had a consistently higher percentage release than the 
Viramune® suspension during the dissolution study. At the ten minute time interval, 
the standard deviation between the Viramune ® suspension and the NVSC co-crystal 
suspension indicated that the dissolution rate of the NVSC co-crystal suspension is 
significantly higher. However, at the 45 minute time interval, the standard deviation 
was low indicating that the dissolution rates of the NVSC co-crystal and the 
Viramune® suspension is similar. The Viramune® suspension is released gradually 
over time whereas 82 % of the NVSC co-crystal suspension is released within ten 
minutes.  
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Upon placing the suspensions in the vessels, the suspensions are seen as small circular 
mass, this is illustrated in figure 5.4. Viramune® suspension remains as a circular 
masses of powder throughout the dissolution study, whereas comparatively the NVSC 
co-crystal suspension reduces its mass over time. Furthermore, this mass of powder is 
greater in the Viramune® suspension than the NVSC co-crystal suspension. This can 
be recognized due to the Viramune® containing an extra excipient -sucrose- which is 
not in the formulation of the NVSC co-crystal suspension.   
  
Viramune® suspension  NVSC co-crystal suspension 
Figure 5.4 Dissolution of Viramune suspension and NVSC co-crystal suspension 
at thirty minutes 
Table 5.6 summarizes the quality control tests of Viramune® suspension and NVSC 
co-crystal suspension. Both the suspensions met the criteria of particle size, 
polydispersity index, pH and dissolution. Viramune® had a better viscosity while the 
NVSC co-crystal suspension did not meet this criteria. The zeta potential for both the 
suspensions did not meet the standard required.  
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Characteristic Standard accepted 
according to 
literature 
Viramune® 
suspension 
NVSC co-
crystal 
suspension  
Particle size measured by 
zeta sizer 
The insoluble particle 
should be between 10 
to 1000 µm1 
935 nm  574.9 nm 
Particle size measured by 
SEM 
248.8 x 428.0 
µm 
113.2 x 121.6 
µm 
Polydispersity Index 0.1 to 0.3  0.405 0.141 
pH 5-81 6.31 8.01 
Viscosity it should have high 
viscosity at low shear 
rates (during storage) 
and low viscosity at 
high shear rates  
2513 cP  
 
 
64.59 cP 
Zeta Potential More than +30mV or 
less than -30 mV1 
-14.2 (average) -2.37 (average) 
Dissolution  81-100% in 30 
minutes1,3 
86 % 94 %  
Table 5.6 Comparison of quality control tests of Viramune® suspension and 
NVSC co-crystal suspension 
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Chapter 6 Conclusion  
According to the objectives in chapter 1, development of a protocol to select an 
appropriate co-former from the five available co-formers with nevirapine was 
achieved, by clustering variables deemed necessary for suspension formulation 
according to their physical, chemical, pharmacological and pharmaceutical properties. 
 
A template to select the best co-former was thus created with the variables chosen.  
Upon completion of the template for the co-formers, an ordinal scale was used to select 
the most appropriate co-former suspension. Consequently, saccharin had the highest 
total score and thus it was the chosen co-former for suspension formulation.  
NVSC co-crystal was then scaled up accordingly and identified through various 
analytical techniques. It was found that the NVSC co-crystal had a percentage yield of 
greater than 75%.  
 
The intention of retaining the co-crystal during formulation was monitored through 
means of DSC, FTIR and where possible by UV. However, as a recommendation 
PXRD is better suited for identification purposes if the co-crystal is retained in the 
suspension.  
The formed NVSC co-crystal suspension performed well in the quality control tests i.e. 
particle size, polydispersity index and pH whilst maintaining the integrity of the co-
crystal. However, the zeta potential and the viscosity was not according to the quality 
desired. The dissolution of the NVSC co-crystal was analysed using HPLC and it 
revealed that 82 % of nevirapine was released within ten minutes. However, 
optimization of the final suspension formulation with improvement on viscosity and 
zeta potential is recommended.  
In the pharmaceutical arena, companies are constantly under pressure to practice 
“greener” approaches during formulation, the NVSC co-crystal suspension had 
eliminated the use of one less excipient (sucrose) compared to the Viramune® 
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formulation, hence substantiating that co-crystals could be used as a means of 
promoting judicious use of resources.  
In this study the NVSC suspension as a ready-to-use suspension was explored, an 
alternative approach to achieve this, could possibly be achieved with 
extemporaneously prepared suspensions. A suspension of this nature would be worth 
investigating, if it meets the USP 32 criteria.  
Furthermore as a recommendation, once the suspension is optimized with respect to its 
viscosity, stability testing under accelerated conditions for a period of time would give 
an indication on the stability of the co-crystal and hence suggest whether the co-crystal 
is stable in a suspension for a longer duration.  
Antiviral testing should also be simultaneously undertaken with stability studies to 
establish if the antiviral activity of the co-crystal against HIV is compromised over a 
period of time.    
 
 
 
 
 
 
Appendix A 
 
 Start  Melting  Decomposition  
Batch 
4  
   
 24°C 230 °C 239 °C 
Batch 
5 
   
 25 °C 236 °C 245 °C 
Batch 
6 
   
 22 °C 235 °C 247 °C 
Batch 
7 
   
 90 °C 215 °C 239 °C 
Batch 
8 
   
 25 °C 215 °C 245 °C 
Batch 
9 
   
 22 °C 231 °C 237 °C 
 
 
 
 
 
 
 
  Start  Melting  Decomposition  
Batch 
10 
   
 24°C 217 °C 239 °C 
Batch 
11 
   
 25 °C 232 °C 242 °C 
Batch 
12 
   
 63 °C 219 °C 255 °C 
Batch 
13 
   
 90 °C 215 °C 249 °C 
Batch 
14 
   
 25 °C 224 °C 252 °C 
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HPLC chromatgram of nevirapine at 280 nm in phosphate buffer 
Time 
(min) 
Vessel Number 
1 2 3 4 5 6 
10 717.2 680.1 660 761.4 578 1162.8 
20 1247.8 1207 1124.3 1297.1 1005.9 1596.3 
30 1519.2 1521.4 1520.8 1562 1340.3 2052.4 
45 1739.3 1779.1 1609.7 1643.6 1628.7 2191.9 
60 1772.4 1950.7 1638.4 1674.2 1685.3 2318.5 
Peak area of Viramune® suspension at 280 nm   
 
Time 
(min) 
Vessel Number 
1 2 3 4 5 6 
10 1798.3 2013.3 1228.2 1947.3 1848.2 2238.5 
20 2013.5 2200 1334.9 2072.7 2057.4 2396.9 
30 2175.2 2299.1 1395.2 2140.0 2207.4 2453.2 
45 2315.7 2401.8 1423.6 2240.3 2297.2 2516.5 
60 2380.9 2484 1455.8 2242.7 2376.9 2570.7 
Peak area of NVSC co-crystal suspension at 280 nm 
 
 
 
 
